triazoles has been researched along with deferasirox in 638 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 156 (24.45) | 29.6817 |
| 2010's | 461 (72.26) | 24.3611 |
| 2020's | 21 (3.29) | 2.80 |
| Authors | Studies |
|---|---|
| Forgiarini, P; Schnebli, HP; Sergejew, T | 1 |
| Breuer, W; Cabantchik, ZI; Hershko, C; Konijn, AM; Link, G; Nick, HP | 1 |
| Buffet, C; Humbert, H; Marfil, F; Masson, L; Maurer, G; Rouan, MC | 1 |
| Buffet, C; Humbert, H; Marfil, F; Maurer, G; Rouan, MC | 1 |
| Humbert, H; Mangoni, P; Marfil, F; Maurer, G; Rouan, MC; Séchaud, R | 1 |
| Gordeuk, VR; Goudeau, C; Kassim, OO; Loyevsky, M; Nick, H | 1 |
| Acklin, P; Faller, B; Hauffe, S; Jin, Y; Lattmann, R; Nick, H; Schnebli, HP; Sergejew, T; Thomas, H; Wong, A | 1 |
| Acklin, P; Alberti, D; Buehlmayer, P; Hauffe, S; Lattmann, R; Nick, H; Schupp, J | 1 |
| Alberti, D; Anderson, JR; Giardina, PJ; Grady, RW; Krebs-Brown, AJ; Nathan, DG; Neufeld, EJ; Nisbet-Brown, E; Olivieri, NF; Séchaud, R; Sizer, KC | 1 |
| Nathan, DG | 2 |
| Alberti, D; Bigler, H; Galanello, R; Piga, A; Rouan, MC; Séchaud, R | 1 |
| Kontoghiorghes, GJ | 11 |
| Hasinoff, BB; Patel, D; Wu, X | 1 |
| Cabantchik, ZI; Hershko, CM; Konijn, AM; Link, GM | 1 |
| Cappellini, MD | 2 |
| Porter, JB | 5 |
| Hershko, C | 2 |
| Cabantchik, ZI; El, RB; Glickstein, H; Shvartsman, M | 1 |
| El Beshlawy, A | 1 |
| Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ | 1 |
| Kolnagou, A; Kontoghiorghes, GJ | 2 |
| Cabantchik, ZI; Hershko, C; Konijn, AM; Link, G | 1 |
| Hider, RC; Zhou, T | 1 |
| Galanello, R | 1 |
| Fischer, R; Harmatz, P; Nielsen, P; Piga, A | 1 |
| Agaoglu, L; Alberti, D; Athanassiou-Metaxa, M; Aydinok, Y; Bejaoui, M; Cappellini, MD; Capra, M; Coates, T; Cohen, A; Drelichman, G; Fattoum, S; Galanello, R; Giardina, P; Janka-Schaub, G; Kattamis, A; Kilinc, Y; Kourakli-Symeonidis, A; Magnano, C; Marks, P; Olivieri, N; Opitz, H; Perrotta, S; Piga, A; Porter, J; Ressayre-Djaffer, C; Thuret, I; Verissimo, M; Vermylen, C | 1 |
| Greenberg, PL | 1 |
| Niederau, C | 1 |
| Tefferi, A | 2 |
| Camenisch, GP; Fresneau, M; Gross, G; Kretz, O; Weiss, HM | 1 |
| Neufeld, EJ | 1 |
| Hagemann, TM; Vanorden, HE | 1 |
| Brissot, P; Chantrel-Groussard, K; Gaboriau, F; Havouis, R; Lescoat, G; Nick, H; Pasdeloup, N; Pierre, JL | 1 |
| Agarwal, MB | 2 |
| Fischer, R | 1 |
| Alberti, D; Bordone, E; Cappellini, MD; Donato, G; Ford, JM; Forni, GL; Galanello, R; Hewson, N; Lavagetto, A; Opitz, H; Origa, R; Piga, A; Sechaud, R; Zanaboni, L; Zappu, A | 1 |
| Arcasoy, MO; Martin, MG | 1 |
| Okpala, I | 1 |
| Hussar, DA | 1 |
| Dassonville, A; Desplat, V; Gaboriau, F; Guillon, J; Jarry, C; Lescoat, G; Nascimento, S; Pires, VS; Rochette, J; Sonnet, P | 1 |
| Fischer, R; Harmatz, P; Nielsen, P | 1 |
| Edwards, JE; Ibrahim, A; Reed, C; Spellberg, B; Walot, I | 1 |
| Alberti, D; Belleli, R; Bertrand, Y; Bordone, E; Forni, GL; Foschini, ML; Galanello, R; Hewson, N; Lavagetto, A; Leoni, G; Longo, F; Maseruka, H; Piga, A; Sechaud, R; Zappu, A | 1 |
| Aguilar, MI; Gonzalez, I; Moats, R; Nelson, M; Nick, H; Otto-Duessel, M; Shimada, H; Wood, JC | 1 |
| Alberti, D; Bernaudin, F; Coates, T; Eckman, J; Files, B; Fischer, R; Forni, GL; Fung, E; Hassell, K; Holland, J; Kelly, P; Lane, P; Marks, P; Mueller, BU; Okpala, I; Onyekwere, O; Porter, J; Ressayre-Djaffer, C; Swerdlow, P; Vichinsky, E; Wilson, F | 1 |
| Al-Fayoumi, S; Castillo, S; Chakraborti, T; Choudary, J; Frankewich, R; Kacuba, A; Pazdur, R; Rieves, D; Robie-Suh, K; Shashaty, G; Weiss, K | 1 |
| Steensma, DP; Tefferi, A | 1 |
| Barton, JC | 1 |
| Stumpf, JL | 1 |
| Scheinfeld, N | 1 |
| Baladi, JF; Coates, TD; Delea, TE; Phatak, PD; Sofrygin, O; Thomas, SK | 1 |
| Rose, C | 2 |
| Waugh, WH | 1 |
| Aguilar, M; Moats, R; Nick, H; Otto-Duessel, M; Wood, JC | 1 |
| Ammosova, T; Charles, S; Debebe, Z; Gordeuk, VR; Jerebtsova, M; Kurantsin-Mills, J; Nekhai, S; Niu, X; Ray, PE; Richardson, DR | 1 |
| Maggio, A | 1 |
| Abetz, L; Abish, S; Agaoglu, L; Baladi, JF; Bejaoui, M; Cappellini, MD; Cario, H; Coates, T; Ferster, A; Girot, R; Jeng, M; Lai, ME; Loggetto, S; Mangiagli, A; Opitz, H; Porter, J; Ressayre-Djaffer, C; Rofail, D; Strauss, G; Vichinsky, E; Watman, N; Zoumbos, N | 1 |
| Choudhry, VP; Naithani, R | 1 |
| Edwards, JE; French, SW; Fu, Y; Gebermariam, T; Husseiny, MI; Ibrahim, AS; Lin, L; Schwartz, J; Skory, CD; Spellberg, BJ | 1 |
| Dubey, AP; Parakh, A; Sudha, S | 1 |
| Brissot, P; Chantrel-Groussard, K; Gaboriau, F; Lescoat, G; Nick, H; Pasdeloup, N | 1 |
| Bernhardt, PV | 1 |
| Drago, V; Foster, P; Heilman, KM; Schmalfuss, IM; Skidmore, FM; Streiff, RR | 1 |
| Keam, SJ; Keating, GM; Yang, LP | 1 |
| Cohen, AR; Glimm, E; Porter, JB | 1 |
| Hajjizadeh, M; Heli, H; Jabbari, A; Karimian, K; Moosavi-Movahedi, AA; Shafiee, A | 1 |
| Alberti, D; Alimena, G; Cappellini, MD; Cario, H; Cazzola, M; Cunningham, MJ; Debusscher, L; Della Porta, M; Ford, JM; Forni, GL; Galanello, R; Gathmann, I; Gattermann, N; Giardina, P; Greenberg, P; Jeng, M; Kwiatkowski, J; Maertens, J; Neufeld, EJ; Olivieri, N; Piga, A; Porter, J; Quarta, G; Rabault, B; Rose, C; Saglio, G; Soulières, D; Stadler, M; Tchernia, G; Vichinsky, E | 1 |
| Goldberg, SL | 1 |
| Lindsey, WT; Olin, BR | 1 |
| Vichinsky, E | 1 |
| Arpa, P; Azzolini, M; De Molfetta, V; Masera, G; Masera, N; Rescaldani, C; Tavecchia, L; Vimercati, C | 1 |
| Berdoukas, V; Modell, B | 1 |
| Cariou, A; Dannaoui, E; Lemiale, V; Lortholary, O; Massault, PP; Mathonnet, A; Mira, JP; Paugam, A; Scatton, O; Soummer, A | 1 |
| Balez, S; Brun, E; Dumortier, T; Dutreix, C; Morisson, S; Pommier, F; Séchaud, R | 1 |
| Hampton, T | 1 |
| Alberti, D; Balez, S; Belleli, R; Cappellini, MD; Dutreix, C; Ford, JM; Forni, GL; Galanello, R; Origa, R; Piga, A; Rivière, GJ; Séchaud, R; Zappu, A | 1 |
| Bring, P; Ford, JA; Partovi, N; Yoshida, EM | 1 |
| Brissot, P; Deugnier, Y; Loréal, O | 1 |
| Chan, GC; Cheung, YF; Ha, SY | 1 |
| Ozawa, K | 2 |
| Suzuki, T | 2 |
| Ohyashiki, K | 1 |
| Kwiatkowski, JL | 1 |
| Abetz, L; Baladi, JF; Coates, T; Coïc, L; Files, B; Fischer, R; Forni, GL; Lane, P; Marks, P; Mueller, BU; Onyekwere, O; Pakbaz, Z; Porter, J; Rofail, D; Swerdlow, P; Vichinsky, E | 1 |
| Angelucci, E; Barosi, G; Camaschella, C; Cappellini, MD; Cazzola, M; Galanello, R; Marchetti, M; Piga, A; Tura, S | 1 |
| Bardou-Jacquet, E; Brissot, P; Deugnier, Y; Jouanolle, AM; Le Lan, C; Loréal, O; Troadec, MB | 1 |
| Akehurst, R; Jewitt, K; Karnon, J; Ossa, D; Oyee, J; Tolley, K | 1 |
| Alberti, D; Coates, T; Evans, P; Giardina, PJ; Harmatz, P; Holland, J; Kwiatkowski, JL; Macklin, EA; Neufeld, EJ; Olivieri, N; Porter, J; Vichinsky, E; Walter, PB | 1 |
| Balez, S; Belleli, R; Robeva, A; Séchaud, R | 2 |
| Bennett, W; Coppo, R; Hirschberg, R; Ponticelli, C; Scheinman, J | 1 |
| Ford, JM; Rojkjaer, L | 1 |
| Brewster, UC; McPhedran, P; Yusuf, B | 1 |
| Kohgo, Y; Kojima, S; Matsumura, I; Miyazaki, Y; Nakao, S; Niitsu, Y; Ohyashiki, K; Ozawa, K; Suzuki, T; Tomonaga, M | 1 |
| Aguilar, M; Moats, R; Nelson, MD; Nick, H; Otto-Duessel, M; Wood, JC | 1 |
| Hata, T; Ishikawa, T; Kato, J; Kondo, M; Miyazawa, K; Mori, H; Nakao, S; Ohyashiki, K; Omine, M; Ozawa, K; Rojkjaer, L; Taniguchi, J; Tanii, H; Tatsumi, Y; Urabe, A | 1 |
| Mahmoud, A; Musallam, KM; Taher, AT | 1 |
| Brosnahan, G; Gokden, N; Swaminathan, S | 1 |
| Cappellini, MD; Taher, A | 2 |
| Dinter, D; Dorn-Beineke, A; Hastka, J; Hehlmann, R; Leismann, O; Lutz, K; Metzgeroth, G; Schultheis, B | 1 |
| Boernsen, KO; Bruin, GJ; Faller, T; Nick, H; Schneider, J; Schweitzer, A; Waldmeier, F; Wiegand, H | 1 |
| Deeren, D | 1 |
| Arruga, F; Cilloni, D; Messa, E; Messa, F; Roetto, A; Saglio, G | 1 |
| Cho, HS; Kang, JI; Kim, DM; Kim, HS; Park, CY | 1 |
| Edwards, J; Ibrahim, AS; Spellberg, B | 1 |
| Hamdan, MA; Hayek, M; Ishaqi, MK; Jamil, A; Khanani, MF; Shamsi, A; Trad, O | 1 |
| Brewer, C; Gonzalez, I; Nick, H; Otto-Duessel, M; Wood, JC | 1 |
| Cappellini, MD; Porter, JB; Taher, AT; Vichinsky, EP | 1 |
| Bagust, A; Boland, A; Chu, P; Dickson, R; Dundar, Y; Fleeman, N; Greenhalgh, J; Kirkham, J; McLeod, C; Modell, B; Olujohungbe, A; Telfer, P; Walley, T | 1 |
| Bernhardt, MB; Mahoney, DH; Mueller, BU; Raphael, JL | 1 |
| Moreau-Marquis, S; O'Toole, GA; Stanton, BA | 1 |
| Al Jefri, A; Al Zir, K; Daar, S; El-Beshlawy, A; Elalfy, MS; Habr, D; Hmissi, A; Kriemler-Krahn, U; Taher, A | 1 |
| Daar, S; Habr, D; Hmissi, A; Kriemler-Krahn, U; Nick, H; Pathare, A; Taher, A | 1 |
| Allegrini, PR; Fozard, L; Junker, U; Nick, H; Niederkofler, V; O'Reilly, T; Rojkjaer, L; Salie, R | 1 |
| Barada, K; Khalife, M; Musallam, KM; Taher, AT | 1 |
| Gutiérrez Macías, A; Lizarralde Palacios, E; Martínez Odriozola, P; Olabarría Santurtún, I | 1 |
| Capalbo, S; Franzese, MG; Palumbo, G; Spinosa, G | 1 |
| Hamamura, R; Kobayashi, C; Ohyashiki, JH; Ohyashiki, K; Okabe, S; Tauchi, T | 1 |
| Baumgartner, C; Nösslinger, T; Pfeilstöcker, M; Sperr, WR; Valent, P; Wimazal, F | 1 |
| Ito, Y; Kiguchi, T; Kimura, Y; Ohyashiki, K | 1 |
| Garcia-Manero, G; Jabbour, E; Kantarjian, HM; Taher, A | 1 |
| McTigue, DM; Schonberg, DL | 1 |
| Kim, DM; Neupane, GP | 2 |
| Inati, A; Koussa, S; Musallam, KM; Taher, AT | 1 |
| Andes, D; Anglim, A; Bonilla, H; Ibrahim, AS; Mathisen, GE; Perez, M; Spellberg, B; Walsh, TJ | 1 |
| Edwards, J; Ibrahim, AS; Kontoyiannis, DP; Spellberg, B; Walsh, TJ | 1 |
| Balez, S; Dumortier, T; Sechaud, R | 1 |
| Delarue, R; Fakhouri, F; Le Quintrec, M; Rafat, C; Ribeil, JA | 1 |
| Cappellini, MD; Pattoneri, P | 1 |
| Al-Rousan, RM; Blough, ER; Gutta, AK; Kakarla, SK; Laurino, JP; Paturi, S; Walker, EM | 1 |
| Imran, F; Phatak, P | 1 |
| Stone, RM; Tefferi, A | 1 |
| Cernik, C; Haller, N; Mostow, EN | 1 |
| Arrizabalaga, B; Del Cañizo, C; Remacha, AF; Sanz, G; Villegas, A | 1 |
| Bergmann, AK; Braunstein, J; Chirnomas, D; Finkelstein, Y; Grant, FD; Neufeld, EJ; Paley, C; Pereira, L; Shannon, M; Smith, AL | 1 |
| Alvarez, O; Lewis, N; Lopez-Mitnik, G; Paley, C; Pow Sang, CD; Robinson, N; Rodriguez-Cortes, H | 1 |
| Cappellini, MD; Clark, J; Galanello, R; Habr, D; Lawniczek, T; Piga, A; Porter, JB; Taher, A; Vichinsky, E | 1 |
| Ahmad, F; Amani, M; Babaahmadi, A; Divsalar, A; Farzami, B; Hakimelahi, GH; Kamarie, M; Karimian, K; Moosavi-Movahedi, AA; Mousavy, SJ; Poursasan, N; Riazi, GH; Saboury, AA; Shafiee, A; Tsai, FY | 1 |
| Daar, S; Pathare, A; Taher, A | 1 |
| Chang, JS; Chiou, SS; Hsiao, CC; Hung, GY; Peng, CT; Wang, LY; Wang, SC; Wu, KH | 1 |
| Chan, GC; Chan, S; Ha, SY; Ho, PL | 1 |
| Efstathiou, A; Kleanthous, M; Kolnagou, A; Kontoghiorghes, GJ; Michaelides, Y | 1 |
| Christoulas, D; Delaki, EE; Douskou, M; Papadakis, M; Plata, E; Terpos, E; Voskaridou, E | 1 |
| Dassonville-Klimpt, A; Gaboriau, F; Guillon, J; Leger, JM; Lescoat, G; Nascimento, SD; Pires, VS; Rouge, P; Sonnet, P | 1 |
| Fibach, E; Prus, E | 1 |
| Aloizos, G; Kikilas, A; Papadopoulos, N; Tapinis, P; Vasiliki, A | 1 |
| Maren, K; Rojkjaer, L; Skerjanec, A; Wang, J | 1 |
| Edwards, JE; French, SW; Gebremariam, T; Ibrahim, AS; Spellberg, B | 1 |
| Cappellini, MD; Chan, LL; Domokos, G; El-Beshlawy, A; Elalfy, M; Gattermann, N; Giraudier, S; Habr, D; Kattamis, A; Lee, JW; Li, CK; Lin, KH; Porter, J; Rose, C; Roubert, B; Seymour, JF; Taher, A; Thein, SL; Viprakasit, V | 1 |
| Aydinok, Y; Cappellini, MD; Chan, LL; Domokos, G; El-Beshlawy, A; Elalfy, MS; Habr, D; Ibrahim, H; Kattamis, A; Li, CK; Pennell, DJ; Porter, JB; Roubert, B; Smith, G; Sutcharitchan, P; Taher, A; Viprakasit, V | 1 |
| Brissot, P; Cannie, I; Gaboriau, F; Gouffier, L; Leray, AM; Lescoat, G; Loréal, O; Ropert, M; Troadec, MB | 1 |
| Telfer, P | 1 |
| HATANO, K; MATSUYAMA, T; MORI, M; MUROI, K; NAGAI, T; OKABE, H; OMORI, T; OZAWA, K; QZAKI, K; SUZUKI, T; TOSHIMA, M; UEDA, M; UEHARA, E | 1 |
| Liu, G; Men, P; Perry, G; Smith, MA | 1 |
| Becker-Cohen, R; Even-Or, E; Miskin, H | 1 |
| Bauters, T; de Moerloose, B; Hunninck, K; Mondelaers, V; Robays, H | 1 |
| Ammirabile, M; Cinque, P; Costantini, S; Di Matola, T; Prossomariti, L; Ricchi, P; Spasiano, A | 1 |
| Burns, LJ; Lazarus, HM; Majhail, NS | 1 |
| Bruin, GJ; Glaenzel, U; Hazell, K; Porter, JB; Sechaud, R; Waldmeier, F; Warrington, S | 1 |
| Delaporta, P; Goussetis, E; Hantzi, E; Kattamis, A; Ladis, V; Margeli, A; Papassotiriou, I; Sergounioti, A | 1 |
| Schmid, M | 1 |
| Fujita, T; Haba, R; Nishiuchi, T; Ohnishi, H; Okutani, Y; Yoshida, K | 1 |
| Ampe, E; Galanti, L; Hecq, JD; Karmani, L; Lebitasy, M; Nick, H | 1 |
| Athanassiou-Metaxa, M; Economou, M; Papachristou, F; Printza, N; Teli, A; Tsatra, I; Tzimouli, V | 1 |
| Hider, RC | 1 |
| Huang, XP; Spino, M; Templeton, DM; Thiessen, JJ | 1 |
| Borsellino, Z; Cuccia, L; Gagliardotto, F; Marocco, MR; Ruffo, GB; Tarantino, R | 1 |
| Arvapalli, RK; Blough, ER; Gadde, MK; Kakarla, SK; Katta, A; Laurino, JP; Paturi, S; Rice, KM; Walker, EM; Wehner, P; Wu, M | 1 |
| Alati, C; Marino, A; Nobile, F; Oliva, EN; Praticò, G; Ronco, F | 1 |
| Fausel, CA | 1 |
| Bouchet, S; Chauzit, E; Mahon, FX; Micheau, M; Molimard, M; Moore, N; Titier, K | 1 |
| Fatemi, SJ; Saljooghi, AS | 1 |
| Fibach, E; Ghoti, H; Grisariu, S; Merkel, D; Perez-Avraham, G; Rachmilewitz, EA | 1 |
| Coates, TD; Giardina, P; Glynos, T; Harmatz, P; Kang, BP; Paley, C; Thompson, A; Wood, JC | 3 |
| Al Jefri, A; Al Zir, K; Baladi, JF; Daar, S; El-Beshlawy, A; Elalfy, MS; Habr, D; Kriemler-Krahn, U; Rofail, D; Taher, A | 1 |
| Domokos, G; Fenaux, P; Finelli, C; Ganser, A; Gattermann, N; Guerci-Bresler, A; Habr, D; Porta, MD; Rose, C; Roubert, B; Schmid, M; Taylor, K; Vassilieff, D | 1 |
| Bertrand, DM; Eas, F; Godin, M; Grangé, S; Guerrot, D | 1 |
| Brown, M; Clayton, P; D'Rozario, J; Falk, MC; Talaulikar, GS; Yew, CT | 1 |
| Jetsrisuparb, A; Jetsrisuparb, C; Komvilaisak, P; Wiangnon, S | 1 |
| Balocco, M; Carrara, P; Forni, GL; Pinto, V | 1 |
| Kolnagou, A; Kontoghiorghes, GJ; Petrikkos, G; Skiada, A | 1 |
| Alberti, D; Arruga, F; Bracco, E; Carturan, S; Cilloni, D; Defilippi, I; Greco, E; Maffè, C; Messa, E; Messa, F; Pautasso, M; Pellegrino, RM; Roetto, A; Rosso, V; Rotolo, A; Saglio, G; Zanone, C | 1 |
| Berdoukas, V; Berdoussi, E; Chouliaras, G; Kattamis, C; Ladis, V; Moraitis, P; Zannikos, K | 1 |
| Domokos, G; Ganser, A; Habr, D; Hsu, HC; Lee, JW; Porter, JB; Roubert, B; Shen, ZX; Yoon, SS | 1 |
| Karasu, G; Kazik, M; Ozturk, Z; Uygun, V; Yesilipek, MA | 1 |
| Aytac, S; Cetin, M; Eldem, G; Gumruk, F; Hazirolan, T; Kuskonmaz, B; Uckan, D; Unal, S | 1 |
| Cabantchik, ZI; Glynos, T; Greenberg, PL; Koller, CA; Paley, C; Schiffer, C; Warsi, G | 1 |
| Alimena, G; Breccia, M; Cannella, L; Loglisci, G; Salaroli, A; Santopietro, M | 1 |
| Christoulas, D; Dimopoulou, M; Douskou, M; Mpoutou, E; Plata, E; Sioni, A; Terpos, E; Voskaridou, E | 1 |
| Baum, M | 1 |
| Antes, G; Bassler, D; Fleeman, N; Meerpohl, JJ; Niemeyer, C; Rücker, G | 1 |
| Fatemi, SJ; Saljooghi, ASh | 1 |
| Aslam, N; Marsano-Obando, LS; Martin, A; Mettu, P | 1 |
| Leitch, HA | 1 |
| Inati, A; Khoriaty, E; Musallam, KM; Taher, AT | 1 |
| Barzilai-Birenbaum, S; Krause, I; Pazgal, I; Stark, P; Tamary, H; Yacobovich, J; Yaniv, I | 1 |
| Bakry, R; Bonn, G; Bösch, S; Creus, M; Finkenstedt, A; Gasser, BI; Höfner, E; Janecke, AR; Kremser, C; Moser, P; Poewe, W; Schocke, M; Schranz, M; Theurl, M; Vogel, W; Wolf, E; Zoller, H | 1 |
| Braunstein, J; Mednick, LM; Neufeld, E | 1 |
| Bozkaya, D; Li, Q; Migliaccio-Walle, K; Miranda, E; Oliver, N; Tolley, K | 1 |
| Adams, PC; Bonkovsky, HL; Brissot, P; Griffel, L; Gross, J; Lynch, N; Malfertheiner, P; McLaren, GD; Niederau, C; Phatak, P; Pietrangelo, A; Piperno, A; Powell, LW; Russo, MW; Stoelzel, U; Stremmel, W; Wurster, M; Zhang, Y | 1 |
| Im, HJ; Kim, BE; Koh, KN; Park, M; Seo, JJ | 1 |
| Bisconte, MG; Capra, M; Caruso, V; Cianciulli, P; Filosa, A; Lippi, A; Lombardi, M; Maggio, A; Malaventura, C; Meloni, A; Midiri, M; Missere, M; Pepe, A; Pitrolo, L; Positano, V; Prossomariti, L; Putti, MC; Quarta, A; Romeo, MA; Rossi, G | 1 |
| Al-Rousan, R; Arvapalli, RK; Blough, ER; Fannin, J; Kakarla, SK; Katta, A; Liu, H; Paturi, S; Rice, KM; Triest, WE; Wang, Y; Wu, M | 1 |
| Berdousi, H; Gotsis, E; Kattamis, A; Ladis, V | 1 |
| Albert, N; Ben-Ami, R; Kontoyiannis, DP; Lewis, RE; Pongas, GN; Walsh, TJ | 1 |
| Antes, G; Bassler, D; Fleeman, N; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G | 2 |
| Aydinok, Y; Cappellini, MD; Chan, LL; Domokos, G; El-Beshlawy, A; Elalfy, MS; Habr, D; Ibrahim, H; Kattamis, A; Li, CK; Pennell, DJ; Porter, JB; Roubert, B; Smith, G; Taher, A; Viprakasit, V | 2 |
| Cançado, RD; Chiattone, CS; Guerra-Shinohara, EM; Krieger, JE; Pereira, AC; Santos, PC | 1 |
| Chang, HH; Chang, TT; Chiou, SS; Jou, ST; Liao, YM; Lin, DT; Lin, KH; Lin, PC; Lu, MY; Yang, YL | 1 |
| Porter, JB; Shah, FT | 1 |
| Cheng, CH; Lo, FS; Wei, HY; Yang, CP | 1 |
| Eldem, G; Gumruk, F; Hazirolan, T; Unal, S | 1 |
| Buchbinder, D; Hsieh, L; Nugent, D; Puthenveetil, G; Soni, A; Stites, J; Vu, D | 1 |
| Chen, BA; Gao, C; Wang, T | 1 |
| Abdin, IA; Ebeid, FS; El Safy, UR; Elalfy, MS; Ibrahim, AS; Salem, DS | 1 |
| Crichton, RR; Della Corte, L; Dexter, DT; Freinbichler, W; Statton, SA; Tipton, KF; Ward, RJ; Weinberger, P; Whitmore, C | 1 |
| Bianchino, G; Bochicchio, GB; D'Auria, F; Grieco, V; Guariglia, R; Lerose, R; Mansueto, G; Martorelli, MC; Musto, P; Pietrantuono, G; Villani, O | 1 |
| Drosou, M; Servos, P; Vini, D | 1 |
| Brittenham, GM | 1 |
| Balooch, FD; Golbafan, MR; Iranmanesh, M; Jamilaldin Fatemi, S; Saljooghi, AS | 1 |
| Rempe, DA; Zhao, Y | 1 |
| Chandra, J; Chaudhary, H; Dutta, AK; Pemde, H; Singh, V | 1 |
| Melpignano, A; Quarta, A; Quarta, G | 1 |
| Cinque, P; Costantini, S; Di Matola, T; Prossomariti, L; Ricchi, P; Spasiano, A | 1 |
| Fallgatter, KC; Griffith, EA; Matteucci, MJ; Tanen, DA; Tantama, SS | 1 |
| Mullié, C; Sonnet, P | 1 |
| Bechtel, H; Kashtan, CE; Neglia, JP; Rheault, MN | 1 |
| Bekiari, E; Chatzinikolaou, K; Klonizakis, F; Tsapas, A; Vlachaki, E | 1 |
| Berdoukas, V; Coates, T; Farmaki, K; Wood, JC | 1 |
| Chao, NJ; Kanda, J; Kawabata, H | 1 |
| Fibach, E; Ganz, T; Ghoti, H; Gordana, O; Rachmilewitz, EA; Westerman, M | 1 |
| Aihara, Y; Fukui, H; Ikenaka, Y; Kaji, K; Kawaratani, H; Kitade, M; Namisaki, T; Noguchi, R; Shirai, Y; Tsujimoto, T; Yanase, K; Yoshii, J; Yoshiji, H | 1 |
| Bowden, DK; Chan, LL; Chiu, CF; Domokos, G; Ha, SY; Habr, D; Ho, PJ; Ibrahim, H; Li, CK; Lin, KH; Roubert, B; Sutcharitchan, P; Viprakasit, V; Xue, HL | 1 |
| López-Hernandez, FJ; López-Novoa, JM; Macías-Nuñez, JF; Morales, AI; Sánchez-González, PD | 1 |
| Patel, P; Rondelli, D; Sweiss, K | 1 |
| Coates, T; Giardina, PJ; Haines, D; Kwiatkowski, J; Mednick, L; Neufeld, EJ; Olivieri, N; Pakbaz, Z; Porter, J; Sobota, A; Thompson, AA; Trachtenberg, F; Vichinsky, E; Yamashita, R | 1 |
| Abu-Taleb, A; Alawadi, AH; Garadah, TS; Kassab, S; Mahdi, N; Shoroqi, I | 1 |
| Al-Rousan, RM; Blough, ER; Katta, A; Laurino, J; Rice, KM; Triest, WE; Walker, EM; Wu, M | 1 |
| Bernaudin, F; Coates, T; Deng, W; Forni, GL; Gardner, R; Giannone, V; Griffel, L; Hassell, K; Heeney, MM; Inusa, B; Kutlar, A; Lane, P; Mathias, L; Porter, J; Tebbi, C; Vichinsky, E; Wilson, F | 1 |
| Corral, M; Duh, MS; Guo, A; Jordan, LB; Sengupta, A; Vekeman, F | 1 |
| Christoulas, D; Terpos, E; Voskaridou, E | 1 |
| Fujita, Y; Fukushima, T; Hirose, Y; Iwao, H; Kawabata, H; Masaki, Y; Miki, M; Nakajima, A; Nakamura, T; Sakai, T; Sawaki, T; Tanaka, M; Umehara, H | 1 |
| Chaiyakunapruk, N; Luangasanatip, N; Upakdee, N; Wong, P | 1 |
| Agaoglu, L; Aydinok, Y; Bejaoui, M; Canatan, D; Cappellini, MD; Capra, M; Clark, J; Cohen, A; Dong, V; Drelichman, G; Economou, M; Fattoum, S; Griffel, L; Kattamis, A; Kilinc, Y; Perrotta, S; Piga, A; Porter, JB | 1 |
| Cho, EJ; Chueh, HW; Kim, JY; Koo, HH; Lee, SH; Sung, KW; Yoo, KH | 1 |
| Beris, P; Domokos, G; Forni, GL; Habr, D; Lin, KH; Porter, JB; Roubert, B; Taher, A; Thein, SL | 1 |
| Gregor, M; Nagler, M; Wuillemin, WA | 1 |
| Al Jefri, A; Al Zir, K; Daar, S; El-Beshlawy, A; Elalfy, MS; Habr, D; Kriemler-Krahn, U; Roubert, B; Taher, A | 1 |
| Al Jefri, A; Al Zir, K; Daar, S; El-Ali, A; El-Beshlawy, A; Elalfy, MS; Habr, D; Kriemler-Krahn, U; Roubert, B; Taher, A | 1 |
| Abbate, G; Anastasi, S; Caruso, V; De Sanctis, V; Giovannini, M; Lisi, R | 1 |
| Barbui, A; Busca, A; De Rosa, FG; Falda, M; Limerutti, G; Locatelli, F | 1 |
| Almeida, A; Angelucci, E; Beris, P; Guerci-Bresler, A; Hofmann, WK; Macwhannell, A; Muus, P; Nolte, F; Porter, J; Schumann, C; Selleslag, D; Sliwa, T; Xicoy, B | 1 |
| Brissot, P; Cappellini, MD; Deugnier, Y; Giannone, V; Griffel, L; Porter, JB; Ropert, M; Turlin, B; Zhang, Y | 1 |
| Chen, GF; Chen, JJ; Gao, HY; Li, CG; Li, Q | 1 |
| Hoffman, RS; Howland, MA; Jang, DH; Parikh, A | 1 |
| Aloj, G; Bonifazi, F; Cappellini, MD; Cassarà, F; Ceci, A; Cianciulli, P; Filosa, A; Fucharoen, S; Gluud, C; Grady, RW; Harmatz, P; Iacono, A; Kattamis, A; Maggio, A; Porter, JB; Prossomariti, L; Vitrano, A; Wood, J | 1 |
| Ariizumi, H; Hattori, A; Hayashi, H; Maeda, T; Nakamaki, T; Nakashima, H; Saito, B; Suzuki, K; Tatsumi, Y; Tomoyasu, S; Yanagisawa, K | 1 |
| Adams, PC | 1 |
| Fujiya, M; Ikuta, K; Ito, S; Kohgo, Y; Sasaki, K; Tanaka, H; Torimoto, Y | 1 |
| Musallam, KM; Taher, AT | 1 |
| Brass, EP; Chin-Hong, PV; Fredricks, D; Ibrahim, AS; Kontoyiannis, DP; Morris, MI; Perfect, JR; Spellberg, B | 2 |
| Belini Junior, E; Bonini-Domingos, CR; Cancado, RD; Chiattone, C; da Silva, DG; de Almeida, EA; Torres, Lde S | 1 |
| Choi, CW; Kang, HN; Kang, MH; Kim, JL; Kim, JS; Yoo, YA | 1 |
| Bowden, DK; Doery, JC; Fuller, PJ; Johnstone, L; Kerr, PG; Milat, F; Strauss, BJ; Wong, P | 1 |
| Ahmed, J; Jankharia, B; Krishnan, P; Merchant, R | 1 |
| El-Beshlawy, A; Evangeli, M; Porter, JB | 1 |
| Al-awar, R; Alizadeh, S; Aman, A; Attisano, L; Bao, RY; Chau, A; Christova, T; Gronda, M; Hogge, DE; Hurren, R; Isaac, M; Jitkova, Y; Joseph, B; Kasper, J; Miller, BW; Perusini, S; Schimmer, AD; Song, S; Subramaniam, R; Weir, SJ; Wrana, JL | 1 |
| Blumenstengel, K; Gattermann, N; Germing, U; Goebeler, M; Groschek, M; Jarisch, A; Junkes, A; Leismann, O; Losem, C; Procaccianti, M; Schlag, R | 1 |
| Cho, B; Chung, NG; Jang, PS; Jeong, DC; Kim, HK; Lee, JW | 1 |
| Saljooghi, AS | 1 |
| Bahcebasi, S; Cetin, M; Deniz, K; Eser, B; Kaynar, L; Kurnaz, F; Ozturk, A; Pala, C; Sivgin, S; Unal, A; Uzer, E | 1 |
| Imran, FS; Phatak, P | 1 |
| Kohli, S; Saxena, R; Verma, IC | 1 |
| Berard, F; Martin, O; Nicolas, JF; Rozieres, A; Said, BB | 1 |
| Alvarez, O; Cohen, AR; Garro, J; Kwiatkowski, JL; Lane, P; Mortier, N; Mueller, B; Nagasubramanian, R; Sarnaik, S; Schultz, W; Thompson, A; Ware, RE; Woods, GM; Yovetich, N | 1 |
| Balooch, FD; Fatemi, SJ; Golbafan, MR; Iranmanesh, M; Saljooghi, AS | 1 |
| Abdollahi, M; Ahmadi, A; Hadjibabaie, M; Hamishehkar, H; Kebriaeezadeh, A; Mojtahedzadeh, M; Mousavi, S; Najafi, A; Pazouki, M; Ziaee, S | 1 |
| Gupta, N; Rodrigues, C; Shetty, A; Soman, R | 1 |
| Campus, S; Galanello, R; Origa, R | 1 |
| Donnelly, JP; Lahav, M | 1 |
| Bansal, D; Marwaha, RK; Panigrahi, I; Vaidya, PC | 1 |
| Ibrahim, A; Kontoyiannis, DP; Lewis, RE; Lortholary, O; Petrikkos, G; Roilides, E; Spellberg, B; Walsh, TJ | 1 |
| Pankaew, T; Torcharus, K | 1 |
| Agarwal, A; Chandra Joshi, S; Mathela, CS; Rao, RD; Sridhar, I; Thomas, S; Vir, D; Xavier, CM | 1 |
| Miyazaki, Y | 1 |
| Kato, J; Matsuki, E; Matsumoto, K; Nakaya, A; Okamoto, S; Yamane, A | 1 |
| Fernandes, JL | 1 |
| Della Porta, M; Fenaux, P; Finelli, C; Gattermann, N; Guerci-Bresler, A; Habr, D; Marcellari, A; Rose, C; Roubert, B; Schmid, M; Stadler, M; Taylor, K; Vassilieff, D | 1 |
| Panderi, I; Pligoropoulou, H; Vonaparti, A | 1 |
| De Francia, S; Di Carlo, F; Massano, D; Piccione, FM; Piga, A; Pirro, E; Racca, S | 1 |
| Bae, SJ; Chueh, HW; Kang, C; Koo, HH; Lee, SH; Son, MH; Sung, KW; Yoo, KH | 1 |
| Karakukcu, C; Karakukcu, M; Ozdemir, MA; Patiroglu, T; Tang, PH; Torun, YA; Unal, E | 1 |
| Bhatia, R; Forman, S; Li, L; Lin, A; Meng, Z; Pullarkat, V; Sehgal, A | 1 |
| Azik, FM; Culha, V; Kara, A; Karakurt, N; Ozkasap, S; Tavil, B; Tunç, B; Yarali, N | 1 |
| Hayashi, H; Maeda, H; Naoe, T; Ohashi, H; Saito, H; Tomita, A | 1 |
| Cochat, P; Dubourg, L; Hadj-Aïssa, A; Laurain, C; Pondarré, C; Ranchin, B; Sigaudo-Roussel, D | 1 |
| Araki, H; Hara, T; Moriwaki, H; Oyama, M; Tsurumi, H; Yoshikawa, T | 1 |
| Baer, MR; Besa, E; Esposito, J; Feigert, J; List, AF; Martinez-Lopez, N; Paley, C; Raza, A; Steensma, DP | 1 |
| Chen, YM; Huang, CC; Kuo, CC; Tsai, CW; Yang, FJ | 1 |
| Aaseth, J; Andersen, O; Flaten, TP; Kontoghiorghes, GJ | 1 |
| Gaur, A | 1 |
| Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A | 1 |
| Brevi, F; Cappellini, MD; Cassinerio, E; Graziadei, G; Milazzo, A; Pattoneri, P; Pedrotti, P; Roghi, A; Zanaboni, L | 1 |
| Asghari, I; Esmaeilzadeh, F | 1 |
| Cappellini, MD; Chuncharunee, S; Galanello, R; Habr, D; Karakas, Z; Kattamis, A; Lawniczek, T; Porter, J; Ros, J; Siritanaratkul, N; Sutcharitchan, P; Taher, AT; Viprakasit, V; Zhang, Y | 1 |
| Fibach, E; Rachmilewitz, EA | 1 |
| Arnold, L; Kurtin, SE; Lindroos-Kolqvist, P; Shah, J; Tinsley, S | 1 |
| Brown, GC; Patton, WN; St Pierre, TG; Tapp, HE; Taylor, DJ | 1 |
| Hayashi, T; Iyama, S; Kaneko, Y; Kato, J; Kawano, Y; Kikuchi, S; Kobune, M; Miyanishi, K; Murase, K; Ono, K; Sato, T; Sato, Y; Takada, K; Takimoto, R | 1 |
| Brewer, C; Lykkesfeldt, J; Nick, H; Otto-Duessel, M; Wood, JC | 1 |
| Bruniera, P; Cancado, R; Chiattone, C; de Moraes Bastos, R; Olivato, MC; Rezende Melo, M; Szarf, G | 1 |
| Marks, PW | 1 |
| Dessi, C; Galanello, R; Giardina, PJ; Grady, RW; Kleinert, DA; Randolph, RE | 1 |
| Bhandari, S; Daar, S | 1 |
| Ashe-Randolph, M; Nezafati, KA; Pandya, AG; Yalamanchili, R | 1 |
| Cappellini, MD; Hoffbrand, AV; Taher, A | 1 |
| Agapidou, A; Economou, M; Efthimia, V; Neokleous, N; Perifanis, V; Teli, A; Vetsiou, E | 1 |
| Armstrong, EP; Ballas, SK; Sasane, M; Skrepnek, GH; Snodgrass, SM | 1 |
| Dreyling, M; Granot, G; Levi, I; Mor-Tzuntz, R; Nathan, I; Shpilberg, O; Vazana-Barad, L | 1 |
| Chandiwana, D; Karnon, J; Tolley, K; Vieira, J | 1 |
| Ajjala, DR; Aleti, R; Kandikere, V; Nirogi, R; Srikakolapu, S; Vurimindi, H | 1 |
| Baier, M; Gattermann, N; Giagounidis, A; Haase, D; Höchsmann, B; Hofmann, WK; Junkes, A; Leismann, O; Lübbert, M; Lück, A; Nolte, F; Platzbecker, U; Schrezenmeier, H; Schumann, C; Taupitz, M | 1 |
| Ford, SJ; Jansson, PJ; Kalinowski, DS; Kovacevic, Z; Lovejoy, DB; Lui, GY; Obeidy, P; Richardson, DR; Sharp, DM; Tselepis, C | 1 |
| Aydinok, Y; Chan, LL; El-Beshlawy, A; Elalfy, MS; Habr, D; Lee, SH; Martin, N; Porter, JB; Sutcharitchan, P; Taher, AT | 1 |
| Alderson, D; Bedford, M; Chadwick, C; Ford, SJ; Iqbal, TH; Jansson, PJ; Kalinowski, DS; Lovejoy, DB; Lui, GY; Nichols, L; Obeidy, P; Richardson, DR; Tselepis, C; Tucker, O | 1 |
| Maekawa, T; Yoshioka, S | 1 |
| Evans, P; Harmatz, P; Kurio, G; Lal, A; Neumayr, L; Ng, V; Porter, J; Sweeters, N; Vichinsky, E | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Yahng, SA | 1 |
| Aylak, F; Canatan, D; Erdoğan, E; Ormeci, AR; Vural, H | 1 |
| Azarkeivan, A; Bordbar, MR; Cohan, N; Haghpanah, S; Karimi, M; Zareifar, S | 1 |
| Ruivard, M | 1 |
| Bekiari, E; Mainou, M; Tsapas, A; Vetsiou, E; Vlachaki, E | 1 |
| Javanbakht, M; Karimi, M; Keshtkaran, A; Mashayekhi, A; Nuri, B; Salavati, S | 1 |
| Balocco, M; Forni, GL; Frassoni, F; Musallam, KM; Musso, M; Piaggio, G; Podestà, M; Pozzi, S; Rosa, A | 1 |
| Wu, LJ; Xie, XM; Xu, ZH; Yu, DJ; Zhao, TL | 1 |
| Braulke, F; Haase, D; Hartmann, J; Konietschke, F; Maas, JH; Sinzig, U; Wulf, G | 1 |
| Brookes, MJ; Keeler, BD | 1 |
| Kurtoglu, E; Uygun, V | 1 |
| Kim, C; Kim, SW; Lee, HS; Lee, JY; Moon, JH | 1 |
| Alves, SH; Fighera, RA; Flores, MM; Pilotto, MB; Santurio, JM; Weiblen, C; Wolkmer, P; Zanette, RA | 1 |
| Batty, KT; Ferrari, P; Maker, GL; Olynyk, JK; Siva, B; Trengove, RD | 1 |
| Al Rawas, A; Bashir, W; Pathare, A; Tony, S; Wali, Y; Zachariah, M | 1 |
| Codd, R; Crouch, PJ; Ganio, G; Liddell, JR; Liu, J; Mok, SS; Obando, D; Volitakis, I; White, AR | 1 |
| Cho, B; Chung, NG; Jang, PS; Jeong, DC; Kim, HK; Lee, DH | 1 |
| Alimena, G; Breccia, M | 1 |
| Campos, VF; Cruz, LR; Danilow, MZ; dos Santos, VM; Paixão, GT; Ribeiro, EF | 1 |
| Kami, M; Kobayashi, K; Nishikawa, Y; Okuda, S; Takebayashi, C; Tanimoto, T | 1 |
| Cid, J; Díaz, M; Palomera, L; Solano, F; Zamora, C | 1 |
| Chang, HH; Chung, KP; Ho, WL; Jou, ST; Lin, DT; Lin, KH; Lu, MY; Yang, SS; Yang, YL | 1 |
| Ihling, C; Tesch, H | 1 |
| Cappellini, MD; Chuncharunee, S; Galanello, R; Habr, D; Karakas, Z; Kattamis, A; Lawniczek, T; Porter, JB; Ros, J; Siritanaratkul, N; Sutcharitchan, P; Taher, AT; Viprakasit, V; Zhang, Y | 1 |
| Pongtanakul, B; Viprakasit, V | 1 |
| El-Ali, A; Ganser, A; Habr, D; Hsu, HC; Lee, JW; Martin, N; Porter, JB; Shen, ZX; Yoon, SS | 1 |
| Butler, J; Curley, C; Durrant, S; Kennedy, GA; Morris, KL; Subramonpillai, E | 1 |
| Cappellini, MD; Caruso, V; Chiavilli, F; Commendatore, F; Forni, GL; Galanello, R; Longo, F; Mulas, S; Musallam, KM; Piga, A; Quarta, G | 1 |
| Chirnomas, D; Esposito, J; Giardina, PJ; Goldberg, SL; Paley, C; Vichinsky, E | 1 |
| Adamaki, M; Athanasiadou, A; Ktena, YP; Lambrou, G; Moschovi, M | 1 |
| Dahooee Balooch, F; Ebrahimpour, R; Fatemi, SJ; Iranmanesh, M | 1 |
| Laws, JL; McTigue, DM; Sauerbeck, A; Schonberg, DL | 1 |
| Ahmad, N; Ahmed, J; Jankharia, B; Krishnan, P; Merchant, RH | 1 |
| Brittenham, GM; Olivieri, NF | 1 |
| Ahn, HS; Choi, JY; Jang, MK; Kang, HJ; Kim, H; Kim, NH; Lee, JW; Lee, SS; Park, JD; Park, KD; Shin, HY; Shin, JG; Yeo, CW | 1 |
| Bedford, MR; Ford, SJ; Horniblow, RD; Iqbal, TH; Tselepis, C | 1 |
| Amanlou, M; Arabzadeh, AJ; Ardestani, MS; Delbaz, SA; Ebrahimi, SE; Javidi, A; Mahian, H; Rad, AM | 1 |
| Cappellini, MD; Chuncharunee, S; Galanello, R; Habr, D; Karakas, Z; Kattamis, A; Lawniczek, T; Porter, JB; Ros, J; Siritanaratkul, N; Sutcharitchan, P; Taher, AT; Viprakasit, V; Zhu, Z | 1 |
| Guinea de Castro, JM; Moreno de Gusmão, B; Oiartzabal, I; Perez-Persona, E | 1 |
| Ammirabile, M; Casale, M; Cinque, P; Costantini, S; Di Matola, T; Filosa, A; Prossomariti, L; Ricchi, P; Spasiano, A | 1 |
| Aburakawa, Y; Kimura, T; Kono, S; Kuroda, K; Miyajima, H; Suzuki, Y; Terada, T; Yahara, O; Yoshida, K | 1 |
| Al Jefri, A; Al Zir, K; Daar, S; El-Beshlawy, A; Elalfy, M; Habr, D; Kriemler-Krahn, U; St Pierre, TG; Taher, A | 1 |
| Akianidis, V; Christoulas, D; Karavas, A; Komninaka, V; Terpos, E; Voskaridou, E | 1 |
| Alkhaeir, S; Callens, C; Damaj, G; Dussiot, M; Gorin, NC; Hermine, O; Isnard, F; Marolleau, JP; Monteiro, RC; Moura, IC; Paubelle, E; Rubio, MT; Suarez, F; Zylbersztejn, F | 1 |
| Balooch, FD; Fatemi, SJ; Golbafan, MR; Iranmanesh, M | 1 |
| Alvarez, O; Aygun, B; Bonner, M; Flanagan, J; Lockhart, A; Miller, ST; Mueller, BU; Owen, W; Schultz, W; Scott, JP; Ware, RE; Yovetich, NA | 1 |
| Walia, HS; Yan, J | 1 |
| Akyol, G; Baldane, S; Cetin, M; Eser, B; Kaynar, L; Keklik, M; Kurnaz, F; Pala, C; Sivgin, S; Unal, A; Zararsiz, G | 1 |
| Riva, A | 1 |
| Belohlavkova, P; Cermak, J; Cervinek, L; Jonasova, A; Neuwirtova, R; Vondrakova, J | 1 |
| Barrette, S; Files, B; Habr, D; Minniti, CP; Torres, M; Vichinsky, E; Zhang, Y | 1 |
| Cuzzola, M; Gentile, M; Morabito, F; Morabito, L; Recchia, AG; Vigna, E | 1 |
| Brunskill, SJ; Chowdhury, O; Doree, C; Fisher, SA; Gooding, S; Roberts, DJ | 1 |
| Bianchetti, MG; Brazzola, P; Dell'Orto, VG | 1 |
| Babaie, M; Mendi, FD; Saljooghi, AS; Saljooghi, ZS; Zahmati, M | 1 |
| Chew, SH; Misawa, N; Nagai, H; Okazaki, Y; Toyokuni, S; Yasui, H | 1 |
| Bina, P; Cossa, S; Danjou, F; Defraia, E; Dessì, C; Foschini, ML; Galanello, R; Leoni, G; Matta, G; Morittu, M; Origa, R | 1 |
| Amini, M; Atyabi, F; Dinarvand, R; Kamalinia, G; Khodagholi, F; Shaerzadeh, F; Sharifzadeh, M | 1 |
| Haghpanah, S; Karimi, M; Zahedi, Z; Zarei, T | 1 |
| Cappellini, MD; Taher, AT; Temraz, S | 1 |
| Katoh, N; Konishi, K; Nakai, N; Ohshita, A | 1 |
| Alizadeh, S; Bamedi, T; Dorgalaleh, A; Jahantigh, A; Naderi, M; Sadeghi-Bojd, S; Tabibian, S; Valeshabad, AK | 1 |
| Habr, D; Huang, SL; Lai, YR; Li, CF; Li, Q; Liu, RR; Martin, N; Shen, ZX | 1 |
| Ando, K; Kojima, M; Machida, S; Miyamoto, M; Moriuchi, M; Ohbayashi, Y; Sato, A | 1 |
| de Witte, T | 1 |
| Arvin, M; Dehghan, G; Jouyban, A; Shaghaghi, M; Sistani, P | 1 |
| Toyokuni, S | 1 |
| Chung, J; Jang, JH; Jo, DY; Kim, HJ; Lee, JH; Lee, JW; Yoon, SS | 1 |
| Bayer, A; French, SW; Gebremariam, T; Ibrahim, AS; Lee, H; Luo, G; Spellberg, B; Xiong, YQ | 1 |
| Abe, T; Fujii, S; Fujita, M; Iyama, S; Jomen, W; Kato, J; Kobune, M; Kuroda, H; Maeda, M; Matsuno, T; Miyanishi, K; Nagashima, K; Sakurai, T; Sato, M; Yamada, M | 1 |
| Balooch, FD; Fatemi, SJ; Iranmanesh, M | 1 |
| Cheong, JW; Chung, J; Hyun, MS; Jo, DY; Joo, YD; Jung, CW; Kim, BS; Kim, CS; Kim, HJ; Kim, HY; Lee, JH; Lee, KH; Min, YH; Park, CY; Park, HS; Seong, CM; Shim, H; Sohn, SK; Yoon, HJ; Yoon, SS | 1 |
| Bardou-Jacquet, E; Beaumont-Epinette, MP; Ben Ali, Z; Brissot, P; Jouanolle, AM; Loreal, O | 1 |
| Huang, L; Jiang, H; Xia, S; Zhang, W | 1 |
| Abdollah Gorji, F; Alavi, S; Arzanian, MT; Ebadi, M; Ghazizadeh, F; Shamsian, B | 1 |
| Aydinok, Y; Belhoul, KM; El-Beshlawy, A; Elalfy, M; Habr, D; Kilinç, Y; Lai, Y; Lawniczek, T; Pennell, DJ; Piga, A; Porter, JB; Weisskopf, M; Yesilipek, A; Zhang, Y | 1 |
| Giardini, C; Guiducci, B; Isidori, A; Loscocco, F; Ricciardi, T; Visani, G | 1 |
| Asli, MJ; Bardajee, GR; Dianatnejad, N; Hooshyar, Z; Shahidi, FE | 1 |
| Economou, M; Garypidou, V; Gombakis, N; Kargioti, A; Neokleous, N; Papachristou, F; Teli, A; Theodoridou, S; Vakalopoulou, S; Vlachaki, E; Vyzantiadis, TA | 1 |
| Cappellini, MD; Chuncharunee, S; Habr, D; Karakas, Z; Kattamis, A; Origa, R; Porter, JB; Siritanaratkul, N; Sutcharitchan, P; Taher, AT; Viprakasit, V; Zhu, Z | 2 |
| Tohyama, K | 1 |
| Alimena, G; Angelucci, E; Borin, L; Caocci, G; Cilloni, D; Di Tucci, AA; Fazi, P; Fenu, S; Finelli, C; Latte, G; Molteni, A; Piciocchi, A; Quaresmini, G; Quarta, G; Rivellini, F; Salvi, F; Sanpaolo, G; Santini, V; Storti, S; Tura, S; Vallisa, D; Vignetti, M; Volpe, A; Voso, MT | 1 |
| Abuhandan, M; Aycicek, A; Koc, A | 1 |
| Coates, TD | 1 |
| Merkel, DG; Nagler, A | 1 |
| Clissa, C; Finelli, C; Stanzani, M | 1 |
| Chan, MR; Elramah, M; Murphy, N; Vats, H; Zhong, W | 1 |
| Bedford, MR; Ford, SJ; Iqbal, T; Pang, W; Tselepis, C; Tucker, O; Wood, A | 1 |
| Cappellini, MD; Cassinerio, E; Duca, L; Fraquelli, M; Orofino, N; Poggiali, E; Roghi, A; Zanaboni, L | 1 |
| Hayakawa, F; Naoe, T; Tomita, A | 1 |
| Alam, MH; Carpenter, JP; Garbowski, MW; He, T; Pennell, DJ; Porter, JB; Roughton, M; Smith, G | 1 |
| Plosker, GL; Shirley, M | 1 |
| Brown, M; Niv, Y; Pazgal, I; Perets, TT; Rachmilewitz, E; Stark, P | 1 |
| Chou, HC; Hsiao, FY; Huang, WF; Tsai, YW | 1 |
| Cappellini, MD; Castiglioni, C; Longo, F; Origa, R; Piga, A; Pinna, F; Roggero, S; Zappu, A | 1 |
| Hikota, R; Horiuchi, T; Kato, S; Kimura, F; Kobayashi, A; Kobayashi, S; Maekawa, T; Osawa, Y; Sato, K; Watanabe, J; Yamamura, T | 1 |
| Chan, GC; Cheuk, DK; Chiang, AK; Dee, CM; Ha, SY | 1 |
| Franz, KJ; Hašková, P; Jansová, H; Jirkovská, A; Kielar, F; Macháček, M; Potůčková, E; Simůnek, T; Wang, Q | 1 |
| Tanaka, C | 1 |
| Batlle, M; Belloch, V; Duarte, R; Hernández, D; Jarque, I; Jiménez, M; Jiménez, S; López, J; Rovira, M; Sampol, A; Solano, C; Valcárcel, D; Vallejo, C; Vázquez, L | 1 |
| Bhatia, R; Donohue, C; Forman, SJ; Krishnan, A; Meng, Z; Pullarkat, V; Synold, TW; Tomassetti, S; Yamamoto, VN | 1 |
| Baer, J; Brewer, C; Garner, M; Stadler, CK; Tyszka, JM; Wood, JC | 1 |
| Díaz-García, JD; Gallegos-Villalobos, A; Gonzalez-Espinoza, L; Ortiz, A; Sanchez-Niño, MD; Villarrubia, J | 1 |
| Atipas, S; Kusuwan, T; Limviriyakul, S; Pooliam, J; Sangpraypan, T; Tanphaichitr, A; Tanphaichitr, VS; Viprakasit, V | 1 |
| Al-Momen, A; Aleem, A; Algahtani, F; Alsaleh, K; Iqbal, Z; Shakoor, Z | 1 |
| Forni, GL; Fucile, C; Marini, V; Martelli, A; Mattioli, F; Milano, G; Perrotta, S; Pinto, V; Puntoni, M; Robbiano, L | 1 |
| Grodde, T; Habeck, JO; Kirchhof, K; Lindner, U; Schleithoff, L; Schuppan, D; Stoelzel, U | 1 |
| A Bed, MA; Al Khawaldeh, OA; Al Tawarah, YM; Al-Kloub, MI; Froelicher, ES | 1 |
| Gadong, N; Hemmaway, C; Kaya, B; Newell, H; Simmons, A; Telfer, P; Tsouana, E; Whitmarsh, S | 1 |
| Alfonso, P; Andrade-Campos, M; Andreu, V; Gervas-Arruga, J; Giraldo, P; Irun, P; Medrano-Engay, B; Pocovi, M | 1 |
| Bridle, KR; Campbell, CM; Clouston, AD; Crawford, DH; de Guzman, CE; Jaskowski, L; Santrampurwala, N; Sobbe, A; Subramaniam, VN | 1 |
| Biesma, DH; Coeleveld, K; Lafeber, FP; Mastbergen, SC; Nieuwenhuizen, L; Roosendaal, G; Schutgens, RE | 1 |
| Albert, ND; Kontoyiannis, DP; Lewis, RE | 1 |
| Heath, JL; Lavau, CP; Wechsler, DS; Weiss, JM | 1 |
| Amendola, G; Casale, M; Cinque, P; Citarella, S; De Michele, E; Della Rocca, F; Filosa, A; Nobili, B; Palmieri, F; Perrotta, S; Pugliese, U; Ragozzino, A; Tartaglione, I | 1 |
| Chen, CH; Shu, KH; Yang, Y | 1 |
| Alimena, G; Angelucci, E; Borin, L; Cilloni, D; Cottone, F; Di Tucci, AA; Efficace, F; Fenu, S; Finelli, C; La Nasa, G; Mandelli, F; Molteni, A; Quaresmini, G; Quarta, G; Rivellini, F; Salvi, F; Sanpaolo, G; Santini, V; Volpe, A; Voso, MT | 1 |
| Banerjee, A; Bentley, M; Bird, R; Forsyth, C; Grigg, A; Grigoriadis, G; Kellner, S; Mifsud, NA; Motum, P; Opat, S; Szer, J; Tam, C | 1 |
| Aydinok, Y; El-Beshlawy, A; Elalfy, M; Habr, D; Kilinç, Y; Lai, YR; Musallam, KM; Pennell, DJ; Piga, A; Porter, JB; Shen, J; Yesilipek, A | 1 |
| Allegra, S; Cusato, J; D'Avolio, A; De Francia, S; Massano, D; Piga, A | 3 |
| Bassler, D; Fleeman, N; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G; Schell, LK | 1 |
| Bouillaud, E; Cappellini, MD; Forni, GL; Fracchia, S; Habr, D; Hirschberg, R; Lai, ME; Piga, A; Wegener, A | 1 |
| Aaseth, J; Andersen, O; Cao, Y; Skaug, MA | 1 |
| Alves, SH; Ferreiro, L; Jesus, FP; Pilotto, MB; Pötter, L; Santurio, JM; Weiblen, C; Zanette, RA | 1 |
| Cappellini, MD; Cassinerio, E; Consonni, D; Giuditta, M; Orofino, N; Pedrotti, P; Poggiali, E; Roghi, A; Zanaboni, L | 1 |
| Genc, GE; Gumuslu, S; Kupesiz, A; Kurtoglu, E; Ozturk, Z | 1 |
| Haghpanah, S; Karimi, M | 1 |
| Divsalar, A; Ghalandari, B; Harifi, AR; Moradi, M; Saboury, AA | 1 |
| Adly, AM; Elalfy, MS; Elhenawy, YI; Samir, A; Tony, S; Wali, Y | 1 |
| Ballas, SK; Cançado, R; Chiattone, C; de Moraes Bastos, R; Guerra-Shinohara, EM; Melo, MR; Santos, PC | 1 |
| Cappellini, MD; Chan, LL; El-Alfy, M; El-Ali, A; Giraudier, S; Han, J; Lai, Y; Porter, JB; Viprakasit, V | 1 |
| Dabholkar, BV; Havaldar, FH; Kulkarni, S; Mule, GB | 1 |
| Eguchi, A; Fujii, A; Hirotani, S; Iwasaku, T; Masuyama, T; Morisawa, D; Naito, Y; Oboshi, M; Okuhara, Y; Sawada, H | 1 |
| Arslan, M; Ila, HB | 1 |
| Alves, SH; Bitencourt, PE; Fighera, RA; Flores, MM; Kommers, GD; Kontoyiannis, DP; Ludwig, A; Moretto, MB; Santurio, JM; Silva, PS; Zanette, RA | 1 |
| Alimena, G; Aloe Spiriti, MA; Breccia, M; Buccisano, F; Fenu, S; Maurillo, L; Tafuri, A; Voso, MT | 1 |
| Gumruk, F; Piperno, A; Unal, S | 1 |
| Bae, SH; Chung, JS; Hyun, MS; Joo, YD; Kim, H; Kim, HG; Kim, IH; Kim, SH; Kim, YS; Kwon, KY; Lee, GW; Lee, HS; Lee, SM; Lee, WS; Lim, SN; Moon, JH; Park, KT; Ryoo, HM; Sohn, SK | 1 |
| Aloe Spiriti, MA; Breccia, M; Buccisano, F; Criscuolo, M; D'Addosio, A; Fenu, S; Fragasso, A; Latagliata, R; Maurillo, L; Musto, P; Niscola, P; Piccioni, AL; Refrigeri, M; Tatarelli, C; Trapè, G; Venditti, A; Voso, MT | 1 |
| Choi, SE; Han, SJ; Jung, IR; Jung, JG; Kang, Y; Kim, DJ; Kim, HJ; Lee, KW; Lee, SA | 1 |
| Arandi, N; Ashrafi, A; Eatemadfar, P; Haghpanah, S; Karimi, M; Radwan, AH; Safaei, S; Taher, AT; Zahedi, Z; Zarei, T | 1 |
| Hitomi, H; Ichihara, A; Kitada, K; Kobori, H; Morimoto, S; Morita, T; Nakano, D; Nishiyama, A; Shiojima, I | 1 |
| Attri, SV; Bansal, D; Bhatia, P; Marwaha, RK; Totadri, S; Trehan, A | 1 |
| Agriesti, F; Capitanio, N; D'Auria, F; Di Ianni, M; Falzetti, F; Laurenzana, I; Mazzoccoli, C; Musto, P; Piccoli, C; Ruggieri, V; Scrima, R; Tataranni, T | 1 |
| Aydinok, Y; Cappellini, MD; Constantinovici, N; El-Beshlawy, A; Elalfy, M; Habr, D; Karakas, Z; Kattamis, A; Kilinç, Y; Origa, R; Perrotta, S; Porter, JB; Shen, J; Viprakasit, V | 1 |
| Erman, A; Feige Gross Nevo, R; Gafter, U; Gafter-Gvili, A; Milo, G; Pazgal, I; Shpilberg, O; Stark, P | 1 |
| Abkowitz, JL; Egan, DN; Phillips, J; Yang, Z | 1 |
| Espósito, BP; Goswami, D; Machini, MT; Vitorino, HA | 1 |
| Bhathal, P; Doyle, A; Rusli, F | 1 |
| Amini, M; Atyabi, F; Chaharband, F; Dinarvand, R; Kamalinia, G; Khodagholi, F; Shaerzadeh, F; Sharifzadeh, M; Tavssolian, F | 1 |
| Chuang, GT; Lu, MY; Tsai, IJ; Tsau, YK | 1 |
| Garbowski, M; Porter, J; Vlachodimitropoulou Koumoutsea, E | 1 |
| Imanishi, S; Ohsuga, M; Ohyashiki, JH; Ohyashiki, K; Takahashi, R | 1 |
| Cohen, AR; Davis, BR; Heeney, MM; Kwiatkowski, JL; Lee, MT; Odame, I; Owen, WC; Pressel, S; Rogers, ZR; Schultz, WH; St Pierre, T; Ware, RE; Wood, JC | 1 |
| Chiang, PH; Kuo, PH; Lai, CW; Lin, KH; Lu, MY; Wang, N; Wu, TH; Wu, WH | 1 |
| Ansari, S; Arandi, N; Azarkeyvan, A; Bordbar, M; Haghpanah, S; Karimi, M; Safaei, S | 1 |
| Agaoglu, L; Glaser, S; Kilinç, Y; Kohgo, Y; Lim, LC; Miyamura, K; Urabe, A; Wang, C; Warzocha, K; Wiktor-Jedrzejczak, W | 1 |
| Alta, RY; Espósito, BP; Goswami, D; Machini, MT; Nomura, CS; Silvestre, DM; Vitorino, HA | 1 |
| Agapidou, A; Boura, P; Klonizakis, P; Mavroudi, M; Spanos, G; Vetsiou, E; Vlachaki, E | 1 |
| Genc, GE; Gumuslu, S; Kupesiz, A; Ozturk, Z | 1 |
| Hagag, AA; Hamam, MA; Hazaa, SM; Taha, OA | 1 |
| Adil, SN; Shaikh, MS | 1 |
| Chen, V; Clemons, KV; Cohen, K; Ferreira, JA; Haagensen, JA; Hsu, JL; Martinez, M; Nazik, H; Penner, JC; Spormann, AM; Stevens, DA | 1 |
| Baer, MR; Davidoff, AJ; Friedmann, E; Gore, SD; Hendrick, F; Paley, C; Sasane, M; Zeidan, AM | 1 |
| Alimena, G; Andriani, A; Bagnato, A; Breccia, M; Cedrone, M; Ciccone, F; De Muro, M; Di Veroli, A; Latagliata, R; Leonetti, SC; Maurillo, L; Montagna, C; Montanaro, M; Montefusco, E; Niscola, P; Porrini, R; Rago, A; Spadea, A; Spirito, F | 1 |
| Angelucci, E; Breccia, M; Gattermann, N; Hofmann, WK; Nolte, F; Santini, V; Vey, N | 1 |
| Al-Ali, HK; Albrecht, S; Altamura, S; Bug, G; de Haas, K; Hubert, K; Jaekel, N; Kröger, N; Leismann, O; Lieder, K; Muckenthaler, MU; Niederwieser, D; Platzbecker, U; Stadler, M | 1 |
| Bottaro, G; Clementi, E; Deodato, F; Dionisi-Vici, C; Falvella, FS; Goffredo, B; Marano, M; Marinaro, AM; Pisani, M; Stoppa, F | 1 |
| Chang, HH; Jou, ST; Lin, DT; Lin, KH; Lu, MY; Peng, SS; Yang, YL | 1 |
| D'Ascola, DG; Fragomeno, C; Roccabruna, E | 1 |
| Anand, S; Banerjee, P; Bir, A; Chakrabarti, S; Sahoo, A | 1 |
| El Rassi, F; Saliba, AN; Taher, AT | 1 |
| Aygener, N; Eyigor, H; Kurtoglu, E; Osma, U; Yilmaz, MD | 1 |
| Marsella, M; Ricchi, P | 1 |
| Escudero-Vilaplana, V; Garcia-Gonzalez, X; Osorio-Prendes, S; Romero-Jimenez, RM; Sanjurjo-Saez, M | 1 |
| Bowden, DK; Doery, JC; Fuller, PJ; Gillespie, MT; Kerr, PG; Larmour, I; Milat, F; Polkinghorne, K; Wong, P | 1 |
| Jeong, YA; Joung, SY; Kang, S; Kim, BR; Kim, JL; Lee, DH; Lee, SI; Lee, SY; Min, BW; Na, YJ; Oh, SC | 1 |
| Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kumfu, S | 1 |
| Avril, S; Garcion, E; Guillet, C; Legendre, C | 1 |
| Aydinok, Y; Cappellini, MD; Joaquin, V; Karakas, Z; Kattamis, A; Lai, YR; Porter, JB; Siritanaratkul, N; Taher, AT; Uwamahoro, MJ; Viprakasit, V; Wang, C; Zhu, Z | 1 |
| Agapidou, A; Diamantidis, MD; Fotiou, P; Manafas, A; Neokleous, N; Vetsiou, E; Vlachaki, E | 1 |
| Choi, CW; Kang, MH; Kim, DS; Na, YJ; Yoon, SY | 1 |
| Chang, H; Hu, D; Hu, L; Huang, J; Liu, F; Nie, N; Quan, R; Shao, Y; Shi, J; Tang, X; Xiao, H; Zhang, F; Zhang, J; Zhang, L; Zheng, C; Zheng, Y; Zhou, Y | 1 |
| Kontoghiorghe, CN; Kontoghiorghes, GJ | 1 |
| Al Durdunji, A; Al-Ghazawi, M; AlKhatib, HS | 1 |
| Corpino, M; Dessì, C; Foschini, ML; Leoni, G; Moi, P; Morittu, M; Origa, R; Zappu, A | 1 |
| Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V | 1 |
| Choi, JH; Kim, JS; Lee, YY; Park, BB; Uhm, J; Won, YW | 1 |
| Angelucci, E; Pilo, F | 1 |
| Gomber, S; Jain, P; Narang, M; Sharma, S | 1 |
| Abolhasani, J; Hassanzadeh, J; Naderali, R | 1 |
| Arora, S; Athale, UH; Bhatt, MD; Kirby-Allen, M; Papneja, K; Wiernikowski, JT | 1 |
| Salehi, S; Saljooghi, ASh; Shiri, A | 1 |
| Allegra, S; Cusato, J; D'Avolio, A; De Francia, S; Massano, D; Piga, A; Pirro, E | 2 |
| Giagounidis, A; Groepper, S; Haferlach, C; Schlue, J | 1 |
| Izadyar, M; Salehi, S; Saljooghi, AS | 1 |
| Hashimoto, M; Imoto, S; Iwamoto, S; Kawano, S; Kono, M; Minami, Y; Saigo, K; Shirai, K; Takahashi, T; Takenokuchi, M; Uematsu, T; Wada, A; Yamamoto, S | 1 |
| Beydoun, HG; Saliba, AN; Taher, AT | 1 |
| Chattipakorn, N; Chattipakorn, SC; Krintratun, W; Sripetchwandee, J; Wongjaikam, S | 1 |
| Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Khamseekaew, J; Kumfu, S; Srichairatanakool, S; Sripetchwandee, J; Wongjaikam, S | 1 |
| Arnon, R; Chu, J; Ramaswami, A; Rosen, DJ; Wistinghausen, B | 1 |
| Bruch, HR; Dencausse, Y; Heßling, J; Michl, G; Schlag, R; Schneider-Schranz, C; Schulte, C; Skorupa, A; Tesch, H; Wolf, S | 1 |
| Fujiwara, T; Nishitani, S; Noma, K; Ohara, T; Shirakawa, Y; Tazawa, H; Tomono, Y; Watanabe, S | 1 |
| Badcock, CA; Bowden, DK; Brown, G; Gervasio, OL; Grigg, A; Ho, PJ; Marlton, P; St Pierre, T; Tay, L; Teo, J; Traficante, R | 1 |
| Avazpour, A; Badie, A; Haghpanah, S; Karimi, M; Toosi, F | 1 |
| Abbas, HA; Cappellini, MD; Inati, A; Kahale, M; Koussa, S; Musallam, KM; Nasr, TA; Porter, JB; Sbeiti, N; Taher, AT | 1 |
| Fujisawa, K; Harima, H; Kaino, S; Matsumoto, T; Sakaida, I; Shinoda, S; Takami, T; Yamamoto, N; Yamasaki, T | 1 |
| Arihara, Y; Hayasaka, N; Iyama, S; Kamihara, Y; Kato, J; Kawano, Y; Kikuchi, S; Kobune, M; Miyanishi, K; Murase, K; Sato, T; Sato, Y; Takada, K; Usami, M | 1 |
| Deghedy, MR; Ebeid, WM; El-Shazly, AA; Elkitkat, RS | 1 |
| Chiou, SS; Hsieh, KP; Kou, HS; Lin, HJ; Wu, SM | 1 |
| Arboscello, E; Biale, L; Del Corso, L; Filiberti, R; Parodi, EL; Russo, R | 1 |
| Barnes, SL; Bowden, D; Charles, S; Davies, D; Davies, GI | 1 |
| Bayhan, T; Gümrük, F; Karabulut, E; Küçüker, H; Tutal, AD; Ünal, Ş; Ünlü, O | 1 |
| Fujisawa, K; Hidaka, I; Ishikawa, T; Iwamoto, T; Maeda, M; Matsumoto, T; Saeki, I; Sakaida, I; Takami, T; Tani, K; Uchida, K; Yamamoto, N; Yamasaki, T | 1 |
| Chuansumrit, A; Kadegasem, P; Khlairit, P; Mahachoklertwattana, P; Pengpis, P; Poomthavorn, P; Sirachainan, N; Sungkarat, W; Wongwerawattanakoon, P | 1 |
| Aydinok, Y; El-Ali, A; El-Beshlawy, A; Elalfy, M; Han, J; Lee, SH; Porter, JB; Sutcharitchan, P; Taher, A | 1 |
| Allegra, S; Arduino, A; Cusato, J; D'Avolio, A; De Francia, S; Longo, F; Massano, D; Piga, A; Pirro, E | 1 |
| Atilla, E; Demirer, T; Toprak, SK | 1 |
| Bell, S; Calder, GL; Lee, MH; MacIsaac, RJ; Sachithanandan, N; Zeimer, H | 1 |
| Carrasco, S; Egido, J; Fontecha-Barriuso, M; Gallegos-Villalobos, A; Lopez-Hernandez, FJ; Martin-Sanchez, D; Ortiz, A; Ruiz-Ortega, M; Sanchez-Niño, MD; Sanz, AB | 1 |
| Chang, YC; Cheng, HC; Feng, CC; Huang, YT; Lin, CL; Lin, HT; Lo, WJ; Yeh, SP | 1 |
| Chiang, PH; Kuo, PH; Lin, KH; Lin, TH; Lu, MY; Wang, N; Wu, TH; Wu, WH | 1 |
| Cortoos, A; Goh, AS; Huang, V; Kattamis, A; Kourakli, A; Merino Herranz, R; Origa, R; Perrotta, S; Porter, JB; Ruffo, GB; Taher, AT; Weill, M | 1 |
| Bentley, A; Caruso, V; Cuccia, L; D'Ascola, DG; Filosa, A; Frizziero, L; Hanif, A; Meloni, A; Pepe, A; Putti, MC; Rossi, G; Spasiano, A | 1 |
| Chandra, J; Dhingra, B; Jain, R; Mahto, D; Parakh, N; Sharma, S | 1 |
| Halligan, K; Hickling, M; Menaker, N; Nepo, A; Paige, J; Shur, N; Weintraub, L | 1 |
| Cen, WJ; Jiang, JW; Ke, JY; Kong, WD; Li, YR; Zhou, XZ | 1 |
| Al Zoebie, A; Bruederle, A; Chotsampancharoen, T; El-Beshlawy, A; Elalfy, M; Gilotti, G; Han, J; Kamdem, A; Koussa, S; Vichinsky, E | 1 |
| Ambrogio, AG; Baldini, M; Cassinerio, E; Mancarella, M; Marcon, A; Motta, I | 1 |
| Bazargan, A; Chai, KL; Kostos, L; Tam, CS | 1 |
| Biliotti, E; Esvan, R; Franchi, C; Palazzo, D; Serani, M; Silvestri, AM; Sorrentino, F; Spaziante, M; Taliani, G; Volpicelli, L | 1 |
| Chen, Q; Gu, J; Li, N; Li, S; Wang, W; Wang, X; Wang, Z; Zhao, G | 1 |
| Angelucci, E; Balleari, E; Breccia, M; Clissa, C; Cortelezzi, A; Fenu, S; Finelli, C; Levis, A; Mansueto, G; Marziano, G; Maurillo, L; Milella, MR; Musto, P; Niscola, P; Poloni, A; Ricco, A; Rivellini, F; Sanna, A; Santini, V; Scapicchio, D; Simeon, V; Tarantini, G; Venditti, A; Villani, O; Voso, MT | 1 |
| Powell, JL; Shah, L; Zaritsky, JJ | 1 |
| Benjamín-Rivera, JA; Delgado, Y; Loza-Rosas, SA; Munet-Colón, C; Negrón, LJ; Parks, TB; Rivero, KI; Tinoco, AD; Vázquez-Maldonado, AL; Vázquez-Salgado, AM | 1 |
| Allert, R; Bassler, D; Bollig, C; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G; Schell, LK | 1 |
| Akay, C; Bayhan, T; Çırak, E; Eker, İ; Erdem, O; Gümrük, F; Gürsel, O; Karabulut, E; Ünal, Ş | 1 |
| Antonucci, R; Asara, MA; Caggiari, S; Capobianco, G; Dessole, S; Dore, F; Fozza, C; Monti, A; Vacca, N; Zaccheddu, F | 1 |
| Davies, M; Layton, D; Osborne, V; Shakir, SAW | 1 |
| Shen, JC; Zhang, YC; Zhao, MF | 1 |
| Allegra, S; Cusato, J; D'Avolio, A; De Francia, S; Longo, F; Massano, D; Piga, A; Pirro, E | 1 |
| Leitch, HA; Wong, SA | 1 |
| Gattermann, N | 1 |
| Belli, AA; Dere, Y; Karakus, V; Polat, AK | 1 |
| Kanamori, H; Kanda, J; Kanda, Y; Koyama, S; Machida, S; Miyazaki, T; Morita, S; Najima, Y; Okamoto, S; Saito, T; Tachibana, T; Takeuchi, M; Tanaka, M; Yamamoto, E | 1 |
| Cui, Z; Ding, L; Li, D; Li, T; Song, Q; Sun, L; Wang, Y; Yang, W | 1 |
| Aydogdu, S; Bayramoglu, Z; Dursun, M; Karagenc, AO; Karakas, Z; Karaman, S; Tugcu, D; Yilmaz, Y | 1 |
| Doery, JC; Kaplan, Z; Kerr, PG; Yii, E | 1 |
| Sivaramakrishnan, G; Sridharan, K | 1 |
| Doree, C; Estcourt, LJ; Fisher, SA; Fortin, PM; Hopewell, S; Madgwick, KV; Trivella, M | 1 |
| Hu, H; Liu, W; Wen, X; Wu, D; Ye, B; Zhou, Y | 1 |
| Hassan, MK; Mohsin, AM | 1 |
| Sari, TT; Wahidiyat, PA; Yosia, M | 1 |
| Amanlou, M; Azizian, H; Balalaie, S; Biglar, M; Fathi Vavsari, V; Mahernia, S; Sadeghi Alavijeh, N; Salehi Ashani, R; Sheysi, N | 1 |
| Buaboonnam, J; Narkbunnam, N; Phuakpet, K; Pongtanakul, B; Sanpakit, K; Takpradit, C; Vathana, N; Viprakasit, V | 1 |
| Allò, M; Campisi, S; Casale, M; Cassinerio, E; Cattoni, A; De Michele, E; Di Concilio, R; Ferrara, F; Forni, GL; Ladogana, S; Lazzarino, AI; Marcon, A; Notarangelo, LD; Origa, R; Pasquali, D; Peluso, A; Perrotta, S; Picariello, S; Poggi, M; Putti, MC; Quarta, A; Renni, R; Roberti, D; Sau, A; Serra, M; Sportelli, F; Sturiale, P; Tartaglione, I | 1 |
| Aboobacker, FN; Abraham, A; Dixit, G; George, B; Korula, A; Lakshmi, KM; Mathews, V; Srivastava, A | 1 |
| Geara, A; Sayani, F; Yui, JC | 1 |
| Chhabra, IK; Ibrahim, HM; Mohammed, NS; Shafie, AA; Wong, JHY | 1 |
| Etemadfar, P; Ghaedi, M; Ghatee, MA; Moghaddam, AG; Omidifar, N; Rad, F; Zardkhoni, SZ | 1 |
| Bolaman, AZ; Turgutkaya, A; Yavaşoğlu, İ | 1 |
| Bintoro, SUY; Qatrunnada, H; Wahyuni, S | 1 |
| Aparicio López, C; Cervera Bravo, Á; Niño Taravilla, C; Otaola Arca, H; Sevilla, J | 1 |
| Cheng, K; Greenway, A; Kaplan, Z; Wu, S; Zargari, A | 1 |
| Borella, E; Della Pasqua, O; Magni, P; Oosterholt, S | 1 |
| Babu, T; Panachiyil, GM; Ravi, MD; Sebastian, J | 1 |
| Cao, P; Chen, S; Cui, Y; Duan, X; Fan, Y; Hou, J; Kuang, Y; Ma, W; Tan, K; Xu, X; Zhou, N; Zhu, R; Zhu, Y | 1 |
| Han, B; Zhang, R | 1 |
| Ahmed, J; Moeed, A; Naeem, U; Rais, H; Saleem, A; Shuja, SH; Waqar, E | 1 |
| Kleanthous, M; Kolnagou, A; Kontoghiorghes, GJ | 1 |
| Qadah, T | 1 |
| Bova, C; Bruzzese, A; Capodanno, I; Filippelli, G; Gentile, M; Lucia, E; Martino, EA; Mendicino, F; Morabito, F; Neri, A; Olivito, V; Vigna, E | 1 |
| Baker, Z; Dillon, H; Pena, A; Sparks, S; Syed, H; Wang, Y | 1 |
| Aydinok, Y | 1 |
109 review(s) available for triazoles and deferasirox
| Article | Year |
|---|---|
Development of tridentate iron chelators: from desferrithiocin to ICL670.
Topics: Animals; Benzoates; Callithrix; Chemical Phenomena; Chemistry, Physical; Deferasirox; Dihydropyridines; Dogs; Humans; Iron; Iron Chelating Agents; Rats; Thiazoles; Triazoles | 2003 |
Clinical research: a tale of two studies.
Topics: Benzoates; Biomedical Research; Cooperative Behavior; Deferasirox; Deferiprone; Drug Design; Drug Industry; Humans; Iron Chelating Agents; Pyridones; Thalassemia; Triazoles | 2003 |
Iron-chelating therapy with the new oral agent ICL670 (Exjade).
Topics: Administration, Oral; Animals; Benzoates; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2005 |
Monitoring and treatment of iron overload: state of the art and new approaches.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Hemosiderin; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Magnetics; Pyridones; Triazoles | 2005 |
Treating iron overload: the state of the art.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Models, Molecular; Pyridones; Survival Analysis; Triazoles | 2005 |
Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
Topics: Benzoates; Carboxylic Acids; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Siderophores; Thalassemia; Thiazoles; Triazoles | 2005 |
Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2005 |
Objectives and mechanism of iron chelation therapy.
Topics: Animals; Benzoates; Cardiomyopathies; Cells, Cultured; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Routes; Drug Synergism; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Mitochondria, Heart; Mononuclear Phagocyte System; Pyridones; Rats; Thalassemia; Transfusion Reaction; Triazoles | 2005 |
Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
Topics: Algorithms; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Monitoring; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Pyridones; Retrospective Studies; Thalassemia; Triazoles | 2005 |
Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
Topics: Administration, Oral; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Triazoles | 2006 |
Deferasirox (Exjade): a new iron chelator.
Topics: Benzoates; Deferasirox; Drug Costs; Humans; Iron Chelating Agents; Iron Overload; Orphan Drug Production; Randomized Controlled Trials as Topic; Triazoles | 2006 |
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Clinical Trials as Topic; Costs and Cost Analysis; Deferasirox; Deferiprone; Deferoxamine; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles | 2006 |
Deferasirox--an oral agent for chronic iron overload.
Topics: Benzoates; Clinical Trials as Topic; Deferasirox; Drug Interactions; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2006 |
Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Topics: Benzoates; Carboxylic Acids; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; Deferoxamine; Drug Evaluation; Drug Therapy, Combination; Forecasting; Hemochromatosis; Humans; Hydroxyethyl Starch Derivatives; Iron Chelating Agents; Iron Overload; Molecular Structure; Pyridones; Starch; Thalassemia; Thiazoles; Transfusion Reaction; Triazoles | 2006 |
Exjade (ICL 670): A new oral iron chelator.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Deferasirox; Humans; Iron Chelating Agents; Models, Structural; Randomized Controlled Trials as Topic; Triazoles | 2006 |
Investigational agents for sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Animals; Antihypertensive Agents; Antisickling Agents; Benzaldehydes; Benzoates; Carnitine; Cell Adhesion; Deferasirox; Endothelium, Vascular; Etilefrine; Female; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Hypertension, Pulmonary; Iron Chelating Agents; Male; Membrane Glycoproteins; Potassium Channels, Calcium-Activated; Priapism; Recombinant Fusion Proteins; Triazoles; Trityl Compounds; Vasoconstrictor Agents | 2006 |
Deferasirox: An effective once-daily orally active iron chelator.
Topics: Administration, Oral; Animals; Benzoates; Deferasirox; Drug Administration Schedule; Humans; Iron Chelating Agents; Iron Overload; Molecular Structure; Randomized Controlled Trials as Topic; Triazoles | 2006 |
Risk-based management of myelodysplastic syndrome.
Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles | 2007 |
Chelation therapy for iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Triazoles | 2007 |
Deferasirox.
Topics: Adult; Benzoates; Child; Deferasirox; Deferoxamine; Hematologic Diseases; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Patient Compliance; Siderophores; Transfusion Reaction; Triazoles | 2007 |
A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.
Topics: Animals; Antineoplastic Agents; Benzoates; Boronic Acids; Bortezomib; Cyclosporine; Dasatinib; Deferasirox; Humans; Iron Chelating Agents; Ophthalmic Solutions; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Randomized Controlled Trials as Topic; Skin Diseases; Skin Neoplasms; Thiazoles; Triazoles | 2007 |
Light and shadows in the iron chelation treatment of haematological diseases.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agents; Iron Overload; Liver; Pyridones; Triazoles | 2007 |
Current status of iron overload and chelation with deferasirox.
Topics: Benzoates; beta-Thalassemia; Clinical Trials as Topic; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2007 |
Deferasirox: the new oral iron chelator.
Topics: Benzoates; Child; Child, Preschool; Deferasirox; Humans; Iron Chelating Agents; Thalassemia; Triazoles | 2007 |
Coordination chemistry and biology of chelators for the treatment of iron overload disorders.
Topics: Benzoates; Chemistry, Pharmaceutical; Crystallography, X-Ray; Deferasirox; Deferiprone; Deferoxamine; Ferric Compounds; Humans; Iron Chelating Agents; Iron Overload; Models, Molecular; Pyridones; Triazoles | 2007 |
Deferasirox : a review of its use in the management of transfusional chronic iron overload.
Topics: Animals; Benzoates; Blood Transfusion; Chronic Disease; Deferasirox; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Transfusion Reaction; Triazoles | 2007 |
Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
Topics: Benzoates; Deferasirox; Deferiprone; Drug-Related Side Effects and Adverse Reactions; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Survival Rate; Transfusion Reaction; Treatment Outcome; Triazoles | 2007 |
Deferasirox for transfusion-related iron overload: a clinical review.
Topics: Administration, Oral; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2007 |
Clinical application of deferasirox: practical patient management.
Topics: Administration, Oral; Adult; Benzoates; Chemical and Drug Induced Liver Injury; Child; Clinical Trials as Topic; Contraindications; Creatinine; Deferasirox; Disease Management; Drug Eruptions; Gastrointestinal Diseases; Hematologic Diseases; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Kidney Diseases; Transfusion Reaction; Triazoles | 2008 |
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Approval; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Risk Assessment; Siderophores; Thalassemia; Triazoles | 2008 |
Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Diet; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Mutation; Phlebotomy; Pyridones; Triazoles | 2008 |
Iron and the liver: update 2008.
Topics: Antimicrobial Cationic Peptides; Benzoates; Deferasirox; Hemochromatosis; Hepcidins; Homeostasis; Humans; Iron; Iron Chelating Agents; Liver; Liver Diseases; Triazoles | 2008 |
[Pathophysiology, diagnosis and treatment of anemia].
Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Thalidomide; Triazoles | 2008 |
[Iron overload and iron chelation therapy in transfusion-dependent patients].
Topics: Benzoates; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Practice Guidelines as Topic; Triazoles | 2008 |
[Development trend in new therapeutic approaches for anemia].
Topics: Anemia; Benzoates; Clinical Trials as Topic; Darbepoetin alfa; Deferasirox; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Lenalidomide; Myelodysplastic Syndromes; Neoplasms; Thalidomide; Triazoles | 2008 |
Oral iron chelators.
Topics: Administration, Oral; Benzoates; Chelating Agents; Child; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Overload; Pyridones; Siderophores; Triazoles | 2008 |
Current approach to hemochromatosis.
Topics: Antimicrobial Cationic Peptides; Benzoates; Cation Transport Proteins; Deferasirox; Hemochromatosis; Hemochromatosis Protein; Hepcidins; Histocompatibility Antigens Class I; Humans; Iron Chelating Agents; Iron Overload; Membrane Proteins; Phlebotomy; Triazoles | 2008 |
Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes.
Topics: Asian People; Benzoates; Bone Marrow Diseases; Data Collection; Deferasirox; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Japan; Practice Guidelines as Topic; Syndrome; Triazoles | 2008 |
Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload.
Topics: Administration, Oral; Benzoates; Clinical Trials as Topic; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Transfusion Reaction; Triazoles | 2008 |
Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment.
Topics: Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Microbial Viability; Mucorales; Mucormycosis; Pyridones; Triazoles | 2008 |
Long-term efficacy and safety of deferasirox.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2008 |
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
Topics: Anemia; Benzoates; Chronic Disease; Contraindications; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemosiderosis; Humans; Iron Chelating Agents; Pyridones; Randomized Controlled Trials as Topic; Technology Assessment, Biomedical; Transfusion Reaction; Treatment Outcome; Triazoles | 2009 |
Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.
Topics: Administration, Oral; Benzoates; Deferasirox; Erythrocyte Transfusion; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Triazoles | 2009 |
Recent advances in the management of mucormycosis: from bench to bedside.
Topics: Amphotericin B; Antifungal Agents; Benzoates; Case Management; Clinical Trials as Topic; Deferasirox; Drug Therapy, Combination; Echinocandins; Humans; Immunologic Factors; Mucormycosis; Polyenes; Triazoles | 2009 |
Oral iron chelators.
Topics: Administration, Oral; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2009 |
[Pathogenesis of transfusional iron overload and iron chelation therapy].
Topics: Administration, Oral; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Drug Design; Erythrocyte Transfusion; Humans; Iron; Iron Chelating Agents; Iron Overload; Practice Guidelines as Topic; Transferrin; Triazoles | 2009 |
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload.
Topics: Adolescent; Adult; Anemia; Benzoates; Child; Child, Preschool; Creatinine; Deferasirox; Drug Administration Schedule; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2009 |
Deferasirox: an update.
Topics: Benzoates; Deferasirox; Humans; Iron; Iron Chelating Agents; Iron Overload; Myocardium; Transfusion Reaction; Treatment Outcome; Triazoles | 2009 |
Update on survival in thalassemia major.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Follow-Up Studies; Humans; Iron Chelating Agents; Pyridones; Survival Rate; Treatment Outcome; Triazoles | 2009 |
Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome.
Topics: Aged; Benzoates; Deferasirox; Erythrocyte Transfusion; Female; Hematopoiesis; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Platelet Transfusion; Treatment Outcome; Triazoles | 2009 |
Iron chelation therapy in MDS: what have we learnt recently?
Topics: Benzoates; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Triazoles | 2009 |
Deferasirox: oral, once daily iron chelator--an expert opinion.
Topics: Benzoates; Cardiovascular Diseases; Chelating Agents; Deferasirox; Expert Testimony; Hemosiderosis; Humans; Iron; Liver; Thalassemia; Triazoles | 2010 |
Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Interactions; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Myocardium; Pyridones; Triazoles | 2010 |
Deferasirox for managing transfusional iron overload in people with sickle cell disease.
Topics: Anemia, Sickle Cell; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Randomized Controlled Trials as Topic; Triazoles | 2010 |
Deferasirox for managing iron overload in people with myelodysplastic syndrome.
Topics: Benzoates; Chelation Therapy; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Triazoles | 2010 |
Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles | 2010 |
[Deferasirox--a new oral iron chelator--review].
Topics: Benzoates; Clinical Trials as Topic; Deferasirox; Humans; Iron Chelating Agents; Triazoles | 2010 |
Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review.
Topics: Administration, Oral; Aged; Benzoates; Chelation Therapy; Deferasirox; Hematopoiesis; Humans; Iron Chelating Agents; Male; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles; Up-Regulation | 2011 |
Iron-chelating therapy for transfusional iron overload.
Topics: Adolescent; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Practice Guidelines as Topic; Triazoles | 2011 |
Iron overload and allogeneic hematopoietic stem-cell transplantation.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Phlebotomy; Pyridones; Transplantation, Homologous; Triazoles | 2011 |
Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Liver; MEDLINE; Myocardium; Pyridones; Randomized Controlled Trials as Topic; Siderophores; Treatment Outcome; Triazoles; Ventricular Function | 2011 |
Iron chelation therapy for transfusional iron overload: a swift evolution.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Treatment Outcome; Triazoles | 2011 |
Past, present & future scenario of thalassaemic care & control in India.
Topics: Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Female; Genetic Carrier Screening; Humans; India; Male; Preimplantation Diagnosis; Prenatal Diagnosis; Pyridones; Thalassemia; Triazoles | 2011 |
Deferasirox: pharmacokinetics and clinical experience.
Topics: Animals; Benzoates; Clinical Trials as Topic; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Iron, Dietary; Transfusion Reaction; Triazoles | 2012 |
Deferasirox for managing iron overload in people with thalassaemia.
Topics: Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Randomized Controlled Trials as Topic; Thalassemia; Triazoles | 2012 |
[Iron overload and iron chelation therapy].
Topics: Benzoates; Deferasirox; Deferoxamine; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2012 |
[MDS].
Topics: Azacitidine; Benzoates; Clinical Trials as Topic; Cytokines; Deferasirox; Drug Therapy, Combination; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Thrombopoietin; Treatment Outcome; Triazoles | 2012 |
Iron chelation therapy in the management of transfusion-related cardiac iron overload.
Topics: Benzoates; Cardiomyopathy, Dilated; Chelation Therapy; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Double-Blind Method; Drug Therapy, Combination; Forecasting; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Practice Guidelines as Topic; Prospective Studies; Pyridones; Randomized Controlled Trials as Topic; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles; Ventricular Dysfunction, Left | 2012 |
Iron mobilization using chelation and phlebotomy.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Phlebotomy; Pyridones; Thalassemia; Triazoles | 2012 |
Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Phlebotomy; Pyridones; Siderophores; Transfusion Reaction; Triazoles | 2012 |
[Iron chelating therapy in adults: How and when ?].
Topics: Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Myelodysplastic Syndromes; Myocardium; Pyridones; Siderophores; Triazoles | 2013 |
Efficacy and safety of deferasirox in myelodysplastic syndromes.
Topics: Benzoates; Chelation Therapy; Clinical Trials, Phase II as Topic; Deferasirox; Drug Eruptions; Drug Therapy, Combination; Ferritins; Gastrointestinal Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Kidney Diseases; Multicenter Studies as Topic; Myelodysplastic Syndromes; NF-kappa B; Oxidative Stress; Prospective Studies; Retrospective Studies; Survival Analysis; Transfusion Reaction; Triazoles | 2013 |
Management of the thalassemias.
Topics: Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Myocardium; Pancreas; Pituitary Gland, Anterior; Pyridones; Thalassemia; Triazoles | 2013 |
Iron chelation in the treatment of cancer: a new role for deferasirox?
Topics: Animals; Antineoplastic Agents; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Neoplasms; Pyridones; Triazoles | 2013 |
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Randomized Controlled Trials as Topic; Siderophores; Thalassemia; Transfusion Reaction; Triazoles | 2013 |
Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.
Topics: Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Transfusion Reaction; Triazoles | 2013 |
Iron overload as a major targetable pathogenesis of asbestos-induced mesothelial carcinogenesis.
Topics: Adsorption; Animals; Asbestos; Asbestosis; Benzoates; Carcinogens, Environmental; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Comparative Genomic Hybridization; Deferasirox; Ferric Compounds; Ferric Oxide, Saccharated; Genes, p16; Glucaric Acid; Humans; Iron Chelating Agents; Iron Overload; Japan; Kidney Neoplasms; Male; Mesothelioma; Mineral Fibers; Peritoneal Neoplasms; Phlebotomy; Pleural Neoplasms; Rats; Triazoles | 2014 |
Non-HFE hemochromatosis: pathophysiological and diagnostic aspects.
Topics: Alcohol Drinking; Benzoates; Biopsy; Cataract; Cation Transport Proteins; Decision Trees; Deferasirox; Diet; Gaucher Disease; Genetic Testing; Hemochromatosis; Hemochromatosis Protein; Hepcidins; Histocompatibility Antigens Class I; Humans; Inflammation; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Iron Overload; Liver; Macrophage Activation Syndrome; Magnetic Resonance Imaging; Membrane Proteins; Metabolic Syndrome; Mutation; Phlebotomy; Receptors, Transferrin; Transferrin; Triazoles | 2014 |
Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Myocardium; Pyridones; Randomized Controlled Trials as Topic; Stroke Volume; Thalassemia; Treatment Outcome; Triazoles | 2013 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
Topics: Administration, Oral; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyridones; Triazoles | 2014 |
A case report of deferasirox-induced kidney injury and Fanconi syndrome.
Topics: Benzoates; Deferasirox; Fanconi Syndrome; Humans; Iron Chelating Agents; Iron Overload; Male; Renal Insufficiency; Triazoles; Young Adult | 2013 |
Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.
Topics: Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Triazoles | 2014 |
Clinical pharmacology of deferasirox.
Topics: Absorption, Physicochemical; Benzoates; Biological Availability; Deferasirox; Drug Interactions; Humans; Iron Chelating Agents; Metabolic Clearance Rate; Molecular Structure; Protein Binding; Tissue Distribution; Triazoles | 2014 |
Deferasirox nephrotoxicity-the knowns and unknowns.
Topics: Acute Kidney Injury; Benzoates; Deferasirox; Glomerular Filtration Rate; Humans; Iron Chelating Agents; Iron Overload; Renal Insufficiency, Chronic; Transfusion Reaction; Triazoles | 2014 |
Deferasirox for managing iron overload in people with myelodysplastic syndrome.
Topics: Benzoates; Chelation Therapy; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Triazoles | 2014 |
Chelation in metal intoxication--Principles and paradigms.
Topics: Administration, Oral; Antidotes; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Deferoxamine; Heavy Metal Poisoning; Humans; Penicillamine; Poisoning; Pyridones; Succimer; Triazoles; Trientine; Unithiol | 2015 |
An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms.
Topics: Benzoates; Blood Platelets; Chelation Therapy; Deferasirox; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Leukocytes; Myelodysplastic Syndromes; Triazoles | 2015 |
Aceruloplasminaemia: a rare but important cause of iron overload.
Topics: Adult; Benzoates; Ceruloplasmin; Chelation Therapy; Deferasirox; Disease Progression; Early Diagnosis; Ferritins; Humans; Iron Chelating Agents; Iron Metabolism Disorders; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Neurodegenerative Diseases; Treatment Outcome; Triazoles | 2015 |
Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome - Emphasis on optimized dosing schedules and new formulations.
Topics: Benzoates; Chelation Therapy; Deferasirox; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles | 2015 |
Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Disease Management; Drug-Related Side Effects and Adverse Reactions; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Myocardium; Pregnancy; Pyridones; Triazoles | 2016 |
Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.
Topics: Benzoates; Biomarkers; Deferasirox; Humans; Iron; Iron Chelating Agents; Iron Overload; Syndrome; Thalassemia; Treatment Outcome; Triazoles | 2015 |
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Syndrome; Thalassemia; Triazoles | 2016 |
Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major.
Topics: Animals; Benzoates; beta-Thalassemia; Deferasirox; Disease Management; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2016 |
Fanconi Syndrome Secondary to Deferasirox in Diamond-Blackfan Anemia: Case Series and Recommendations for Early Diagnosis.
Topics: Adolescent; Adult; Aged; Anemia, Diamond-Blackfan; Benzoates; Blood Transfusion; Child; Deferasirox; Electrolytes; Fanconi Syndrome; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Transfusion Reaction; Triazoles | 2016 |
In brief: Jadenu--a new formulation of deferasirox for iron overload.
Topics: Administration, Oral; Animals; Benzoates; Chemistry, Pharmaceutical; Clinical Trials as Topic; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2016 |
Current Review of Iron Overload and Related Complications in Hematopoietic Stem Cell Transplantation.
Topics: Benzoates; Deferasirox; Ferritins; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Iron Chelating Agents; Iron Overload; Survival Rate; Triazoles | 2017 |
[Transfusions in myelodysplastic syndromes].
Topics: Benzoates; Blood Grouping and Crossmatching; Combined Modality Therapy; Deferasirox; Erythrocyte Transfusion; Hematinics; Hemoglobins; Hepcidins; Humans; Intestinal Absorption; Iron Chelating Agents; Iron Overload; Iron, Dietary; Myelodysplastic Syndromes; Patient Satisfaction; Quality of Life; Rh Isoimmunization; Triazoles | 2017 |
Deferasirox for managing iron overload in people with thalassaemia.
Topics: Administration, Oral; Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Patient Satisfaction; Pyridones; Randomized Controlled Trials as Topic; Thalassemia; Triazoles | 2017 |
Iron overload in myelodysplastic syndromes (MDS).
Topics: Benzoates; Blood Transfusion; Deferasirox; Deferoxamine; Erythropoiesis; Hepcidins; Humans; Intestinal Mucosa; Iron; Iron Chelating Agents; Iron Overload; Liver; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles | 2018 |
Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
Topics: Anemia, Sickle Cell; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Network Meta-Analysis; Pyridones; Randomized Controlled Trials as Topic; Silymarin; Thalassemia; Triazoles | 2018 |
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Patient Compliance; Pyridones; Quality of Life; Randomized Controlled Trials as Topic; Triazoles | 2018 |
Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report.
Topics: Benzoates; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart; Humans; Indonesia; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Pyridones; Thalassemia; Triazoles | 2018 |
Deferasirox-associated Fanconi syndrome in adult patients with transfusional iron overload.
Topics: Adult; Benzoates; Deferasirox; Fanconi Syndrome; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2021 |
No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis.
Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Ferritins; Hemoglobinopathies; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2023 |
Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Pyridones; Risk Assessment; Thalassemia; Triazoles | 2022 |
Deferasirox versus deferoxamine in managing iron overload in patients with Sickle Cell Anaemia: a systematic review and meta-analysis.
Topics: Anemia, Sickle Cell; Benzoates; Deferasirox; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Triazoles | 2022 |
Iron chelation therapy.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2023 |
Combination chelation therapy.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Quality of Life; Triazoles | 2023 |
116 trial(s) available for triazoles and deferasirox
| Article | Year |
|---|---|
Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial.
Topics: Adolescent; Adult; Area Under Curve; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Ferritins; Humans; Intestinal Absorption; Iron; Iron Overload; Male; Triazoles | 2003 |
Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia.
Topics: Administration, Oral; Adult; Area Under Curve; Benzoates; beta-Thalassemia; Deferasirox; Double-Blind Method; Half-Life; Humans; Iron; Iron Chelating Agents; Male; Safety; Triazoles | 2003 |
Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
Topics: Administration, Oral; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Dose-Response Relationship, Drug; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Transfusion Reaction; Treatment Outcome; Triazoles | 2005 |
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.
Topics: Administration, Oral; Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Deferoxamine; Drug Administration Schedule; Female; Humans; Iron; Iron Chelating Agents; Liver; Male; Middle Aged; Safety; Triazoles | 2006 |
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Transfusion Reaction; Treatment Outcome; Triazoles | 2006 |
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
Topics: Administration, Oral; Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Drug Administration Schedule; Female; Humans; Iron Chelating Agents; Male; Triazoles | 2006 |
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood Transfusion; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferoxamine; Drug Administration Schedule; Female; Headache; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Respiratory Tract Infections; Treatment Outcome; Triazoles | 2007 |
Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Siderophores; Triazoles | 2006 |
Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
Topics: Adolescent; Adult; Antidotes; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Humans; Iron Overload; Male; Middle Aged; Prospective Studies; Treatment Outcome; Triazoles | 2007 |
Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major.
Topics: Benzoates; beta-Thalassemia; Child, Preschool; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Splenectomy; Triazoles | 2008 |
Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Cataract; Child; Child, Preschool; Deferasirox; Humans; Iron Chelating Agents; Italy; Time Factors; Triazoles | 2008 |
Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks.
Topics: Administration, Oral; Adult; Area Under Curve; Benzoates; Beverages; Biological Availability; Chromatography, High Pressure Liquid; Citrus sinensis; Cross-Over Studies; Deferasirox; Diarrhea; Drug Stability; Half-Life; Humans; Iron Chelating Agents; Male; Malus; Tablets; Tandem Mass Spectrometry; Triazoles; Water | 2008 |
Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen.
Topics: Adolescent; Adult; Area Under Curve; Benzoates; Biological Availability; Chromatography, High Pressure Liquid; Cross-Over Studies; Deferasirox; Eating; Female; Food; Food-Drug Interactions; Humans; Intestinal Absorption; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Spectrophotometry, Ultraviolet; Triazoles | 2008 |
Effect of deferasirox (ICL670) on arterial function in patients with beta-thalassaemia major.
Topics: Adolescent; Adult; Arteries; Benzoates; beta-Thalassemia; Brachial Artery; Carotid Arteries; Deferasirox; Elasticity; Endothelium, Vascular; Female; Ferritins; Follow-Up Studies; Humans; Iron Chelating Agents; Male; Triazoles; Vasodilation; Ventricular Function, Left | 2008 |
Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
Topics: Absenteeism; Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Male; Middle Aged; Patient Satisfaction; Surveys and Questionnaires; Transfusion Reaction; Treatment Outcome; Triazoles | 2008 |
Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial.
Topics: Adolescent; Adult; Ascorbic Acid; Benzoates; beta-Thalassemia; C-Reactive Protein; Child; Deferasirox; Deferoxamine; Female; Humans; Iron Chelating Agents; Lipid Peroxidation; Male; Oxidants; Oxidative Stress; Triazoles; Vitamin E | 2008 |
Absolute oral bioavailability and disposition of deferasirox in healthy human subjects.
Topics: Adolescent; Adult; Area Under Curve; Benzoates; Biological Availability; Chemistry, Pharmaceutical; Cross-Over Studies; Deferasirox; Double-Blind Method; Half-Life; Humans; Infusions, Intravenous; Iron Chelating Agents; Male; Middle Aged; Tissue Distribution; Triazoles | 2008 |
A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Asian People; Benzoates; Blood Transfusion; Deferasirox; Dose-Response Relationship, Drug; Female; Humans; Iron Chelating Agents; Iron Overload; Japan; Male; Middle Aged; Myelodysplastic Syndromes; Triazoles | 2008 |
Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.
Topics: Aged; Aged, 80 and over; Benzoates; Bone Marrow; Deferasirox; Ferritins; Humans; Iron; Iron Overload; Liver; Magnetic Resonance Imaging; Middle Aged; Myelodysplastic Syndromes; Transfusion Reaction; Treatment Outcome; Triazoles | 2009 |
Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin.
Topics: Adult; Area Under Curve; Benzoates; Cardiotonic Agents; Cross-Over Studies; Deferasirox; Digoxin; Drug Interactions; Humans; Iron Chelating Agents; Male; Middle Aged; Triazoles | 2008 |
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug-Related Side Effects and Adverse Reactions; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Pyridones; Treatment Outcome; Triazoles; Young Adult | 2009 |
Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Treatment Outcome; Triazoles; Young Adult | 2009 |
Deferasirox does not induce QT/QTc-prolongation in healthy subjects.
Topics: Adolescent; Adult; Aged; Area Under Curve; Aza Compounds; Benzoates; Deferasirox; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Humans; Iron Chelating Agents; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Quinolines; Triazoles; Young Adult | 2009 |
Deferasirox pharmacokinetics in patients with adequate versus inadequate response.
Topics: Adolescent; Adult; Anemia; Benzoates; Biological Availability; Child; Child, Preschool; Cohort Studies; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Liver; Male; Pharmacogenetics; Prospective Studies; Transfusion Reaction; Triazoles; Young Adult | 2009 |
Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Ferritins; Heart Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Triazoles; Young Adult | 2010 |
Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers.
Topics: Adult; Anesthetics, Intravenous; Aryl Hydrocarbon Hydroxylases; Benzoates; Carbamates; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Deferasirox; Drug Interactions; Enzyme Inhibitors; Female; Humans; Hypoglycemic Agents; Iron Chelating Agents; Male; Midazolam; Piperidines; Rifampin; Triazoles | 2010 |
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Benzoates; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Iron, Dietary; Male; Middle Aged; Prospective Studies; Thalassemia; Tissue Distribution; Triazoles; Young Adult | 2010 |
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Dose-Response Relationship, Drug; Female; Ferritins; Heart Failure; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Myocardium; Prospective Studies; Triazoles; Young Adult | 2010 |
A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors.
Topics: Adult; Benzoates; Deferasirox; Female; Ferritins; Heart; Hematopoietic Stem Cell Transplantation; Hemoglobins; Humans; Iron; Iron Overload; Liver; Male; Middle Aged; Phlebotomy; Transplantation, Homologous; Treatment Outcome; Triazoles | 2010 |
Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
Topics: Adult; Animals; Area Under Curve; Arylsulfatases; Benzoates; beta-Thalassemia; Cells, Cultured; Deferasirox; Feces; Female; Glucuronidase; Glucuronides; Hepatocytes; Humans; Hydroxylation; Iron Chelating Agents; Iron Overload; Male; Molecular Structure; Rats; Spectrometry, Mass, Electrospray Ionization; Sulfuric Acid Esters; Transfusion Reaction; Triazoles; Young Adult | 2010 |
Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes.
Topics: Administration, Oral; Aged; Benzoates; Biomarkers; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Oxidative Stress; Time Factors; Treatment Outcome; Triazoles | 2010 |
The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Heart; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Metabolic Clearance Rate; Myocardium; Treatment Outcome; Triazoles; Young Adult | 2010 |
Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle East; Patient Satisfaction; Prospective Studies; Triazoles | 2010 |
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Benzoates; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Triazoles; Young Adult | 2010 |
Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial.
Topics: Adolescent; Adult; Anemia, Aplastic; Benzoates; Chelation Therapy; Creatinine; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Male; Middle Aged; Prospective Studies; Triazoles; Young Adult | 2010 |
Posttransplant oral iron-chelating therapy in patients with beta-thalassemia major.
Topics: Adolescent; Alanine Transaminase; Aspartate Aminotransferases; Benzoates; beta-Thalassemia; Bone Marrow Transplantation; Child; Child, Preschool; Creatine; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Treatment Outcome; Triazoles | 2010 |
Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Benzoates; Deferasirox; Dose-Response Relationship, Drug; Erythrocyte Transfusion; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Triazoles | 2010 |
Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/β-thalassemia.
Topics: Adult; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Down-Regulation; Female; Hemoglobin, Sickle; Heterozygote; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Radiography; Triazoles | 2011 |
Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial.
Topics: Benzoates; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Deferasirox; Ferritins; Follow-Up Studies; Humans; Iron Chelating Agents; Liver Diseases; Siderosis; Stroke Volume; Transfusion Reaction; Treatment Outcome; Triazoles | 2010 |
Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
Topics: Adult; Benzoates; beta-Thalassemia; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Treatment Outcome; Triazoles; Young Adult | 2010 |
Effect of deferasirox on iron absorption in a randomized, placebo-controlled, crossover study in a human model of acute supratherapeutic iron ingestion.
Topics: Adult; Antidotes; Benzoates; Cross-Over Studies; Deferasirox; Double-Blind Method; Female; Humans; Iron; Iron Chelating Agents; Male; Triazoles | 2011 |
Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.
Topics: Aged; Antimicrobial Cationic Peptides; Benzoates; Blood Transfusion; Deferasirox; Erythropoiesis; Female; Hepcidins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Oxidative Stress; Transferrin; Triazoles | 2011 |
Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox.
Topics: Adolescent; Adult; Asia, Southeastern; Benzoates; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Male; Thalassemia; Triazoles | 2011 |
Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Ferritins; Heart; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Myocardium; Prognosis; Treatment Outcome; Triazoles | 2011 |
The impact of two different doses of chelating therapy (deferasirox) on echocardiographic tissue Doppler indices in patients with thalassemia major.
Topics: Adolescent; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Dose-Response Relationship, Drug; Echocardiography, Doppler; Female; Hemodynamics; Humans; Male; Triazoles; Young Adult | 2011 |
Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Benzoates; Child; Child, Preschool; Deferasirox; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2011 |
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Cross-Over Studies; Deferasirox; Deferoxamine; Female; Follow-Up Studies; Growth and Development; Humans; Iron; Iron Chelating Agents; Male; Middle Aged; Triazoles; Young Adult | 2011 |
Iron chelation treatment with deferasirox prior to high-dose chemotherapy and autologous stem cell transplantation may reduce the risk of hepatic veno-occlusive disease in children with high-risk solid tumors.
Topics: Acute Kidney Injury; Benzoates; Brain Neoplasms; Child; Child, Preschool; Deferasirox; Erythrocyte Transfusion; Fanconi Syndrome; Female; Ferritins; Hepatic Veno-Occlusive Disease; Humans; Induction Chemotherapy; Infant; Iron Chelating Agents; Male; Neuroblastoma; Stem Cell Transplantation; Transplantation, Autologous; Triazoles | 2012 |
Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.
Topics: Adolescent; Anemia; Benzoates; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Triazoles | 2011 |
Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study.
Topics: Adolescent; Benzoates; beta-Thalassemia; Body Burden; Child; Child, Preschool; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Male; Prospective Studies; Triazoles | 2011 |
Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.
Topics: Adolescent; Adult; Alanine Transaminase; Benzoates; beta-Thalassemia; Biomarkers; Biopsy; Child; Child, Preschool; Cross-Over Studies; Deferasirox; Female; Ferritins; Hepatitis C; Humans; Iron; Iron Chelating Agents; Liver; Liver Cirrhosis; Male; Middle Aged; Severity of Illness Index; Time Factors; Treatment Outcome; Triazoles; Young Adult | 2011 |
[Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Dose-Response Relationship, Drug; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Transfusion Reaction; Triazoles | 2011 |
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.
Topics: Adult; Aged; Amphotericin B; Animals; Antifungal Agents; Benzoates; Deferasirox; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Male; Mice; Middle Aged; Mucormycosis; Placebos; Survival Analysis; Treatment Outcome; Triazoles | 2012 |
Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.
Topics: Adolescent; Benzoates; Child; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Myocardium; Prospective Studies; Thalassemia; Triazoles; Young Adult | 2012 |
Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers.
Topics: Acute Disease; Administration, Oral; Benzoates; beta Catenin; Cell Line, Tumor; Cell Proliferation; Ciclopirox; Colorectal Neoplasms; Deferasirox; Deferoxamine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Hydrazones; Iron; Iron Chelating Agents; Leukemia, Myeloid; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Pyridones; Reverse Transcriptase Polymerase Chain Reaction; Triazoles; Wnt Proteins; Wnt Signaling Pathway | 2011 |
Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.
Topics: Adolescent; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Secondary Prevention; Stroke; Transfusion Reaction; Triazoles; Young Adult | 2012 |
Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Cardiomyopathies; Chelation Therapy; Child; Deferasirox; Drug Administration Schedule; Heart; Humans; Iron; Iron Chelating Agents; Iron Overload; Longitudinal Studies; Magnetic Resonance Angiography; Triazoles | 2012 |
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Child; Deferasirox; Female; Follow-Up Studies; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neutrophils; Prognosis; Prospective Studies; Survival Rate; Transfusion Reaction; Triazoles; Young Adult | 2012 |
Risk factors for mortality in patients with mucormycosis.
Topics: Adult; Aged; Amphotericin B; Benzoates; Deferasirox; Double-Blind Method; Ferritins; Humans; Iron; Kaplan-Meier Estimate; Lung Diseases; Middle Aged; Mucor; Mucormycosis; Risk Factors; Time Factors; Treatment Outcome; Triazoles | 2012 |
Deferasirox therapy in children with Fanconi aplastic anemia.
Topics: Administration, Oral; Adolescent; Benzoates; Blood Transfusion; Child; Child, Preschool; Deferasirox; Fanconi Anemia; Female; Ferritins; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Male; Triazoles | 2012 |
Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Erythrocyte Transfusion; Female; Ferritins; Hemochromatosis Protein; Histocompatibility Antigens Class I; Humans; Iron; Iron Chelating Agents; Male; Membrane Proteins; Middle Aged; Mutation; Myelodysplastic Syndromes; Prospective Studies; Time Factors; Treatment Outcome; Triazoles | 2012 |
Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
Topics: Adult; Benzoates; beta-Thalassemia; Comorbidity; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Follow-Up Studies; Heart; Heart Failure; Humans; Iron Chelating Agents; Male; Myocardium; Patient Compliance; Prospective Studies; Pyridones; Stroke Volume; Triazoles; Young Adult | 2012 |
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Algorithms; Benzoates; Blood Transfusion; Child; Deferasirox; Double-Blind Method; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Placebos; Prospective Studies; Thalassemia; Treatment Outcome; Triazoles; Young Adult | 2012 |
Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Prospective Studies; Triazoles; Young Adult | 2012 |
Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine.
Topics: Adult; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron; Iron Chelating Agents; Male; Triazoles | 2013 |
Deferasirox for porphyria cutanea tarda: a pilot study.
Topics: Benzoates; Blister; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Male; Middle Aged; Pilot Projects; Porphyria Cutanea Tarda; Porphyrins; Treatment Outcome; Triazoles | 2012 |
Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Creatinine; Deferasirox; Drug Eruptions; Female; Ferritins; Gastrointestinal Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Transfusion Reaction; Treatment Outcome; Triazoles | 2013 |
Combined chelation therapy with deferasirox and deferoxamine in thalassemia.
Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Deferasirox; Deferoxamine; Drug Synergism; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Myocardium; Pilot Projects; Thalassemia; Transferrin; Triazoles; Young Adult | 2013 |
The effects of chelators on zinc levels in patients with thalassemia major.
Topics: Adolescent; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Demography; Female; Humans; Iron Chelating Agents; Male; Pyridones; Triazoles; Young Adult; Zinc | 2013 |
Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis.
Topics: Aged; Anemia, Iron-Deficiency; Area Under Curve; Benzoates; Biological Availability; Chromatography, Liquid; Deferasirox; Drug Administration Schedule; Drug Monitoring; Female; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Pilot Projects; Renal Dialysis; Renal Insufficiency, Chronic; Tandem Mass Spectrometry; Triazoles; Western Australia | 2013 |
Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients.
Topics: Adult; Benzoates; Deferasirox; Dose-Response Relationship, Drug; Double-Blind Method; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Liver; Male; Thalassemia; Triazoles; Young Adult | 2013 |
Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study.
Topics: Adolescent; Adult; Anemia, Aplastic; Benzoates; Blood Platelets; Child; Deferasirox; Female; Ferritins; Hemoglobins; Humans; Immunosuppressive Agents; Iron Chelating Agents; Male; Middle Aged; Neutrophils; Prospective Studies; Treatment Outcome; Triazoles; Young Adult | 2013 |
A prospective phase II randomized study of deferasirox to prevent iatrogenic iron overload in patients undertaking induction/consolidation chemotherapy for acute myeloid leukaemia.
Topics: Adult; Aged; Benzoates; Consolidation Chemotherapy; Deferasirox; Early Termination of Clinical Trials; Female; Ferritins; Humans; Iatrogenic Disease; Induction Chemotherapy; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2013 |
The palatability and tolerability of deferasirox taken with different beverages or foods.
Topics: Adolescent; Benzoates; Beverages; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Food; Food-Drug Interactions; Hematologic Diseases; Hemosiderosis; Humans; Iron Chelating Agents; Male; Triazoles | 2013 |
Iron chelation with deferasirox for the treatment of secondary hemosiderosis in pediatric oncology patients: a single-center experience.
Topics: Adolescent; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Female; Ferritins; Hemosiderosis; Humans; Infant; Iron; Iron Chelating Agents; Male; Neoplasms; Transfusion Reaction; Triazoles; Young Adult | 2013 |
Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study.
Topics: Benzoates; Blood Transfusion; Cross-Over Studies; Deferasirox; Double-Blind Method; Humans; Iron Chelating Agents; Iron Overload; Prospective Studies; Thalassemia; Time Factors; Treatment Outcome; Triazoles | 2013 |
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
Topics: Acute Chest Syndrome; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Chelation Therapy; Child; Child, Preschool; Cohort Studies; Deferasirox; Female; Humans; Hydroxyurea; Incidence; Iron Chelating Agents; Iron Overload; Male; Pain Measurement; Phlebotomy; Secondary Prevention; Stroke; Transfusion Reaction; Triazoles; Young Adult | 2013 |
The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload.
Topics: Adult; Allografts; Benzoates; Deferasirox; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Male; Retrospective Studies; Survival Rate; Transfusion Reaction; Triazoles | 2013 |
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Topics: Acute Kidney Injury; Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Cellulitis; Chelation Therapy; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Deferasirox; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Hydroxyurea; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Prospective Studies; Transfusion Reaction; Triazoles; Young Adult | 2013 |
A prospective study of tubular dysfunction in pediatric patients with Beta thalassemia major receiving deferasirox.
Topics: Adolescent; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Creatinine; Deferasirox; Female; Glomerular Filtration Rate; Humans; Iron Chelating Agents; Iron Overload; Kidney Diseases; Male; Metals; Prospective Studies; Triazoles | 2013 |
Efficacy of Deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial.
Topics: Adolescent; Adult; Age Factors; Aged; Asian People; Benzoates; Child; Child, Preschool; China; Deferasirox; Female; Humans; Infant; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Prospective Studies; Thalassemia; Triazoles | 2013 |
Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
Topics: Adult; Aged; Anemia, Aplastic; Benzoates; Deferasirox; Female; Ferritins; Humans; Iron; Iron Overload; Liver; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Transfusion Reaction; Triazoles | 2014 |
Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Drug Eruptions; Female; Ferritins; Gastrointestinal Diseases; Humans; Iran; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Myocardium; Prospective Studies; Stroke Volume; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2014 |
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferoxamine; Female; Ferritins; Heart; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Medication Adherence; Myocardium; Treatment Outcome; Triazoles; Troponin T; Young Adult | 2014 |
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox.
Topics: Benzoates; Deferasirox; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Thalassemia; Transfusion Reaction; Treatment Outcome; Triazoles | 2014 |
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Blood Transfusion; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2014 |
Efficacy of deferasirox in children with β-thalassemia: single-center 3 year experience.
Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Female; Humans; Iron Chelating Agents; Male; Treatment Outcome; Triazoles | 2014 |
Lactose intolerance is not the cause of gastrointestinal adverse effects in beta thalassemia patients treated with deferasirox.
Topics: Adult; Benzoates; beta-Thalassemia; Breath Tests; Chi-Square Distribution; Deferasirox; Excipients; Female; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Lactose; Lactose Intolerance; Male; Middle Aged; Triazoles; Young Adult | 2014 |
Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study.
Topics: Adult; Benzoates; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Deferasirox; Female; Ferritins; Hemosiderosis; Humans; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Male; Medication Adherence; Prospective Studies; Stroke Volume; Transfusion Reaction; Triazoles; Young Adult | 2014 |
Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.
Topics: Adult; Aged; Benzoates; Deferasirox; Female; Ferritins; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Transfusion Reaction; Transplantation, Homologous; Treatment Outcome; Triazoles; Young Adult | 2014 |
Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Bone and Bones; Bone Density; Calcium; Chelation Therapy; Child; Child, Preschool; Deferasirox; Diabetes Mellitus; Diphosphonates; Female; Humans; Hypogonadism; Hypoparathyroidism; Hypothyroidism; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Osteoporosis; Puberty, Delayed; Retrospective Studies; Triazoles; Vitamin D | 2014 |
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia.
Topics: Adolescent; Adult; Benzoates; Deferasirox; Double-Blind Method; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Thalassemia; Triazoles; Young Adult | 2015 |
Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferoxamine; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Myocardium; Prospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles | 2015 |
Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent β thalassaemia.
Topics: Adult; Benzoates; beta-Thalassemia; Biomarkers; Chelation Therapy; Creatinine; Deferasirox; Female; Ferritins; Glomerular Filtration Rate; Hemodynamics; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Renal Circulation; Transfusion Reaction; Triazoles; Young Adult | 2015 |
Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Pyridones; Severity of Illness Index; Triazoles | 2015 |
Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study.
Topics: Adult; Aged; Benzoates; Biomarkers; Deferasirox; Erythrocyte Indices; Female; Hemochromatosis; Hemochromatosis Protein; Histocompatibility Antigens Class I; Humans; Iron Chelating Agents; Iron Overload; Male; Membrane Proteins; Middle Aged; Mutation; Time Factors; Treatment Outcome; Triazoles | 2015 |
Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment.
Topics: Anemia; Benzoates; Biomarkers; Deferasirox; Female; Ferritins; Follow-Up Studies; Humans; Iron; Iron Overload; Male; Transferrin; Triazoles | 2016 |
Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Benzoates; Deferasirox; Erythrocyte Transfusion; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Triazoles | 2015 |
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload.
Topics: Adolescent; Adult; Benzoates; Child; Deferasirox; Deferoxamine; Female; Heart; Humans; Iron Chelating Agents; Iron Overload; Liver; Male; Myocardium; Siderophores; Transfusion Reaction; Triazoles; Young Adult | 2015 |
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Biological Assay; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Humans; Hydroxyurea; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Stroke; Transfusion Reaction; Triazoles; Ultrasonography, Doppler, Transcranial | 2015 |
Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration.
Topics: Adult; Benzoates; beta-Thalassemia; Chromatography, High Pressure Liquid; Deferasirox; Drug Administration Schedule; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Triazoles; Young Adult | 2015 |
Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Benzoates; Child; Child, Preschool; Deferasirox; Humans; Iron Overload; Liver; Middle Aged; Myelodysplastic Syndromes; Triazoles | 2015 |
Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
Topics: Adult; Benzoates; beta-Thalassemia; Cardiomyopathies; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Middle Aged; Stroke Volume; Treatment Outcome; Triazoles; Ventricular Function, Left; Young Adult | 2015 |
Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Aged; Allografts; Benzoates; Cyclosporine; Deferasirox; Female; Ferritins; Hematopoietic Stem Cell Transplantation; Humans; Iron; Iron Metabolism Disorders; Male; Middle Aged; Prospective Studies; Triazoles | 2016 |
The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Male; Taiwan; Time Factors; Triazoles | 2015 |
Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study.
Topics: Adolescent; Adult; Benzoates; Blood Transfusion; Chelation Therapy; Child; Deferasirox; Diarrhea; Drug Administration Schedule; Drug Dosage Calculations; Female; Follow-Up Studies; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Nausea; Thalassemia; Treatment Outcome; Triazoles | 2016 |
CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Dose-Response Relationship, Drug; Drug Monitoring; Female; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Transfusion Reaction; Treatment Outcome; Triazoles | 2016 |
Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).
Topics: Adolescent; Adult; Aged; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Female; Ferritins; Heart Function Tests; Hemoglobinopathies; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2017 |
One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.
Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Combined Modality Therapy; Deferasirox; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Male; Phlebotomy; Prognosis; Prospective Studies; Triazoles | 2017 |
Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Animals; Benzoates; Carcinoma, Hepatocellular; Deferasirox; Drug Screening Assays, Antitumor; Female; Hep G2 Cells; Humans; Iron Chelating Agents; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Middle Aged; Triazoles | 2016 |
Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassaemia.
Topics: Adolescent; Benzoates; Blood Glucose; Blood Transfusion; Chelation Therapy; Deferasirox; Drug Administration Schedule; Fasting; Female; Ferritins; Glucose Tolerance Test; Humans; Insulin Resistance; Insulin-Secreting Cells; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Myocardium; Prospective Studies; Thalassemia; Treatment Outcome; Triazoles; Young Adult | 2017 |
Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
Topics: Adolescent; Adult; Benzoates; Biomarkers; Chelation Therapy; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Prognosis; ROC Curve; Thalassemia; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2017 |
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Chemistry, Pharmaceutical; Child; Deferasirox; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Patient Compliance; Quality of Life; Tablets, Enteric-Coated; Thalassemia; Triazoles; Young Adult | 2017 |
Heavy metal levels in patients with ineffective erythropoiesis.
Topics: Adolescent; Adult; Anemia, Dyserythropoietic, Congenital; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Erythropoiesis; Female; Humans; Male; Metals, Heavy; Triazoles | 2017 |
Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302).
Topics: Adult; Aged; Allografts; Benzoates; Deferasirox; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Time Factors; Treatment Outcome; Triazoles; Young Adult | 2018 |
Efficacy and Tolerability of Twice-Daily Dosing Schedule of Deferasirox in Transfusion-Dependent Paediatric Beta-Thalassaemia Patients: A Randomized Controlled Study.
Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Prospective Studies; Thalassemia; Triazoles | 2023 |
413 other study(ies) available for triazoles and deferasirox
| Article | Year |
|---|---|
Chelator-induced iron excretion in iron-overloaded marmosets.
Topics: Animals; Benzoates; Callithrix; Cebus; Chelating Agents; Deferasirox; Dose-Response Relationship, Drug; Edetic Acid; Feces; Female; Iron; Iron Overload; Liver; Male; Models, Animal; Pyridines; Triazoles | 2000 |
ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.
Topics: Animals; Benzoates; Bile; Cells, Cultured; Deferasirox; Deferoxamine; Drug Evaluation, Preclinical; Erythrocyte Transfusion; Erythrocytes, Abnormal; Feces; Female; Ferritins; Heart; Hepatocytes; Hot Temperature; Injections, Intravenous; Iron Chelating Agents; Iron Overload; Iron Radioisotopes; Liver; Mice; Molecular Structure; Mononuclear Phagocyte System; Myocardium; Organ Specificity; Rats; Rats, Wistar; Tissue Distribution; Transfusion Reaction; Triazoles; Urine | 2001 |
Practice of solid-phase extraction and protein precipitation in the 96-well format combined with high-performance liquid chromatography-ultraviolet detection for the analysis of drugs in plasma and brain.
Topics: Animals; Anticonvulsants; Benzoates; Brain Chemistry; Chemical Precipitation; Chromatography, High Pressure Liquid; Deferasirox; Molecular Structure; Pharmaceutical Preparations; Polystyrenes; Rats; Resins, Synthetic; Triazoles | 2001 |
Plasma deproteinization by precipitation and filtration in the 96-well format.
Topics: Benzoates; Blood Proteins; Chemical Precipitation; Chromatography, High Pressure Liquid; Deferasirox; Filtration; Iron Chelating Agents; Reference Standards; Spectrophotometry, Ultraviolet; Triazoles | 2001 |
Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection.
Topics: Benzoates; Calibration; Chromatography, High Pressure Liquid; Deferasirox; Deferiprone; Deferoxamine; Drug Stability; Humans; Hydrogen-Ion Concentration; Iron; Iron Chelating Agents; Iron Overload; Molecular Structure; Pyridones; Reproducibility of Results; Spectrophotometry, Ultraviolet; Temperature; Thalassemia; Triazoles | 2001 |
Assessment of antimalarial effect of ICL670A on in vitro cultures of Plasmodium falciparum.
Topics: Analysis of Variance; Animals; Antimalarials; Benzoates; Cells, Cultured; Chelating Agents; Deferasirox; Deferoxamine; Dose-Response Relationship, Drug; Erythrocytes; Hypoxanthine; Plasmodium falciparum; Triazoles | 2001 |
ICL670A: preclinical profile.
Topics: Administration, Oral; Animals; Benzoates; beta-Thalassemia; Callithrix; Deferasirox; Dogs; Drug Evaluation, Preclinical; Drug Tolerance; Humans; Iron; Iron Chelating Agents; Iron Overload; Molecular Structure; Rats; Triazoles | 2002 |
Do we need more iron-chelating drugs?
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles | 2003 |
The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin.
Topics: Administration, Oral; Animals; Animals, Newborn; Antibiotics, Antineoplastic; Antioxidants; Benzoates; Chelating Agents; CHO Cells; Cricetinae; Deferasirox; Dose-Response Relationship, Drug; Doxorubicin; Electron Spin Resonance Spectroscopy; Free Radicals; Image Processing, Computer-Assisted; In Situ Nick-End Labeling; Iron; Kinetics; L-Lactate Dehydrogenase; Microscopy, Fluorescence; Models, Chemical; Muscle Cells; Myocytes, Cardiac; Oxidative Stress; Oxygen; Rats; Rats, Sprague-Dawley; Spectrometry, Fluorescence; Time Factors; Triazoles | 2003 |
Acceptance of the 2003 John Howland Award: a journey in clinical research.
Topics: Awards and Prizes; Benzoates; Biomedical Research; Deferasirox; Education, Medical; Hemoglobins; Humans; Pediatrics; Societies, Medical; Triazoles | 2004 |
Iron chelation therapy.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver Injury; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Infusions, Intravenous; Iron Chelating Agents; Iron Overload; Isoniazid; Pyridones; Pyridoxal; Survival; Triazoles | 2005 |
Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells.
Topics: Animals; Benzoates; Catalysis; Cell Line; Cell Survival; Cells; Cytosol; Deferasirox; Deferiprone; Deferoxamine; Endosomes; Humans; Iron; Iron Chelating Agents; Mice; Microscopy, Fluorescence; Mitochondria; Pyridones; Time Factors; Triazoles | 2005 |
The Egyptian experience with oral iron chelators.
Topics: Benzoates; Deferasirox; Deferiprone; Egypt; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Treatment Outcome; Triazoles | 2005 |
The design of orally active iron chelators.
Topics: Administration, Oral; Benzoates; Clinical Trials as Topic; Deferasirox; Dihydropyridines; Drug Design; Drug Evaluation, Preclinical; Humans; Iron; Iron Chelating Agents; Ligands; Models, Molecular; Molecular Structure; Oxidation-Reduction; Pyridones; Thiazoles; Triazoles | 2005 |
Molecule of the month. Deferasirox.
Topics: Benzoates; Chelating Agents; Deferasirox; Humans; Iron Overload; Multicenter Studies as Topic; Transfusion Reaction; Triazoles | 2005 |
[Clinical findings and therapy of classical hereditary haemochromatosis (type 1)].
Topics: Benzoates; Deferasirox; Deferoxamine; Ferritins; Genes, MHC Class I; Genes, Recessive; Hemochromatosis; Humans; Phlebotomy; Point Mutation; Prognosis; Siderophores; Triazoles | 2005 |
Iron chelation therapy for myelodysplastic syndrome: if and when.
Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Humans; Iron Chelating Agents; Myelodysplastic Syndromes; Survival Rate; Triazoles | 2006 |
In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human.
Topics: Animals; Benzoates; Binding, Competitive; Callithrix; Deferasirox; Diazepam; Dogs; Female; Ferrous Compounds; Humans; In Vitro Techniques; Iron Chelating Agents; Male; Mice; Protein Binding; Rabbits; Rats; Serum Albumin; Triazoles; Warfarin | 2006 |
The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox.
Topics: Acetyltransferases; Apoptosis; Benzoates; Biogenic Polyamines; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Deferasirox; DNA Replication; Ethylamines; Hepatocytes; Humans; Hydroxyquinolines; Iron Chelating Agents; Ornithine Decarboxylase; RNA, Messenger; Triazoles | 2006 |
The oral chelator deferasirox--a new perspective for patients with iron overload.
Topics: Benzoates; Clinical Trials as Topic; Deferasirox; Half-Life; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2006 |
Deferasirox versus deferoxamine.
Topics: Benzoates; Data Interpretation, Statistical; Deferasirox; Deferoxamine; Humans; Patient Compliance; Randomized Controlled Trials as Topic; Triazoles | 2006 |
New drugs 06, part II.
Topics: Analgesics; Benzeneacetamides; Benzoates; Bone Density Conservation Agents; Deferasirox; Diphosphonates; Docosahexaenoic Acids; Drug Approval; Drug Combinations; Drug Interactions; Drug Monitoring; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Eicosapentaenoic Acid; gamma-Aminobutyric Acid; Humans; Ibandronic Acid; Iloprost; Indenes; Minocycline; Patient Education as Topic; Phenylacetates; Pregabalin; Tigecycline; Triazoles; Vasodilator Agents | 2006 |
Modulation of cell proliferation in rat liver cell cultures by new calix[4]arenes.
Topics: Animals; Benzoates; Calixarenes; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Deferasirox; Drug Screening Assays, Antitumor; Hydroxyl Radical; Iron Chelating Agents; Molecular Structure; Phenols; Rats; Solubility; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured | 2006 |
Does liver biopsy overestimate liver iron concentration?
Topics: Benzoates; Biopsy; Clinical Trials as Topic; Defensins; Deferasirox; Humans; Iron; Liver; Reproducibility of Results; Triazoles | 2006 |
Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis.
Topics: Adult; Amphotericin B; Antifungal Agents; Benzoates; Brain Stem; Caspofungin; Cavernous Sinus; Central Nervous System Fungal Infections; Deferasirox; Diabetic Ketoacidosis; Drug Therapy, Combination; Echinocandins; Humans; Iron Chelating Agents; Lipopeptides; Magnetic Resonance Imaging; Male; Mucormycosis; Nose Diseases; Peptides, Cyclic; Salvage Therapy; Triazoles | 2006 |
Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil.
Topics: Animals; Benzoates; Deferasirox; Deferiprone; Disease Models, Animal; Female; Gerbillinae; Heart; Iron; Iron Chelating Agents; Iron Overload; Liver; Organ Size; Pyridones; Triazoles | 2006 |
Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Blood Transfusion; Cost-Benefit Analysis; Deferasirox; Delivery of Health Care; Drug Administration Schedule; Drug Utilization Review; Economics, Pharmaceutical; Humans; Infusions, Intravenous; Insurance Claim Review; Iron Chelating Agents; Iron Overload; Markov Chains; Treatment Outcome; Triazoles; United States | 2007 |
[Post transfusionnal iron overload].
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Pyridones; Randomized Controlled Trials as Topic; Triazoles | 2006 |
Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities.
Topics: Acute Kidney Injury; Agranulocytosis; Benzoates; Chelating Agents; Deferasirox; Humans; Iron; Product Surveillance, Postmarketing; Triazoles | 2007 |
Cognitive declines therapy by iron burden reduction.
Topics: Alzheimer Disease; Benzoates; Deferasirox; Ferritins; Humans; Iron; Iron Chelating Agents; Middle Aged; Triazoles | 2007 |
Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy.
Topics: Animals; Benzoates; Cardiomyopathies; Deferasirox; Disease Models, Animal; Drug Administration Schedule; Female; Gerbillinae; Iron; Iron Chelating Agents; Iron Overload; Liver; Myocardium; Triazoles | 2007 |
Iron chelators ICL670 and 311 inhibit HIV-1 transcription.
Topics: Benzoates; Cells, Cultured; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 9; Deferasirox; Gene Expression Regulation, Viral; HIV-1; Humans; Iron; Iron Chelating Agents; Isoniazid; Transcription, Genetic; Triazoles; Virus Replication | 2007 |
The iron chelator deferasirox protects mice from mucormycosis through iron starvation.
Topics: Amphotericin B; Animals; Benzoates; Deferasirox; Diabetes Mellitus; Drug Therapy, Combination; Iron; Iron Chelating Agents; Liposomes; Male; Mice; Mice, Inbred BALB C; Mucorales; Mucormycosis; Survival Rate; Th1 Cells; Th2 Cells; Triazoles | 2007 |
Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism.
Topics: Animals; Apoptosis; Base Sequence; Benzoates; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotherapy, Adjuvant; Deferasirox; Deferiprone; DNA Primers; DNA Replication; Humans; Iron Chelating Agents; Liver Neoplasms; Liver Neoplasms, Experimental; Polyamines; Pyridones; Rats; Triazoles | 2007 |
Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation.
Topics: Atrophy; Benzoates; Biopsy; Brain; Ceruloplasmin; Chelation Therapy; Chorea; Deferasirox; Diagnosis, Differential; Disease Progression; Female; Ferritins; Gait Disorders, Neurologic; Humans; Iron Overload; Liver; Magnetic Resonance Imaging; Middle Aged; Muscle Spasticity; Muscle, Skeletal; Neurodegenerative Diseases; Neurologic Examination; Neuropsychological Tests; Spleen; Triazoles | 2008 |
Electrocatalytic oxidation and determination of deferasirox and deferiprone on a nickel oxyhydroxide-modified electrode.
Topics: Benzoates; Deferasirox; Deferiprone; Electrochemistry; Ion-Selective Electrodes; Iron Chelating Agents; Microscopy, Electron, Scanning; Nickel; Oxidation-Reduction; Pyridones; Triazoles | 2008 |
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Diamond-Blackfan; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Thalassemia; Treatment Outcome; Triazoles | 2008 |
Transfusion-dependent thalassaemia: a new era.
Topics: Benzoates; Cardiomyopathies; Deferasirox; Deferiprone; Deferoxamine; Drug Prescriptions; Erythrocyte Transfusion; Ferritins; Humans; Iron Chelating Agents; Magnetic Resonance Imaging; Myocardium; Patient Compliance; Pyridones; Siderophores; Thalassemia; Triazoles | 2008 |
Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis.
Topics: Adolescent; Antifungal Agents; Benzoates; Deferasirox; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Peritonitis; Radiography, Abdominal; Severity of Illness Index; Treatment Failure; Triazoles; Zygomycosis | 2008 |
Strides made in red blood cell disorders, but substantial barriers to care remain.
Topics: Anemia, Sickle Cell; Antisickling Agents; Benzoates; Brain Diseases; Chelation Therapy; Deferasirox; Hematologic Diseases; Hematology; Humans; Hydroxyurea; Iron Chelating Agents; Triazoles | 2008 |
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Decision Support Techniques; Deferasirox; Deferiprone; Deferoxamine; Hematology; Humans; Iron Chelating Agents; Iron Overload; Liver; Practice Guidelines as Topic; Pyridones; Siderophores; Triazoles | 2008 |
Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom.
Topics: Adult; Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deferasirox; Deferoxamine; Female; Humans; Interviews as Topic; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Siderophores; State Medicine; Triazoles; United Kingdom | 2008 |
Acute kidney injury due to deferoxamine in a renal transplant patient.
Topics: Acute Kidney Injury; Benzoates; Creatinine; Deferasirox; Deferoxamine; Humans; Kidney Transplantation; Siderophores; Triazoles | 2008 |
Comment to: Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox. Haematologica 2008;93:e9-10.
Topics: Benzoates; beta-Thalassemia; Cataract; Deferasirox; Humans; Iron Chelating Agents; Research Design; Sample Size; Triazoles | 2008 |
Hypocalcemia in a dialysis patient treated with deferasirox for iron overload.
Topics: Adult; Anemia, Sickle Cell; Benzoates; Deferasirox; Erythropoietin; Female; Humans; Hypertension; Hypocalcemia; Iron Chelating Agents; Iron Overload; Kidney Failure, Chronic; Peritoneal Dialysis; Transfusion Reaction; Triazoles | 2008 |
Influence of iron chelation on R1 and R2 calibration curves in gerbil liver and heart.
Topics: Animals; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Gerbillinae; Iron; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Myocardium; Pyridones; Siderophores; Tissue Distribution; Triazoles | 2008 |
Iron and hepatitis C: what can we learn from thalassemia major?
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferoxamine; Female; Ferritins; Hepacivirus; Hepatitis C, Chronic; Humans; Iron; Iron Deficiencies; Male; Phlebotomy; Siderophores; Triazoles | 2008 |
Acute interstitial nephritis due to deferasirox: a case report.
Topics: Acute Disease; Benzoates; Deferasirox; Drug Hypersensitivity; Eosinophils; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Nephritis, Interstitial; Triazoles | 2008 |
Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats.
Topics: Animals; Animals, Suckling; ATP-Binding Cassette Transporters; Benzoates; Bile; Blood Chemical Analysis; Deferasirox; Enterohepatic Circulation; Feces; Female; Fetus; Iron; Iron Chelating Agents; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Milk, Human; Models, Biological; Molecular Structure; Placenta; Pregnancy; Rats; Rats, Long-Evans; Rats, Transgenic; Rats, Wistar; Tissue Distribution; Triazoles; Urine | 2008 |
Deferasirox in pyruvate kinase deficiency.
Topics: Adult; Benzoates; Deferasirox; Female; Humans; Iron Overload; Pyruvate Kinase; Treatment Outcome; Triazoles | 2009 |
Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.
Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Treatment Outcome; Triazoles | 2008 |
Deferasirox plus ciprofloxacin combination therapy after rapid diagnosis of Vibrio vulnificus sepsis using real-time polymerase chain reaction.
Topics: Aged; Anti-Bacterial Agents; Benzoates; Ciprofloxacin; Deferasirox; DNA, Bacterial; Drug Therapy, Combination; Female; Hemochromatosis; Humans; Polymerase Chain Reaction; Sepsis; Triazoles; Vibrio Infections; Vibrio vulnificus | 2008 |
Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients.
Topics: Benzoates; Deferasirox; Deferiprone; Drug Therapy, Combination; Heart; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles | 2008 |
Reversal of iron-induced dilated cardiomyopathy during therapy with deferasirox in beta-thalassemia.
Topics: Adolescent; Benzoates; beta-Thalassemia; Cardiomyopathy, Dilated; Deferasirox; Humans; Iron; Male; Triazoles | 2009 |
Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.
Topics: Animals; Benzoates; Deferasirox; Deferoxamine; Disease Models, Animal; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Gerbillinae; Heart; Iron Overload; Liver; Organ Size; Treatment Outcome; Triazoles | 2008 |
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Hematologic Diseases; Humans; Iron Chelating Agents; Pyridones; Risk Assessment; Siderophores; Triazoles | 2008 |
Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide.
Topics: Acute Kidney Injury; Benzoates; Chelation Therapy; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Drug Costs; Drug Industry; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles; Truth Disclosure | 2008 |
Oral iron chelation and the treatment of iron overload in a pediatric hematology center.
Topics: Administration, Oral; Benzoates; Child; Child, Preschool; Deferasirox; Female; Ferritins; Hematology; Hospitals; Humans; Infant; Infant, Newborn; Iron Chelating Agents; Iron Overload; Male; Pediatrics; Triazoles | 2009 |
Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells.
Topics: Anti-Bacterial Agents; Benzoates; Biofilms; Cells, Cultured; Conalbumin; Cystic Fibrosis; Deferasirox; Deferoxamine; Epithelial Cells; Humans; Iron Chelating Agents; Pseudomonas Infections; Tobramycin; Triazoles; United States; United States Food and Drug Administration | 2009 |
Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis.
Topics: Animals; Benzoates; Deferasirox; Disease Models, Animal; Drug Evaluation, Preclinical; GPI-Linked Proteins; Hemochromatosis; Hemochromatosis Protein; Humans; Iron; Iron Chelating Agents; Magnetic Resonance Imaging; Membrane Proteins; Mice; Mice, Knockout; Organ Specificity; Triazoles | 2009 |
Hepatitis C antiviral response in thalassemia: what is the role of liver iron concentration?
Topics: Antiviral Agents; Benzoates; Deferasirox; Hepatitis C; Humans; Iron; Iron Chelating Agents; Liver; Male; Thalassemia; Treatment Outcome; Triazoles; Young Adult | 2009 |
[Deferasirox-induced delayed hypersensitivity syndrome].
Topics: Benzoates; Deferasirox; Female; Humans; Hypersensitivity, Delayed; Iron Chelating Agents; Middle Aged; Triazoles | 2010 |
Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements.
Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Treatment Outcome; Triazoles | 2009 |
The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.
Topics: Animals; Apoptosis; Benzoates; Cell Line, Tumor; Deferasirox; Disease Progression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Iron Chelating Agents; Leukemia, Myeloid; Mice; Mice, Nude; Protein Kinases; Ribosomal Protein S6; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Triazoles; Up-Regulation; Xenograft Model Antitumor Assays | 2009 |
Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes.
Topics: Administration, Oral; Aged; Benzoates; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Triazoles | 2009 |
Restoration of cardiac function by an iron chelator, deferasirox, in a patient with aplastic anemia and cardiac iron overload.
Topics: Anemia, Aplastic; Benzoates; Deferasirox; Female; Heart; Humans; Iron Chelating Agents; Magnetic Resonance Imaging; Triazoles; Young Adult | 2009 |
Iron is essential for oligodendrocyte genesis following intraspinal macrophage activation.
Topics: Animals; Antigens; Benzoates; Bromodeoxyuridine; CD11b Antigen; Cell Proliferation; Deferasirox; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Ferritins; Gene Expression Regulation; Injections, Spinal; Intracellular Signaling Peptides and Proteins; Iron; Iron Chelating Agents; Lipopolysaccharides; Macrophage Activation; Macrophages; Oligodendroglia; Proteoglycans; Rats; Rats, Sprague-Dawley; Time Factors; Triazoles | 2009 |
Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Overload; Pyridones; Siderophores; Triazoles; Vibrio Infections; Vibrio vulnificus | 2009 |
Transfusion independence in Diamond-Blackfan anemia after deferasirox therapy.
Topics: Adult; Anemia, Diamond-Blackfan; Benzoates; Blood Transfusion; Deferasirox; Female; Ferritins; Hemoglobins; Humans; Iron Chelating Agents; Triazoles | 2009 |
Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
Topics: Adult; Aged; Benzoates; Chelation Therapy; Deferasirox; Exanthema; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Mucormycosis; Treatment Outcome; Triazoles | 2009 |
Fanconi syndrome due to deferasirox.
Topics: Aged; Benzoates; Deferasirox; Fanconi Syndrome; Humans; Iron Chelating Agents; Male; Triazoles | 2009 |
Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil.
Topics: Animals; Benzoates; Cardiotonic Agents; Deferasirox; Extracellular Signal-Regulated MAP Kinases; Gerbillinae; Heart; Iron; Iron Chelating Agents; Iron Overload; Male; MAP Kinase Kinase 4; Myocardium; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Triazoles | 2009 |
Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.
Topics: Administration, Oral; Anemia; Benzoates; Cost-Benefit Analysis; Deferasirox; Drug Costs; Economics, Pharmaceutical; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Medication Adherence; Quality of Life; Randomized Controlled Trials as Topic; Triazoles | 2009 |
Iron chelation therapy in myelodysplastic syndrome - Cui bono?
Topics: Aged; Benzoates; Biomarkers; Chelation Therapy; Deferasirox; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Life Expectancy; Middle Aged; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles | 2009 |
Adult-onset erythropoietic porphyria in the setting of MDS.
Topics: Aged, 80 and over; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Male; Myelodysplastic Syndromes; Porphyria, Erythropoietic; Triazoles | 2009 |
Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Multicenter Studies as Topic; Myelodysplastic Syndromes; Triazoles | 2010 |
Adherence to deferasirox in children and adolescents with sickle cell disease during 1-year of therapy.
Topics: Adolescent; Anemia, Sickle Cell; Benzoates; Blood Transfusion; Child; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Parents; Patient Compliance; Surveys and Questionnaires; Triazoles | 2009 |
The effects of deferiprone and deferasirox on the structure and function of beta-thalassemia hemoglobin.
Topics: Benzoates; beta-Thalassemia; Circular Dichroism; Deferasirox; Deferiprone; Hemoglobins; Humans; Iron Chelating Agents; Pyridones; Spectrometry, Fluorescence; Structure-Activity Relationship; Triazoles | 2009 |
Update on thalassemia treatment in Taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects.
Topics: Benzoates; beta-Thalassemia; Blood Transfusion; Bone Marrow Transplantation; Cardiomyopathies; Chelation Therapy; Clinical Trials as Topic; Combined Modality Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Guidelines as Topic; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Pyridones; Siderophores; Siderosis; Taiwan; Treatment Outcome; Triazoles | 2009 |
Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients.
Topics: Aeromonas hydrophila; Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Gram-Negative Bacterial Infections; Humans; Iron Chelating Agents; Iron Overload; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Prevalence; Pyridones; Thalassemia; Triazoles | 2009 |
Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.
Topics: Animals; Antioxidants; Benzoates; Chelation Therapy; Copper; Deferasirox; Deferiprone; Deferoxamine; Free Radicals; Humans; Iron; Iron Chelating Agents; Iron Overload; Oxidative Stress; Pyridones; Risk Assessment; Siderophores; Thalassemia; Triazoles | 2009 |
Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study.
Topics: Adult; Benzoates; beta-Thalassemia; Deferasirox; Female; Ferritins; Heart; Humans; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Pilot Projects; Prospective Studies; Treatment Outcome; Triazoles | 2010 |
Antiproliferative effect on HepaRG cell cultures of new calix[4]arenes.
Topics: Benzoates; Calixarenes; Cell Line, Tumor; Cell Proliferation; Deferasirox; Drug Design; Humans; Iron; Iron Chelating Agents; Phenols; Triazoles | 2010 |
Deferasirox (Exjade) for the treatment of iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Rare Diseases; Thalassemia; Triazoles | 2009 |
Effect of iron chelators on labile iron and oxidative status of thalassaemic erythroid cells.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Erythrocytes; Erythroid Cells; Ferritins; Flow Cytometry; Humans; In Vitro Techniques; Iron; Iron Chelating Agents; Iron Overload; Oxidative Stress; Phosphatidylserines; Pyridones; Reactive Oxygen Species; Reticulocytes; Triazoles | 2010 |
Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major.
Topics: Acidosis; Benzoates; beta-Thalassemia; Chlorides; Deferasirox; Female; Humans; Iron Chelating Agents; Middle Aged; Triazoles | 2010 |
The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillus fumigatus; Benzoates; Deferasirox; Drug Synergism; Drug Therapy, Combination; Humans; Invasive Pulmonary Aspergillosis; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Microbial Viability; Survival Analysis; Treatment Outcome; Triazoles | 2010 |
Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG.
Topics: Benzoates; Carcinoma, Hepatocellular; Cell Line, Tumor; Deferasirox; Deferiprone; Dose-Response Relationship, Drug; Female; Ferritins; Hepatocytes; Humans; Iron; Iron Chelating Agents; Liver Neoplasms; Molecular Structure; Pyridones; Receptors, Transferrin; Triazoles | 2010 |
Nanoparticle and iron chelators as a potential novel Alzheimer therapy.
Topics: Aged; Alzheimer Disease; Benzoates; Blood-Brain Barrier; Brain; Chelation Therapy; Deferasirox; Deferoxamine; Drug Carriers; Ferritins; Humans; Iron; Iron Chelating Agents; Metals; Molecular Structure; Nanoparticles; Triazoles | 2010 |
Deferasirox treatment may be associated with reversible renal Fanconi syndrome.
Topics: Adolescent; Benzoates; Child; Deferasirox; Fanconi Syndrome; Female; Humans; Iron Chelating Agents; Iron Overload; Kidney; Male; Transfusion Reaction; Triazoles | 2010 |
Gastric ulcer in a child treated with deferasirox.
Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Humans; Iron Chelating Agents; Stomach Ulcer; Triazoles | 2010 |
Paradoxically increased ferritin level in a beta-thalassemia major patient following the start of deferasirox chelation therapy.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Triazoles | 2010 |
Cystatin C levels in patients with beta-thalassemia during deferasirox treatment.
Topics: Acute-Phase Proteins; Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Cystatin C; Deferasirox; Female; Glomerular Filtration Rate; Humans; Iron Chelating Agents; Lipocalin-2; Lipocalins; Male; Natriuretic Peptide, Brain; Peptide Fragments; Proto-Oncogene Proteins; Triazoles; Young Adult | 2010 |
Iron toxicity: optimizing chelation therapy across transfusion-dependent anaemias. Introduction.
Topics: Anemia; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Overload; Pyridones; Triazoles | 2009 |
In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus.
Topics: Anti-Bacterial Agents; Benzoates; Chelating Agents; Ciprofloxacin; Deferasirox; Drug Synergism; Hospitals; Humans; Microbial Sensitivity Tests; Microbial Viability; Republic of Korea; Time Factors; Triazoles; Vibrio Infections; Vibrio vulnificus | 2010 |
Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome.
Topics: Aged; Anemia; Benzoates; Chronic Disease; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Radiography; Thrombocytopenia; Transfusion Reaction; Triazoles | 2010 |
Ability of deferasirox to bind iron during measurement of iron.
Topics: Benzoates; Deferasirox; Humans; Iron; Iron Chelating Agents; Iron Overload; Triazoles | 2010 |
Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
Topics: Adolescent; Adult; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Biomarkers; Chelation Therapy; Child; Child, Preschool; Cystatin C; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Early Diagnosis; Female; Humans; Hypercalciuria; Iron Chelating Agents; Kidney Diseases; Kidney Function Tests; Male; Proteinuria; Pyridones; Triazoles; Young Adult | 2010 |
Charge states of deferasirox-ferric iron complexes.
Topics: Benzoates; Deferasirox; Electrophysiological Phenomena; Fanconi Syndrome; Ferric Compounds; Humans; Iron Chelating Agents; Triazoles | 2010 |
Transport of iron chelators and chelates across MDCK cell monolayers: implications for iron excretion during chelation therapy.
Topics: Adenosine Triphosphate; Animals; Benzoates; Biological Transport; Cell Line; Cell Polarity; Deferasirox; Deferoxamine; Dogs; Epithelial Cells; Exocytosis; Iron; Iron Chelating Agents; Iron Overload; Iron Radioisotopes; Kidney; Models, Biological; Pyridones; Siderophores; Temperature; Triazoles | 2010 |
Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Deferasirox; Dose-Response Relationship, Drug; Female; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Myocardium; Time Factors; Triazoles; Ventricular Function, Left; Young Adult | 2010 |
Deferasirox decreases age-associated iron accumulation in the aging F344XBN rat heart and liver.
Topics: Aging; Animals; Apoptosis; Benzoates; Body Weight; Deferasirox; Heart; In Situ Nick-End Labeling; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Myocardium; Myocytes, Cardiac; Organ Size; Rats; Rats, Inbred F344; Trace Elements; Triazoles | 2010 |
Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients.
Topics: Anemia, Aplastic; Benzoates; Blood Transfusion; Deferasirox; Female; Hematopoiesis; Humans; Iron Chelating Agents; Male; Middle Aged; Myelodysplastic Syndromes; Triazoles | 2010 |
Iron chelation therapy in myelodysplastic syndromes.
Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Education, Continuing; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Quality-Adjusted Life Years; Siderophores; Treatment Outcome; Triazoles | 2010 |
A method to measure deferasirox in plasma using HPLC coupled with MS/MS detection and its potential application.
Topics: Benzoates; Blood Specimen Collection; Calibration; Chromatography, High Pressure Liquid; Deferasirox; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Iron Chelating Agents; Iron Overload; Quality Control; Reference Standards; Reproducibility of Results; Solvents; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Triazoles | 2010 |
Clinical evaluation of Deferasirox for removal of cadmium ions in rat.
Topics: Animals; Benzoates; Cadmium; Cadmium Poisoning; Chelation Therapy; Deferasirox; Humans; Iron Chelating Agents; Male; Molecular Structure; Rats; Rats, Wistar; Triazoles | 2010 |
Acute renal failure and Fanconi syndrome due to deferasirox.
Topics: Acute Kidney Injury; Aged; Benzoates; Chronic Disease; Deferasirox; Fanconi Syndrome; Humans; Iron Chelating Agents; Iron Overload; Kidney; Male; Triazoles | 2010 |
Acute interstitial nephritis secondary to deferasirox causing acute renal injury needing short-term dialysis.
Topics: Acute Kidney Injury; Aged; Benzoates; Biopsy; Deferasirox; Glucocorticoids; Humans; Iron Chelating Agents; Male; Nephritis, Interstitial; Prednisolone; Renal Dialysis; Time Factors; Treatment Outcome; Triazoles | 2010 |
Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years.
Topics: Adolescent; Adult; Benzoates; Child; Deferasirox; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Retrospective Studies; Siderophores; Survival Rate; Thalassemia; Treatment Outcome; Triazoles; Young Adult | 2010 |
Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Topics: Administration, Oral; Arthralgia; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Infusions, Subcutaneous; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles; Young Adult | 2010 |
The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.
Topics: Anti-Infective Agents; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Infections; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2010 |
Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.
Topics: Aged; Aged, 80 and over; Apoptosis; Benzoates; Blotting, Western; Deferasirox; Electrophoretic Mobility Shift Assay; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Iron; Iron Chelating Agents; K562 Cells; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; NF-kappa B; Protein Binding; Reactive Oxygen Species; Triazoles | 2010 |
Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.
Topics: Adolescent; Adult; Age Factors; Benzoates; beta-Thalassemia; Child; Death; Deferasirox; Deferiprone; Deferoxamine; Female; Greece; Heart Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Spectroscopy; Male; Pyridones; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2010 |
Deferasirox use after hematopoietic stem cell transplantation in pediatric patients with beta-thalassemia major: preliminary results.
Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Ferritins; Hematopoietic Stem Cell Transplantation; Humans; Magnetic Resonance Imaging; Male; Treatment Outcome; Triazoles | 2010 |
Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response.
Topics: Benzoates; Blood Transfusion; Deferasirox; Erythroid Cells; Ferritins; Hemoglobins; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Triazoles | 2010 |
Renal Fanconi syndrome secondary to deferasirox: where there is smoke there is fire.
Topics: Benzoates; Deferasirox; Fanconi Syndrome; Humans; Iron Chelating Agents; Kidney Tubules, Proximal; Triazoles | 2010 |
Removal of thallium by deferasirox in rats as biological model.
Topics: Animals; Benzoates; Body Weight; Chelating Agents; Chelation Therapy; Deferasirox; Disease Models, Animal; Dose-Response Relationship, Drug; Heavy Metal Poisoning; Iron; Male; Metals, Heavy; Poisoning; Random Allocation; Rats; Rats, Wistar; Spectrophotometry, Atomic; Thallium; Triazoles | 2011 |
Deferasirox induced liver injury in haemochromatosis.
Topics: Benzoates; Chemical and Drug Induced Liver Injury; Deferasirox; Female; Hemochromatosis; Humans; Iron Chelating Agents; Middle Aged; Triazoles | 2010 |
Pathogenesis and management of iron toxicity in thalassemia.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Homeostasis; Humans; Iron; Iron Chelating Agents; Iron Overload; Models, Molecular; Pyridones; Reactive Oxygen Species; Thalassemia; Transferrin; Transfusion Reaction; Triazoles | 2010 |
Deferasirox--current knowledge and future challenges.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Ferritins; Humans; Iron; Iron Chelating Agents; Myocardium; Triazoles | 2010 |
Delineating parameters of iron overload in MDS patients treated with deferasirox.
Topics: Aged; Aged, 80 and over; Benzoates; Deferasirox; Dose-Response Relationship, Drug; Erythrocyte Transfusion; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Triazoles | 2010 |
Iron chelation therapy for patients with sickle cell disease and iron overload.
Topics: Administration, Oral; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Monitoring; Erythrocyte Transfusion; Humans; Infusion Pumps; Infusions, Subcutaneous; Iron Chelating Agents; Iron Overload; Male; Pain; Patient Compliance; Pyridones; Sensation Disorders; Social Isolation; Triazoles; Young Adult; Zinc | 2010 |
Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox.
Topics: Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Combined Modality Therapy; Deferasirox; Fanconi Syndrome; Female; Humans; Iron Chelating Agents; Kidney Tubules, Proximal; Male; Triazoles; Water-Electrolyte Imbalance | 2010 |
Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation.
Topics: Antimicrobial Cationic Peptides; Benzoates; Brain; Ceruloplasmin; Consanguinity; Deferasirox; Female; Hepcidins; Homozygote; Humans; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Liver; Male; Middle Aged; Mutation; Neurodegenerative Diseases; Pedigree; RNA, Messenger; Triazoles | 2010 |
Oral chelation: should it be used with young children?
Topics: Benzoates; Child, Preschool; Deferasirox; Drug Prescriptions; Humans; Iron Chelating Agents; Medication Adherence; Triazoles | 2010 |
Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients.
Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Humans; Insurance Claim Review; Iron Chelating Agents; Iron Overload; Longitudinal Studies; Myelodysplastic Syndromes; Quality-Adjusted Life Years; Siderophores; State Medicine; Survival Analysis; Triazoles; United Kingdom | 2010 |
A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.
Topics: Adult; Aged; Amino Acid Substitution; Benzoates; Creatinine; Deferasirox; Dose-Response Relationship, Drug; Female; Ferritins; Hemochromatosis; Homozygote; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Phlebotomy; Safety; Transferrin; Triazoles | 2010 |
Myelodysplastic syndromes--many new drugs, little therapeutic progress.
Topics: Age Distribution; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Triazoles | 2010 |
Restoration of hematopoiesis after iron chelation therapy with deferasirox in 2 children with severe aplastic anemia.
Topics: Anemia, Aplastic; Benzoates; Child; Deferasirox; Hematopoiesis; Humans; Iron Chelating Agents; Iron Overload; Male; Severity of Illness Index; Transfusion Reaction; Triazoles | 2010 |
Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Pyridones; Retrospective Studies; Siderophores; Triazoles; Ventricular Function; Young Adult | 2011 |
Iron-induced cardiac damage: role of apoptosis and deferasirox intervention.
Topics: Animals; Apoptosis; Benzoates; Deferasirox; Gerbillinae; Iron; Iron Chelating Agents; Iron Overload; Male; Myocardium; Triazoles | 2011 |
Activity of deferasirox in Mucorales: influences of species and exogenous iron.
Topics: Antifungal Agents; Benzoates; Deferasirox; Iron; Microbial Sensitivity Tests; Mucorales; Triazoles | 2011 |
Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Prognosis; Prospective Studies; Triazoles; Ventricular Function, Left; Young Adult | 2011 |
HJV hemochromatosis, iron overload, and hypogonadism in a Brazilian man: treatment with phlebotomy and deferasirox.
Topics: Benzoates; Brazil; Cation Transport Proteins; Combined Modality Therapy; Deferasirox; Exons; Gene Amplification; Hemochromatosis; Hemochromatosis Protein; Histocompatibility Antigens Class I; Humans; Hypogonadism; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Membrane Proteins; Phlebotomy; Polymorphism, Single Nucleotide; Receptors, Transferrin; Stroke Volume; Triazoles; Young Adult | 2010 |
Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
Topics: Administration, Oral; Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Drug Administration Schedule; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Maximum Tolerated Dose; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2011 |
Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months.
Topics: Adolescent; Benzoates; beta-Thalassemia; Deferasirox; Fanconi Syndrome; Hospitalization; Humans; Iron Chelating Agents; Iron Overload; Kidney; Male; Transfusion Reaction; Triazoles | 2011 |
The effects of deferasirox on renal, cardiac and hepatic iron load in patients with β-thalassemia major: preliminary results.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Heart; Humans; Iron Chelating Agents; Iron Overload; Kidney; Liver; Male; Prospective Studies; Treatment Outcome; Triazoles; Young Adult | 2011 |
Unrelated hematopoietic stem cell transplantation in a patient with congenital dyserythropoietic anemia and iron overload.
Topics: Anemia, Dyserythropoietic, Congenital; Benzoates; Bone Marrow Transplantation; Child, Preschool; Deferasirox; Deferoxamine; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Iron; Iron Chelating Agents; Iron Overload; Male; Triazoles; Unrelated Donors | 2012 |
Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine.
Topics: Adolescent; Age Factors; Benzoates; beta-Thalassemia; Child; Child, Preschool; Death; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Egypt; Electrocardiography; Female; Ferritins; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Prospective Studies; Pyridones; Sex Factors; Siderophores; Siderosis; Triazoles | 2010 |
Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration.
Topics: Animals; Benzoates; Brain; Deferasirox; Deferiprone; Deferoxamine; Free Radicals; Immunohistochemistry; Injections, Intraventricular; Iron Chelating Agents; Male; Microdialysis; Neuroprotective Agents; Parkinsonian Disorders; Pyridones; Rats; Rats, Sprague-Dawley; Sorbic Acid; Triazoles | 2011 |
Normal pregnancy in a patient with β-thalassaemia major receiving iron chelation therapy with deferasirox (Exjade®).
Topics: Adult; Benzoates; beta-Thalassemia; Contraindications; Deferasirox; Female; Humans; Infant, Newborn; Iron Chelating Agents; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Triazoles | 2011 |
Chelation of cadmium by combining deferasirox and deferiprone in rats.
Topics: Animals; Benzoates; Cadmium Compounds; Cadmium Poisoning; Chelation Therapy; Deferasirox; Deferiprone; Drug Combinations; Iron Chelating Agents; Iron Compounds; Male; Pyridones; Rats; Rats, Wistar; Spectrophotometry, Atomic; Triazoles | 2011 |
Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function.
Topics: Animals; Astrocytes; Benzoates; Brain; Cyclic AMP Response Element-Binding Protein; Deferasirox; Deferoxamine; Erythropoietin; Extracellular Signal-Regulated MAP Kinases; Gene Deletion; Hypoxia-Inducible Factor 1; Iron Chelating Agents; Mice; Mice, Knockout; Neurons; Neuroprotective Agents; Phosphorylation; Proto-Oncogene Proteins c-akt; Stroke; Triazoles | 2011 |
Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major.
Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Female; Humans; India; Iron Chelating Agents; Iron Overload; Male; Transfusion Reaction; Triazoles | 2011 |
Oral iron chelator deferasirox in the treatment of secondary hemochromatosis following bone marrow transplantation in a patient with severe aplastic anemia.
Topics: Adult; Anemia, Aplastic; Benzoates; Bone Marrow Transplantation; Deferasirox; Ferritins; Hemochromatosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Triazoles | 2011 |
A case of well-tolerated and safe deferasirox administration during the first trimester of a spontaneous pregnancy in an advanced maternal age thalassemic patient.
Topics: Administration, Oral; Adult; Benzoates; beta-Thalassemia; Deferasirox; Female; Humans; Iron Chelating Agents; Maternal Age; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Pregnancy Trimester, First; Triazoles | 2011 |
In vitro antimalarial activity of ICL670: a further proof of the correlation between inhibition of β-hematin formation and of peroxidative degradation of hemin.
Topics: Antimalarials; Benzoates; Chloroquine; Deferasirox; Deferiprone; Deferoxamine; Glutathione; Hemeproteins; Hemin; Hydrogen Peroxide; Inhibitory Concentration 50; Iron Chelating Agents; Plasmodium falciparum; Pyridones; Structure-Activity Relationship; Triazoles; Triterpenes; Ursolic Acid | 2011 |
Reversible Fanconi syndrome in a pediatric patient on deferasirox.
Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Erythrocyte Transfusion; Fanconi Syndrome; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Triazoles | 2011 |
Is deferasirox implicated in multiple organ failure in a patient with homozygous β-thalassemia?
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Fatal Outcome; Humans; Iron Chelating Agents; Male; Multiple Organ Failure; Risk Factors; Triazoles | 2011 |
Iron chelation in thalassemia: time to reconsider our comfort zones.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Pyridones; Survival Analysis; Thalassemia; Triazoles | 2011 |
Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.
Topics: Administration, Oral; Angiogenesis Inhibitors; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzoates; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Choline Deficiency; Deferasirox; Disease Progression; Drug Therapy, Combination; Fatty Liver; Hepatic Stellate Cells; Iron Chelating Agents; Liver Cirrhosis, Experimental; Liver Neoplasms, Experimental; Losartan; Male; Neovascularization, Pathologic; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Rats; Rats, Inbred F344; Time Factors; Transforming Growth Factor beta1; Triazoles | 2011 |
Effects of deferasirox on renal function and renal epithelial cell death.
Topics: Acetylglucosaminidase; Animals; Apoptosis; Benzoates; Cell Adhesion Molecules; Cell Line; Chick Embryo; Clusterin; Cystatin C; Deferasirox; Epithelial Cells; Glomerular Filtration Rate; Histocytochemistry; Iron Chelating Agents; Kidney; Kidney Diseases; Lipocalins; Male; Rats; Rats, Wistar; Triazoles | 2011 |
Deferasirox increases BU blood concentrations.
Topics: Benzoates; Busulfan; Deferasirox; Female; Humans; Immunosuppressive Agents; Iron Chelating Agents; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Triazoles | 2012 |
Iron chelation adherence to deferoxamine and deferasirox in thalassemia.
Topics: Adolescent; Adult; Age Factors; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Humans; Iron Chelating Agents; Male; Medical Records; Medication Adherence; Middle Aged; North America; Retrospective Studies; Self Report; Thalassemia; Triazoles; United Kingdom; Young Adult | 2011 |
Deferasirox protects against iron-induced hepatic injury in Mongolian gerbil.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Benzoates; Caspase 3; Chemical and Drug Induced Liver Injury; Deferasirox; Disease Models, Animal; DNA Fragmentation; Ferritins; Gerbillinae; Iron Chelating Agents; Iron Overload; Iron-Dextran Complex; Male; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Translational Research, Biomedical; Triazoles | 2011 |
Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Sickle Cell; Benzoates; Child; Child, Preschool; Cohort Studies; Deferasirox; Deferoxamine; Female; Florida; Hospitalization; Humans; Iron Chelating Agents; Kaplan-Meier Estimate; Male; Medicaid; Medication Adherence; Middle Aged; Missouri; New Jersey; Retrospective Studies; Triazoles; United States; Young Adult | 2012 |
A record of 1320 suspect, deferasirox-related, patient deaths reported in 2009: insufficient toxicity testing, low efficacy and lack of transparency may endanger the lives of iron loaded patients.
Topics: Benzoates; Deferasirox; Drug-Related Side Effects and Adverse Reactions; Ethics, Medical; Ethics, Research; Humans; Iron Overload; Triazoles | 2011 |
Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Treatment Outcome; Triazoles | 2011 |
Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzoates; Chelation Therapy; Deferasirox; Drug Resistance, Neoplasm; Erythrocyte Transfusion; Gemtuzumab; Humans; Iron Chelating Agents; Leukemia, Myelomonocytic, Acute; Male; Remission Induction; Salvage Therapy; Treatment Outcome; Triazoles | 2011 |
Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study.
Topics: Benzoates; beta-Thalassemia; Blood Transfusion; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Health Care Costs; Humans; Iron Chelating Agents; Markov Chains; Models, Economic; Pyridones; Quality-Adjusted Life Years; Thailand; Triazoles | 2011 |
Iron chelation with deferasirox in two patients with HFE hemochromatosis and chronic anemia.
Topics: Aged; Benzoates; Chelation Therapy; Deferasirox; Female; Genotype; Hemochromatosis; Hemochromatosis Protein; Histocompatibility Antigens Class I; Humans; Iron Chelating Agents; Male; Membrane Proteins; Treatment Outcome; Triazoles | 2011 |
Importance of optimal dosing ≥ 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Female; Humans; Iron Chelating Agents; Male; Triazoles | 2011 |
Absence of teratogenicity of deferasirox treatment during pregnancy in a thalassaemic patient.
Topics: Adult; Benzoates; beta-Thalassemia; Deferasirox; Female; Humans; Infant, Newborn; Iron Chelating Agents; Male; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Teratogens; Triazoles | 2011 |
The reversed halo sign as the initial radiographic sign of pulmonary zygomycosis.
Topics: Amphotericin B; Antifungal Agents; Benzoates; Caspofungin; Deferasirox; Echinocandins; Fatal Outcome; Female; Humans; Iron Chelating Agents; Lipopeptides; Lung; Lung Diseases, Fungal; Middle Aged; Mucormycosis; Rhizopus; Stem Cell Transplantation; Tomography, X-Ray Computed; Triazoles | 2012 |
Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox.
Topics: Benzoates; Chelation Therapy; Deferasirox; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Myelodysplastic Syndromes; Practice Guidelines as Topic; Triazoles | 2011 |
Response to effect of deferasirox on iron absorption in a randomized, placebo-controlled, crossover study in a human model of acute supratherapeutic iron ingestion.
Topics: Antidotes; Benzoates; Deferasirox; Humans; Iron; Iron Chelating Agents; Triazoles | 2011 |
Hemojuvelin hemochromatosis receiving iron chelation therapy with deferasirox: improvement of liver disease activity, cardiac and hematological function.
Topics: Adult; Benzoates; Deferasirox; GPI-Linked Proteins; Heart Function Tests; Hemochromatosis; Hemochromatosis Protein; Humans; Iron Chelating Agents; Liver Function Tests; Male; Triazoles | 2011 |
Chelation therapy for secondary iron overload: is the primary effect less iron or less liver fibrosis?
Topics: Benzoates; beta-Thalassemia; Deferasirox; Female; Humans; Iron Chelating Agents; Liver; Liver Cirrhosis; Male; Triazoles | 2011 |
Interference of deferasirox with assays for serum iron and serum unsaturated iron binding capacity during iron chelating therapy.
Topics: Benzoates; Deferasirox; Humans; Iron; Iron Chelating Agents; Triazoles | 2011 |
Oxidative stress and antioxidant capacity in sickle cell anaemia patients receiving different treatments and medications for different periods of time.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antioxidants; Benzoates; Biomarkers; Blood Transfusion; Child; Deferasirox; Female; Humans; Iron Chelating Agents; Lipid Peroxidation; Longitudinal Studies; Male; Middle Aged; Oxidative Stress; Thiobarbituric Acid Reactive Substances; Triazoles; Young Adult | 2012 |
The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Benzoates; Caspases; Cell Cycle; Cell Proliferation; Cell Survival; Deferasirox; Enzyme Activation; HL-60 Cells; Humans; Injections, Intraperitoneal; Iron Chelating Agents; Leukemia, Myeloid; Mice; Mice, Nude; Neoplasm Proteins; Poly(ADP-ribose) Polymerases; Proteolysis; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
A case of hypophosphatemic osteomalacia secondary to deferasirox therapy.
Topics: Adult; Benzoates; Bone Density; Deferasirox; Dose-Response Relationship, Drug; Female; Humans; Hypophosphatemia; Lumbar Vertebrae; Osteomalacia; Phosphates; Triazoles | 2012 |
Challenges of adherence and persistence with iron chelation therapy.
Topics: Administration, Oral; Adolescent; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Dosage Forms; Humans; Infusions, Intravenous; Iron Chelating Agents; Iron Overload; Patient Care Team; Patient Compliance; Pyridones; Time Factors; Triazoles | 2011 |
Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Transfusion Reaction; Triazoles | 2012 |
Iron chelation therapy with deferasirox results in recovery of hematopoiesis in a child with aplastic anemia.
Topics: Anemia, Aplastic; Benzoates; Child, Preschool; Deferasirox; Hematopoiesis; Humans; Iron Chelating Agents; Male; Treatment Outcome; Triazoles | 2011 |
Chelation of aluminum by combining deferasirox and deferiprone in rats.
Topics: Aluminum; Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Iron; Male; Pyridones; Rats; Rats, Wistar; Triazoles | 2012 |
Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT).
Topics: Adolescent; Adult; Benzoates; Deferasirox; Female; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Kidney; Leukemia; Leukemia, Myeloid, Acute; Liver; Male; Middle Aged; Phlebotomy; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous; Triazoles; Young Adult | 2012 |
Deferasirox induced liver injury in haemochromatosis.
Topics: Administration, Oral; Benzoates; Chemical and Drug Induced Liver Injury; Deferasirox; Diagnosis, Differential; Dose-Response Relationship, Drug; Female; Hemochromatosis; Humans; Iron Chelating Agents; Middle Aged; Triazoles | 2011 |
Severe hypocalcemia and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome under deferasirox therapy for myelodysplasic syndrome.
Topics: Aged; Benzoates; Deferasirox; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Female; Humans; Hypocalcemia; Iron Chelating Agents; Myelodysplastic Syndromes; Syndrome; Triazoles | 2012 |
Removal of cadmium by combining deferasirox and desferrioxamine chelators in rats.
Topics: Animals; Benzoates; Body Weight; Cadmium; Chelating Agents; Chelation Therapy; Deferasirox; Deferoxamine; Iron; Male; Rats; Rats, Wistar; Tissue Distribution; Triazoles | 2012 |
The dilemma of hyperoxia following positive pressure mechanical ventilation: role of iron and the benefit of iron chelation with deferasirox.
Topics: Adult; Benzoates; Deferasirox; Female; Ferritins; Humans; Hyperoxia; Iron; Iron Chelating Agents; Lung Injury; Male; Middle Aged; Oxidative Stress; Positive-Pressure Respiration; Triazoles | 2011 |
Deferasirox in mucormycosis: hopefully, not defeated.
Topics: Amphotericin B; Animals; Antifungal Agents; Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Male; Mucormycosis; Triazoles | 2012 |
Deferasirox as adjunctive therapy for mucormycosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Male; Mucormycosis; Triazoles | 2012 |
Efficacy of deferasirox in North Indian β-thalassemia major patients: a preliminary report.
Topics: Adolescent; Adult; Alanine Transaminase; Aspartate Aminotransferases; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Male; Triazoles | 2012 |
Combination therapy for mucormycosis: why, what, and how?
Topics: Animals; Antifungal Agents; Benzoates; Clinical Trials as Topic; Deferasirox; Drug Therapy, Combination; Echinocandins; Humans; Lipids; Mice; Mucormycosis; Polyenes; Treatment Outcome; Triazoles | 2012 |
Health-related quality of life in Thai thalassemic children treated with iron chelation.
Topics: Adolescent; Age Factors; Benzoates; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Emotions; Female; Health Status; Humans; Interpersonal Relations; Iron Chelating Agents; Male; Pyridones; Quality of Life; Severity of Illness Index; Social Support; Thailand; Thalassemia; Triazoles | 2011 |
Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC-ESI-QT/MS/MS.
Topics: Benzoates; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Chromatography, Liquid; Deferasirox; Drug Contamination; Guidelines as Topic; Iron Chelating Agents; Isomerism; Limit of Detection; Magnetic Resonance Spectroscopy; Molecular Structure; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Tandem Mass Spectrometry; Technology, Pharmaceutical; Triazoles | 2012 |
[Marked improvement of anemia during treatment with deferasirox in patients with primary myelofibrosis and acute myeloid leukemia with myelodysplasia-related changes].
Topics: Aged; Aged, 80 and over; Benzoates; Deferasirox; Erythrocyte Transfusion; Female; Hematopoiesis; Humans; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Treatment Outcome; Triazoles | 2012 |
Hydrophilic interaction liquid chromatography/positive ion electrospray mass spectrometry for the quantification of deferasirox, an oral iron chelator, in human plasma.
Topics: Acetates; Acetonitriles; Adult; Benzoates; beta-Thalassemia; Chromatography, Liquid; Deferasirox; Female; Humans; Hydrophobic and Hydrophilic Interactions; Linear Models; Male; Methanol; Mianserin; Mirtazapine; Spectrometry, Mass, Electrospray Ionization; Triazoles | 2012 |
A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients.
Topics: Benzoates; Chromatography, High Pressure Liquid; Deferasirox; Female; Ferritins; Humans; Linear Models; Male; Reproducibility of Results; Sensitivity and Specificity; Statistics, Nonparametric; Thalassemia; Triazoles | 2012 |
Iron overload during follow-up after tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Child; Child, Preschool; Creatinine; Deferasirox; Ferritins; Follow-Up Studies; Humans; Infant; Iron Chelating Agents; Iron Overload; Neuroblastoma; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Transfusion Reaction; Transplantation, Autologous; Triazoles | 2012 |
Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron Chelating Agents; Male; Pyridones; Treatment Outcome; Triazoles; Ubiquinone; Young Adult | 2012 |
Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors.
Topics: Aged; Aged, 80 and over; Benzoates; Cell Proliferation; Cell Survival; Cells, Cultured; Deferasirox; Down-Regulation; Female; Fetal Blood; Hematopoietic Stem Cells; Humans; Iron Chelating Agents; Male; Middle Aged; Myelodysplastic Syndromes; Reactive Oxygen Species; Triazoles; Up-Regulation | 2012 |
Determination of ferritin and hemosiderin iron in patients with normal iron stores and iron overload by serum ferritin kinetics.
Topics: Anemia; Benzoates; Biomarkers; Computer Simulation; Deferasirox; Female; Ferritins; Hemochromatosis; Hemosiderin; Hepatitis C, Chronic; Humans; Iron; Iron Chelating Agents; Iron Overload; Japan; Kinetics; Liver; Male; Middle Aged; Models, Biological; Triazoles | 2012 |
Deferasirox-induced renal impairment in children: an increasing concern for pediatricians.
Topics: Administration, Oral; Adolescent; Age Factors; Benzoates; Child; Deferasirox; Female; Glomerular Filtration Rate; Humans; Inulin; Iron Chelating Agents; Iron Overload; Kidney Diseases; Kidney Glomerulus; Kidney Tubules, Proximal; Male; Prospective Studies; Time Factors; Transfusion Reaction; Triazoles | 2012 |
First report of drug-induced esophagitis by deferasirox.
Topics: Benzoates; Deferasirox; Esophagitis; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles | 2012 |
The administration of deferasirox in an iron-overloaded dialysis patient.
Topics: Benzoates; Deferasirox; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Triazoles | 2013 |
Thalassemia: cardiac iron and chelators.
Topics: Benzoates; Deferasirox; Deferoxamine; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; Myocardium; Thalassemia; Triazoles; Ventricular Function, Left | 2012 |
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Benzoates; Chelating Agents; Deferasirox; Drug Eruptions; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematinics; Humans; Iron Overload; Kidney Diseases; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Thalidomide; Treatment Outcome; Triazoles | 2012 |
Formation of ultrafine deferasirox particles via rapid expansion of supercritical solution (RESS process) using Taguchi approach.
Topics: Benzoates; Deferasirox; Drug Compounding; Iron Chelating Agents; Nanoparticles; Particle Size; Solubility; Solvents; Technology, Pharmaceutical; Temperature; Triazoles | 2012 |
Selective toxicity towards myelodysplastic hematopoietic progenitors - another rationale for iron chelation in MDS.
Topics: Benzoates; Cell Proliferation; Deferasirox; Female; Hematopoietic Stem Cells; Humans; Male; Myelodysplastic Syndromes; Reactive Oxygen Species; Triazoles | 2012 |
Spin density projection-assisted R2 magnetic resonance imaging of the liver in the management of body iron stores in patients receiving multiple red blood cell transfusions: an audit and retrospective study in South Australia.
Topics: Adolescent; Adult; Aged; Benzoates; Chelation Therapy; Child; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Female; Ferritins; Hematologic Diseases; Hemosiderosis; Humans; Infant; Infusions, Intravenous; Injections, Subcutaneous; Iron; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Male; Medical Audit; Middle Aged; Retrospective Studies; ROC Curve; Sensitivity and Specificity; South Australia; Triazoles | 2012 |
Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Antigens, CD; Benzoates; Case-Control Studies; Deferasirox; Deoxyguanosine; DNA Damage; Erythrocyte Transfusion; Ferritins; Genome, Human; Humans; Iron Chelating Agents; Iron Overload; Leukocytes, Mononuclear; Myelodysplastic Syndromes; Prospective Studies; Reactive Oxygen Species; Statistics, Nonparametric; Triazoles | 2012 |
Ascorbate status modulates reticuloendothelial iron stores and response to deferasirox iron chelation in ascorbate-deficient rats.
Topics: Animals; Ascorbic Acid; Ascorbic Acid Deficiency; Benzoates; Deferasirox; Guinea Pigs; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Mononuclear Phagocyte System; Myocardium; Rats; Rats, Mutant Strains; Triazoles | 2012 |
Iron out for nontransfused thalassemia.
Topics: Benzoates; Deferasirox; Female; Humans; Iron Overload; Male; Thalassemia; Triazoles | 2012 |
Deferasirox and renal dysfunction in children.
Topics: Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Kidney Diseases; Kidney Glomerulus; Kidney Tubules, Proximal; Male; Triazoles | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles | 2012 |
Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Female; Greece; Humans; Hypercalciuria; Hyperuricemia; Iron Chelating Agents; Iron Overload; Male; Nephrolithiasis; Postoperative Complications; Pyridones; Splenectomy; Transfusion Reaction; Triazoles; Young Adult | 2013 |
Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.
Topics: Adolescent; Adult; Age Factors; Anemia, Sickle Cell; Benzoates; Blood Transfusion; Child; Deferasirox; Deferoxamine; Drug Utilization; Female; Health Expenditures; Humans; Insurance Claim Review; Iron Chelating Agents; Kaplan-Meier Estimate; Male; Medicaid; Medication Adherence; Patient Preference; Proportional Hazards Models; Racial Groups; Retrospective Studies; Sex Factors; Triazoles; United States | 2013 |
Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.
Topics: Antineoplastic Agents; Apoptosis; Benzoates; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclin D1; Deferasirox; Gene Expression Regulation, Neoplastic; Humans; Iron; Iron Chelating Agents; Lymphoma, Mantle-Cell; Proteasome Endopeptidase Complex; Proteolysis; RNA, Messenger; Triazoles | 2013 |
Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Blood Transfusion; Cohort Studies; Cost-Benefit Analysis; Deferasirox; Deferoxamine; Drug Costs; Humans; Injections, Subcutaneous; Iron Chelating Agents; Iron Overload; Medication Adherence; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Survival Rate; Triazoles; United Kingdom | 2012 |
Dried blood spot analysis of an iron chelator--deferasirox and its potential application to therapeutic drug monitoring.
Topics: Administration, Intravenous; Administration, Oral; Animals; Benzoates; Chromatography, Liquid; Deferasirox; Dried Blood Spot Testing; Drug Monitoring; Drug Stability; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Indoles; Iron Chelating Agents; Linear Models; Male; Rats; Rats, Wistar; Reproducibility of Results; Tandem Mass Spectrometry; Triazoles | 2012 |
The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
Topics: Administration, Oral; Animals; Antigens, CD; Antineoplastic Agents; Apoptosis; Benzoates; Cell Cycle; Cell Line, Tumor; Copper; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neuroectodermal Tumors, Primitive, Peripheral; Protein Serine-Threonine Kinases; Receptors, Transferrin; Small Cell Lung Carcinoma; Transplantation, Heterologous; Triazoles; Zinc | 2013 |
Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Cholelithiasis; Clinical Trials, Phase III as Topic; Creatinine; Deferasirox; Edema; Ethnicity; Female; Ferritins; Gastrointestinal Diseases; Hematologic Diseases; Hepatitis, Viral, Human; Humans; Infant; Iron; Iron Chelating Agents; Iron Overload; Kidney Diseases; Liver; Magnetic Resonance Imaging; Male; Multicenter Studies as Topic; Prospective Studies; Thalassemia; Transfusion Reaction; Triazoles; Young Adult | 2013 |
Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deferasirox; Deferoxamine; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagus; Female; Humans; Iron; Iron Chelating Agents; Mice; Mice, Inbred BALB C; Mice, Nude; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
[Transfusion reaction and HLA antibodies].
Topics: Acute Lung Injury; Antibody Formation; Benzoates; Blood Transfusion; Deferasirox; Hematologic Neoplasms; Hemochromatosis; HLA Antigens; Humans; Iron Chelating Agents; Isoantibodies; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles | 2012 |
Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
Topics: Adult; Anemia, Aplastic; Benzoates; Chelation Therapy; Deferasirox; Erythrocyte Transfusion; Female; Ferritins; Hematopoiesis; Humans; Immunosuppressive Agents; Iron; Iron Chelating Agents; Iron Overload; Male; Platelet Transfusion; Transfusion Reaction; Triazoles | 2013 |
Iranian experience of deferasirox (Exjade(®)) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels?
Topics: Adolescent; Adult; Benzoates; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2012 |
Safety and efficacy of 4 years of deferasirox treatment for sickle cell disease patients.
Topics: Adult; Anemia, Sickle Cell; Benzoates; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Pilot Projects; Triazoles | 2013 |
Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.
Topics: Administration, Oral; Adult; Benzoates; beta-Thalassemia; Cost-Benefit Analysis; Cross-Sectional Studies; Deferasirox; Deferoxamine; Drug Costs; Female; Humans; Infusions, Intravenous; Iran; Iron Chelating Agents; Iron Overload; Male; Markov Chains; Models, Economic; Quality-Adjusted Life Years; Transfusion Reaction; Treatment Outcome; Triazoles | 2013 |
Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia major.
Topics: Adult; Benzoates; beta-Thalassemia; Blood Cell Count; Chelation Therapy; Colony-Forming Units Assay; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Erythroid Precursor Cells; Female; Ferritins; Flow Cytometry; Hematopoietic Stem Cells; Humans; Iron Chelating Agents; Linear Models; Male; Multivariate Analysis; Myeloid Progenitor Cells; Pyridones; Splenectomy; Triazoles; Young Adult | 2013 |
[Experimental study of the effect of deferasirox on the micro-angiogenesis in narrow pedicle flap through epithelial-mesenchymal transition].
Topics: Animals; Benzoates; Deferasirox; Epithelial-Mesenchymal Transition; Male; Rats; Rats, Sprague-Dawley; Surgical Flaps; Triazoles | 2012 |
Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Cell Count; Cell Proliferation; Cohort Studies; Deferasirox; Erythroid Precursor Cells; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Triazoles | 2013 |
Iron chelation: a potential therapeutic strategy in oesophageal cancer.
Topics: Animals; Antineoplastic Agents; Benzoates; Cell Proliferation; Deferasirox; Esophageal Neoplasms; Esophagus; Female; Humans; Iron Chelating Agents; Triazoles | 2013 |
Iron-chelation therapy with oral chelators in patients with thalassemia major.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Middle Aged; Pyridones; Retrospective Studies; Splenectomy; Triazoles; Young Adult | 2013 |
Antibacterial and antibiofilm effects of iron chelators against Prevotella intermedia.
Topics: Anti-Bacterial Agents; Bacterial Load; Benzoates; Biofilms; Chelating Agents; Deferasirox; Deferoxamine; Iron; Metronidazole; Microbial Sensitivity Tests; Microbial Viability; Prevotella intermedia; Triazoles | 2013 |
Iron chelation therapy as a treatment for Pythium insidiosum in an animal model.
Topics: Animals; Antibodies, Fungal; Benzoates; Chelation Therapy; Deferasirox; Female; Immunotherapy; Iron; Iron Chelating Agents; Microbial Sensitivity Tests; Models, Animal; Pythiosis; Pythium; Rabbits; Treatment Outcome; Triazoles | 2013 |
Comparative assessment of deferiprone and deferasirox in thalassemia major patients in the first two decades-single centre experience.
Topics: Administration, Oral; Adolescent; Age Factors; Benzoates; beta-Thalassemia; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Deferiprone; Female; Ferritins; Humans; Infant; Iron Chelating Agents; Male; Pyridones; Retrospective Studies; Triazoles; Vitamin D Deficiency | 2013 |
Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease.
Topics: Adamantane; Animals; Astrocytes; Benzoates; Cells, Cultured; Deferasirox; Deferoxamine; Dopaminergic Neurons; Humans; Hydrogen Peroxide; Iron Chelating Agents; Mice; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Permeability; Substantia Nigra; Triazoles | 2013 |
Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoates; Cell Line, Tumor; Chlorides; Crosses, Genetic; Deferasirox; Deferoxamine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; fas Receptor; Female; Ferric Compounds; Gene Expression Regulation, Leukemic; Iron; Iron Chelating Agents; Iron Overload; Iron-Dextran Complex; Leukemia L1210; Liver; Lymphoma, T-Cell; Mice; Mice, Inbred Strains; Neoplasm Proteins; Triazoles; Tumor Burden | 2013 |
Mucormycosis in a patient with acute myeloid leukemia successfully treated with liposomal amphotericin B associated with deferasirox and hyperbaric oxygen.
Topics: Adult; Amphotericin B; Antifungal Agents; Benzoates; Bone Marrow; Deferasirox; Drug Therapy, Combination; Female; Humans; Hyperbaric Oxygenation; Immunophenotyping; Karyotyping; Leukemia, Myeloid, Acute; Mucormycosis; Nucleophosmin; Treatment Outcome; Triazoles | 2013 |
A case of late onset erythropoietic protoporphyria associated with myelodysplastic syndrome treated by the combination of beta carotene and azacitidine.
Topics: Aged; Azacitidine; Benzoates; beta Carotene; Deferasirox; Humans; Male; Myelodysplastic Syndromes; Protoporphyria, Erythropoietic; Triazoles | 2013 |
Clinical characteristics and management of iron overload in 631 patients with chronic transfusion dependency: results from a multicentre, observational study.
Topics: Aged; Benzoates; Chelation Therapy; Comorbidity; Deferasirox; Disease Management; Erythrocyte Transfusion; Female; Ferritins; Guideline Adherence; Hematologic Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Practice Guidelines as Topic; Spain; Transfusion Reaction; Triazoles | 2014 |
A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.
Topics: Benzoates; Child, Preschool; Deferasirox; Deferoxamine; Health Care Costs; Humans; Iron Chelating Agents; Iron Overload; Markov Chains; Quality-Adjusted Life Years; Thalassemia; Transfusion Reaction; Triazoles | 2013 |
Loss of transfusion dependency following deferasirox treatment of iron overload in a woman with myelofibrosis and spherocytosis - a case report.
Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Primary Myelofibrosis; Spherocytosis, Hereditary; Treatment Outcome; Triazoles | 2013 |
Turning a blind eye to deferasirox's toxicity?
Topics: Age Factors; Benzoates; Cause of Death; Chronic Disease; Deferasirox; Drug Approval; Europe; Hematologic Diseases; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2013 |
Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose.
Topics: Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Transfusion Reaction; Treatment Outcome; Triazoles | 2013 |
Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project.
Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Disease Management; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Italy; Liver; Male; Pyridones; Software; Triazoles; Young Adult | 2013 |
Chelation of chromium(VI) by combining deferasirox and deferiprone in rats.
Topics: Animals; Benzoates; Body Weight; Chelating Agents; Chelation Therapy; Chromium; Deferasirox; Deferiprone; Male; Molecular Structure; Pyridones; Rats; Rats, Wistar; Tissue Distribution; Triazoles | 2013 |
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Marketing; Patient Safety; Pyridones; Thalassemia; Triazoles | 2013 |
Systemic iron chelation results in limited functional and histological recovery after traumatic spinal cord injury in rats.
Topics: Animals; Benzoates; Cervical Vertebrae; Deferasirox; Disease Models, Animal; Female; Iron Chelating Agents; Motor Activity; Rats; Rats, Sprague-Dawley; Recovery of Function; Spinal Cord; Spinal Cord Injuries; Triazoles | 2013 |
Effect of deferasirox chelation on liver iron and total body iron concentration.
Topics: Adolescent; Adult; Benzoates; Child; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Male; Prospective Studies; Triazoles; Young Adult | 2013 |
Pharmacogenetic study of deferasirox, an iron chelating agent.
Topics: Adolescent; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzoates; Child; Child, Preschool; Creatinine; Deferasirox; Female; Glucuronosyltransferase; Humans; Infant; Iron Chelating Agents; Liver; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmacogenetics; Polymorphism, Genetic; Triazoles; Young Adult | 2013 |
Gadolinium-deferasirox-D-glucosamine: novel anti-tumor and MR molecular (theranostic) imaging agent.
Topics: Animals; Antineoplastic Agents; Benzoates; Cell Line, Tumor; Chromatography, Thin Layer; Contrast Media; Deferasirox; Disease Models, Animal; Gadolinium; Glucosamine; Glucose; Hexokinase; Humans; Magnetic Resonance Imaging; Mice, Nude; Microscopy, Fluorescence; Neoplasms; Phosphorylation; Radionuclide Imaging; Radiopharmaceuticals; Rats; Time Factors; Triazoles; Tumor Necrosis Factor-alpha | 2013 |
[Transfusional independence in a patient with refractory anemia with excess blasts-2 refractory to 5-azacitidine treated with deferasirox and colony stimulating factors].
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Benzoates; Blood Transfusion; Chelation Therapy; Combined Modality Therapy; Deferasirox; Disease Progression; Drug Resistance; Epoetin Alfa; Erythropoietin; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Iron; Iron Chelating Agents; Leukemia, Myeloid, Acute; Male; Recombinant Proteins; Triazoles | 2014 |
Nephrolithiasis in patients exposed to deferasirox and desferioxamine: probably an age-linked event with different effects on some renal parameters.
Topics: Adult; Aging; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferoxamine; Disease Susceptibility; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Incidence; Iron Chelating Agents; Iron Overload; Italy; Kidney; Male; Nephrolithiasis; Retrospective Studies; Transfusion Reaction; Triazoles; Ultrasonography | 2014 |
Effectiveness of oral iron chelator treatment with deferasirox in an aceruloplasminemia patient with a novel ceruloplasmin gene mutation.
Topics: Administration, Oral; Benzoates; Ceruloplasmin; Deferasirox; Humans; Iron Chelating Agents; Iron Metabolism Disorders; Male; Middle Aged; Mutation; Neurodegenerative Diseases; Treatment Outcome; Triazoles | 2013 |
Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration.
Topics: Adolescent; Adult; Benzoates; Biopsy, Needle; Calibration; Chelation Therapy; Child; Child, Preschool; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Prospective Studies; Treatment Outcome; Triazoles | 2014 |
Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
Topics: Adult; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Triazoles | 2014 |
Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzoates; Case-Control Studies; Cell Differentiation; Deferasirox; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Cells; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Triazoles; Vitamin D | 2013 |
Treatment of mercury vapor toxicity by combining deferasirox and deferiprone in rats.
Topics: Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Disease Models, Animal; Drug Therapy, Combination; Male; Mercury; Molecular Structure; Pyridones; Rats; Rats, Wistar; Tissue Distribution; Triazoles; Volatilization | 2013 |
Reversible retinopathy associated with oral deferasirox therapy.
Topics: Administration, Oral; Adolescent; Anemia, Sickle Cell; Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Retinal Diseases; Triazoles; Visual Acuity | 2013 |
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?
Topics: Benzoates; Deferasirox; Humans; Iron Chelating Agents; Patient Safety; Triazoles | 2013 |
A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Pyridones; Transfusion Reaction; Triazoles | 2013 |
Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment?
Topics: Aged; Anemia, Macrocytic; Benzoates; Chromosome Deletion; Chromosomes, Human, Pair 5; Deferasirox; Erythroid Cells; Erythropoiesis; Female; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome; Triazoles | 2014 |
Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: a case report and review of the literature.
Topics: Acidosis; Acidosis, Renal Tubular; Adolescent; Benzoates; beta-Thalassemia; Chlorine; Deferasirox; Female; Humans; Iron Chelating Agents; Triazoles | 2013 |
Chelation of thallium by combining deferasirox and desferrioxamine in rats.
Topics: Animals; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Disease Models, Animal; Dose-Response Relationship, Drug; Iron; Iron Chelating Agents; Male; Rats; Rats, Wistar; Spectrophotometry, Atomic; Thallium; Triazoles | 2016 |
Deferasirox induces mesenchymal-epithelial transition in crocidolite-induced mesothelial carcinogenesis in rats.
Topics: Animals; Asbestos, Crocidolite; Benzoates; Cell Transformation, Neoplastic; Deferasirox; Epithelial-Mesenchymal Transition; Female; Iron; Iron Chelating Agents; Male; Mesothelioma; Phlebotomy; Rats; Spleen; Triazoles | 2013 |
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.
Topics: Adult; Area Under Curve; Arrhythmias, Cardiac; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heart Failure; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Myocardium; Patient Compliance; Predictive Value of Tests; Pyridones; Risk; ROC Curve; Sampling Studies; Transfusion Reaction; Triazoles; Young Adult | 2013 |
Enhanced brain delivery of deferasirox-lactoferrin conjugates for iron chelation therapy in neurodegenerative disorders: in vitro and in vivo studies.
Topics: Alzheimer Disease; Animals; Apoptosis; Apoptosis Regulatory Proteins; Benzoates; Brain; Carbodiimides; Cell Line, Tumor; Chelating Agents; Chelation Therapy; Deferasirox; Disease Models, Animal; Drug Delivery Systems; Iron; Lactoferrin; Male; Nanostructures; Neurodegenerative Diseases; Neuroprotective Agents; PC12 Cells; Permeability; Rats; Rats, Wistar; Transcytosis; Triazoles | 2013 |
Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
Topics: Administration, Oral; Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Deferoxamine; Female; Humans; Infant; Injections; Iron Chelating Agents; Male; Patient Compliance; Personal Satisfaction; Triazoles; Young Adult | 2014 |
A maculopapular-type eruption associated with deferasirox administration.
Topics: Aged; Benzoates; Deferasirox; Drug Eruptions; Female; Humans; Iron Chelating Agents; Skin Diseases, Papulosquamous; Triazoles | 2013 |
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? Author's response.
Topics: Benzoates; Deferasirox; Humans; Iron Chelating Agents; Patient Safety; Triazoles | 2013 |
Deferasirox treatment improved hematopoiesis and led to complete remission in a patient with pure red cell aplasia.
Topics: Benzoates; Deferasirox; Erythrocyte Transfusion; Erythropoiesis; Female; Humans; Iron Chelating Agents; Middle Aged; Red-Cell Aplasia, Pure; Treatment Outcome; Triazoles | 2013 |
Iron chelators in myelodysplastic syndrome: to lower ferritin levels or to improve survival?
Topics: Benzoates; Deferasirox; Deferiprone; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Pyridones; Transfusion Reaction; Triazoles | 2013 |
Studies of interaction between terbium(III)-deferasirox and double helix DNA by spectral and electrochemical methods.
Topics: Animals; Benzoates; Cattle; Circular Dichroism; Deferasirox; DNA; Electrochemical Techniques; Fluorescent Dyes; Iron Chelating Agents; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Terbium; Triazoles | 2014 |
Korean guideline for iron chelation therapy in transfusion-induced iron overload.
Topics: Anemia, Aplastic; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Republic of Korea; Transfusion Reaction; Triazoles | 2013 |
Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Bacterial Load; Benzoates; Chelating Agents; Deferasirox; Disease Models, Animal; Drug Therapy, Combination; Iron; Kidney; Methicillin-Resistant Staphylococcus aureus; Mice, Inbred BALB C; Microbial Sensitivity Tests; Microbial Viability; Severity of Illness Index; Spleen; Staphylococcal Infections; Treatment Outcome; Triazoles; Vancomycin | 2014 |
[Hematologic improvement with deferasirox following tandem antithymocyte globulin treatment in a transfusion-dependent patient with severe aplastic anemia].
Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Blood Transfusion; Cyclosporine; Deferasirox; Humans; Iron Chelating Agents; Male; Middle Aged; Transfusion Reaction; Treatment Outcome; Triazoles | 2013 |
Combined chelation of lead (II) by deferasirox and deferiprone in rats as biological model.
Topics: Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Lead; Male; Models, Biological; Molecular Structure; Pyridones; Rats; Rats, Wistar; Triazoles | 2014 |
Deferasirox improves hematopoiesis after allogeneic hematopoietic SCT.
Topics: Benzoates; Deferasirox; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Transplantation, Homologous; Triazoles | 2014 |
Synthesis of a novel supermagnetic iron oxide nanocomposite hydrogel based on graft copolymerization of poly((2-dimethylamino)ethyl methacrylate) onto salep for controlled release of drug.
Topics: Anti-Bacterial Agents; Benzoates; Cell Death; Cell Line; Deferasirox; Delayed-Action Preparations; Dextrans; Epithelial Cells; Escherichia coli; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Hydrogen-Ion Concentration; Kinetics; Magnetite Nanoparticles; Methacrylates; Microbial Sensitivity Tests; Nanocomposites; Nylons; Polymerization; Polysaccharides; Spectroscopy, Fourier Transform Infrared; Staphylococcus aureus; Temperature; Thermogravimetry; Triazoles; X-Ray Diffraction | 2014 |
Laboratory investigation of platelet function in patients with thalassaemia.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Platelets; Child; Deferasirox; Deferiprone; Deferoxamine; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Pyridones; Triazoles; Young Adult | 2014 |
Bad liver and a broken heart.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Myocardium; Triazoles | 2014 |
[The role of iron metabolism in myelodysplastic syndromes].
Topics: Anemia; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Ferritins; Hematopoietic Stem Cell Transplantation; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Risk; Transfusion Reaction; Triazoles | 2014 |
A comparative study of the iron status of patients with oesophageal adenocarcinoma to determine suitability for a clinical trial of iron chelation therapy.
Topics: Adenocarcinoma; Aged; Anemia, Iron-Deficiency; Benzoates; Chelation Therapy; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deferasirox; Esophageal Neoplasms; Esophagectomy; Female; Ferritins; Hemoglobins; Humans; Iron; Iron Chelating Agents; Male; Patient Selection; Prospective Studies; Triazoles | 2014 |
Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Overload; Male; Treatment Outcome; Triazoles | 2014 |
Development of acute pure red cell aplasia after deferasirox administration in two cases of myelodysplastic syndrome.
Topics: Acute Disease; Administration, Oral; Aged; Benzoates; Deferasirox; Erythrocyte Transfusion; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Red-Cell Aplasia, Pure; Triazoles | 2014 |
Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan.
Topics: Algorithms; Benzoates; Biomarkers; Biopsy; Calibration; Deferasirox; Hemosiderosis; Humans; Image Interpretation, Computer-Assisted; Iron; Iron Chelating Agents; Least-Squares Analysis; Linear Models; Liver; Magnetic Resonance Imaging; Observer Variation; Predictive Value of Tests; Reproducibility of Results; Retrospective Studies; Transfusion Reaction; Triazoles | 2014 |
Safety of deferasirox: a retrospective cohort study on the risks of gastrointestinal, liver and renal events.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Benzoates; Chemical and Drug Induced Liver Injury; Deferasirox; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Necrosis; Proportional Hazards Models; Retrospective Studies; Taiwan; Triazoles | 2014 |
Elevated total iron-binding capacity as a predictor of response to deferasirox therapy in the setting of chronic iron overload.
Topics: Benzoates; Blood Proteins; Deferasirox; Drug Monitoring; Female; Ferritins; Hematologic Neoplasms; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Multivariate Analysis; Prognosis; Protein Binding; Retrospective Studies; ROC Curve; Transfusion Reaction; Treatment Outcome; Triazoles | 2014 |
Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
Topics: Adolescent; Alkalosis; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Fanconi Syndrome; Female; Humans; Iron Chelating Agents; Kidney Diseases; Kidney Tubules; Male; Pyridones; Retrospective Studies; Transfusion Reaction; Triazoles; Water-Electrolyte Imbalance; Young Adult | 2014 |
Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury.
Topics: Aldehydes; Animals; Apoptosis; Benzoates; Boron Compounds; Boronic Acids; Cell Line; Cell Membrane Permeability; Cytoprotection; Deferasirox; Hydrazones; Hydrogen Peroxide; Iron; Iron Chelating Agents; Isonicotinic Acids; Membrane Potential, Mitochondrial; Mitochondria, Heart; Myocytes, Cardiac; Oxidative Stress; Rats; Rats, Wistar; Semicarbazones; Triazoles | 2014 |
Iron chelators induce autophagic cell death in multiple myeloma cells.
Topics: Autophagy; Benzoates; Cell Line, Tumor; Cell Proliferation; Deferasirox; Deferoxamine; Drug Evaluation, Preclinical; Humans; Iron Chelating Agents; Multiple Myeloma; Primary Cell Culture; Reactive Oxygen Species; Triazoles | 2014 |
Dose titration of deferasirox iron chelation therapy by magnetic resonance imaging for chronic iron storage disease in three adult red bald-headed uakari (Cacajao calvus rubicundus).
Topics: Animals; Benzoates; Deferasirox; Female; Hemochromatosis; Iron Chelating Agents; Male; Monkey Diseases; Pitheciidae; Triazoles | 2014 |
Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Developing Countries; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hearing Loss, Sensorineural; Humans; Incidence; Iron Chelating Agents; Iron Overload; Male; Pyridones; Retrospective Studies; Thailand; Thalassemia; Transfusion Reaction; Triazoles; Young Adult | 2014 |
Immunological evaluation of β-thalassemia major patients receiving oral iron chelator deferasirox.
Topics: Adolescent; Adult; Age Distribution; Antibodies, Antinuclear; Benzoates; beta-Thalassemia; Blood Transfusion; Case-Control Studies; Deferasirox; Female; Ferritins; Humans; Immunoglobulin G; Incidence; Iron Chelating Agents; Lymphocytes; Male; Middle Aged; Saudi Arabia; Splenectomy; Triazoles | 2014 |
Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Benzoates; Child; Child, Preschool; Chromatography, High Pressure Liquid; Deferasirox; Female; Genotype; Glucuronosyltransferase; Humans; Iron Chelating Agents; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Risk Factors; Sex Factors; Treatment Outcome; Triazoles; Young Adult | 2015 |
Aceruloplasminaemia: a family with a novel mutation and long-term therapy with deferasirox.
Topics: Adult; Benzoates; Blood Glucose; Ceruloplasmin; Chelating Agents; Chromosomes, Human, Pair 3; Deferasirox; Female; Germany; Humans; Iron; Iron Metabolism Disorders; Liver; Magnetic Resonance Imaging; Male; Mutation; Neurodegenerative Diseases; Pedigree; Treatment Outcome; Triazoles | 2015 |
Predictors of non-adherence to follow-up visits and deferasirox chelation therapy among jordanian adolescents with Thalassemia major.
Topics: Adolescent; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Cross-Sectional Studies; Deferasirox; Female; Ferritins; Follow-Up Studies; Humans; Male; Patient Compliance; Triazoles | 2014 |
Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
Topics: Adolescent; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Kidney Function Tests; Liver; London; Male; Medication Adherence; Retrospective Studies; Time Factors; Transfusion Reaction; Treatment Outcome; Triazoles | 2015 |
Iron homeostasis and infIammatory biomarker analysis in patients with type 1 Gaucher disease.
Topics: Adult; Aged; Benzoates; Biomarkers; Cytokines; Deferasirox; Deferoxamine; Female; Ferritins; Follow-Up Studies; Gaucher Disease; Hepcidins; Hexosaminidases; Homeostasis; Humans; Inflammation; Iron; Iron Chelating Agents; Iron Overload; Macrophage Activation; Macrophages; Male; Middle Aged; Quality of Life; Triazoles | 2014 |
Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox.
Topics: Actins; Administration, Oral; Animals; Benzoates; Cells, Cultured; Deferasirox; Disease Models, Animal; Gene Expression; Hepatic Stellate Cells; Humans; Iron Chelating Agents; Liver; Liver Cirrhosis; Male; Matrix Metalloproteinase 2; Mice; Mice, Transgenic; Procollagen; Triazoles | 2015 |
Deferasirox limits cartilage damage following haemarthrosis in haemophilic mice.
Topics: Animals; Benzoates; Cartilage, Articular; Chelation Therapy; Deferasirox; Drug Evaluation, Preclinical; Ferritins; Hemarthrosis; Hemophilia A; Iron Chelating Agents; Mice; Mice, Mutant Strains; Random Allocation; Synovitis; Triazoles | 2014 |
Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Area Under Curve; Aspergillosis; Aspergillus fumigatus; Benzoates; Caspofungin; Deferasirox; Disease Models, Animal; Drug Therapy, Combination; Echinocandins; Female; Invasive Pulmonary Aspergillosis; Lipopeptides; Lung; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mucormycosis; Neutropenia; Rhizopus; Treatment Outcome; Triazoles | 2014 |
Effects of iron depletion on CALM-AF10 leukemias.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Biological Transport; Cell Line, Tumor; Chelation Therapy; Combined Modality Therapy; Deferasirox; Deferoxamine; Fibroblasts; Hematopoietic Stem Cells; Heterozygote; Humans; Iron; Iron Chelating Agents; Iron, Dietary; Leukemia, Experimental; Mice; Mice, Knockout; Monomeric Clathrin Assembly Proteins; Oncogene Proteins, Fusion; Radiation Chimera; Spleen; Triazoles; Tumor Burden | 2014 |
Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
Topics: Administration, Oral; Adult; Aged; Anemia; Benzoates; Chelation Therapy; Deferasirox; Female; Hematopoiesis; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles | 2015 |
Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Quality of Life; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2016 |
The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia.
Topics: Anemia, Aplastic; Animals; Benzoates; Bone Marrow Cells; Cell Line; Cells, Cultured; Deferasirox; Deferoxamine; Gene Expression Regulation, Neoplastic; Humans; Iron Chelating Agents; Macrophages; Male; Mice; Myelodysplastic Syndromes; NF-kappa B; RNA, Long Noncoding; Transcription, Genetic; Triazoles; Tumor Necrosis Factor-alpha | 2015 |
Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness.
Topics: Adult; Alleles; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzoates; Chromatography, High Pressure Liquid; Cohort Studies; Cytochrome P-450 Enzyme System; Deferasirox; Female; Genotype; Glucuronosyltransferase; Humans; Iron Overload; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Polymorphism, Single Nucleotide; Triazoles | 2015 |
Micafungin alone and in combination therapy with deferasirox against Pythium insidiosum.
Topics: Animals; Antifungal Agents; Benzoates; Deferasirox; Disease Models, Animal; Drug Therapy, Combination; Echinocandins; Female; Horse Diseases; Horses; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Pythiosis; Pythium; Rabbits; Triazoles | 2015 |
A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients.
Topics: Adult; Benzoates; beta-Thalassemia; Deferasirox; Female; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Liver; Male; Myocardium; Treatment Outcome; Triazoles | 2015 |
Thalassemia major patients using iron chelators showed a reduced plasma thioredoxin level and reduced thioredoxin reductase activity, despite elevated oxidative stress.
Topics: Adolescent; Adult; Antioxidants; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Female; Glutathione Transferase; Humans; Iron Chelating Agents; Male; Oxidative Stress; Oxidoreductases; Peroxiredoxins; Pyridones; Thioredoxin Reductase 1; Thioredoxins; Triazoles; Young Adult | 2015 |
The effects of economic sanctions on disease specific clinical outcomes of patients with thalassemia and hemophilia in Iran.
Topics: Adolescent; Adult; Benzoates; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Ferritins; Health Status; Hemophilia A; Humans; Internationality; Iran; Male; Plasma; Surveys and Questionnaires; Thalassemia; Triazoles; Young Adult | 2015 |
Inhibitory effects of deferasirox on the structure and function of bovine liver catalase: a spectroscopic and theoretical study.
Topics: Animals; Benzoates; Binding, Competitive; Catalase; Catalytic Domain; Cattle; Circular Dichroism; Deferasirox; Enzyme Inhibitors; Heme; Hydrophobic and Hydrophilic Interactions; Iron; Iron Chelating Agents; Kinetics; Liver; Molecular Docking Simulation; Protein Binding; Protein Structure, Secondary; Solutions; Spectrometry, Fluorescence; Temperature; Thermodynamics; Triazoles; Tryptophan | 2015 |
Synthesis of deuterium-labelled isotopomer of deferasirox.
Topics: Benzoates; Blood Chemical Analysis; Chromatography, Liquid; Deferasirox; Deuterium; Humans; Iron Chelating Agents; Isotope Labeling; Mass Spectrometry; Reproducibility of Results; Sensitivity and Specificity; Triazoles | 2015 |
Association between renal iron accumulation and renal interstitial fibrosis in a rat model of chronic kidney disease.
Topics: Animals; Benzoates; Blood Pressure; Deferasirox; Fibrosis; Gene Expression; Iron; Iron Chelating Agents; Kidney; Male; Nephrectomy; Nephritis, Interstitial; Proteinuria; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Triazoles | 2015 |
Deferasirox-induced cytogenetic responses.
Topics: Adult; Animals; Benzoates; Bone Marrow Cells; Cells, Cultured; Chromosome Aberrations; Deferasirox; Female; Humans; Iron Chelating Agents; Lymphocytes; Male; Mutagens; Rats; Sister Chromatid Exchange; Triazoles; Young Adult | 2015 |
Complex interaction of deferasirox and Pythium insidiosum: iron-dependent attenuation of growth in vitro and immunotherapy-like enhancement of immune responses in vivo.
Topics: Animals; Benzoates; Deferasirox; Hyphae; Immunomodulation; Immunotherapy; Iron; Iron Chelating Agents; Pythiosis; Pythium; Rabbits; Triazoles | 2015 |
Iron chelation with deferasirox in a patient with de-novo ferroportin mutation.
Topics: Adolescent; Benzoates; Cation Transport Proteins; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Mutation; Triazoles | 2015 |
Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Female; Ferritins; Hematopoiesis; Humans; Iron; Iron Chelating Agents; Iron Overload; Italy; Male; Middle Aged; Myelodysplastic Syndromes; Registries; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles | 2015 |
Involvement of iron depletion in palmitate-induced lipotoxicity of beta cells.
Topics: Animals; Apoferritins; Benzoates; Cell Death; Cell Line, Tumor; Chlorides; Deferasirox; Deferoxamine; eIF-2 Kinase; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; Ferric Compounds; Ferrous Compounds; Gene Expression Regulation; Humans; Insulin-Secreting Cells; Iron Chelating Agents; Iron Deficiencies; JNK Mitogen-Activated Protein Kinases; Palmitic Acid; Rats; Receptors, Transferrin; Signal Transduction; Transcription Factor CHOP; Transferrin; Triazoles | 2015 |
Combination therapy - deferasirox and deferoxamine - in thalassemia major patients in emerging countries with limited resources.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferoxamine; Developing Countries; Drug Therapy, Combination; Female; Ferritins; Humans; Iran; Lebanon; Male; Siderophores; Triazoles | 2015 |
Chelation of dietary iron prevents iron accumulation and macrophage infiltration in the type I diabetic kidney.
Topics: Animals; Benzoates; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Deferasirox; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Gene Knockout Techniques; Iron; Iron Chelating Agents; Iron, Dietary; Kidney; Macrophages; Male; Mice; Mice, Inbred C57BL; Triazoles | 2015 |
The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Deferasirox; Deferiprone; Drug Eruptions; Drug Therapy, Combination; Female; Ferritins; Gastrointestinal Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Joint Diseases; Male; Prospective Studies; Proteinuria; Pyridones; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2015 |
The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells.
Topics: Benzoates; Cell Differentiation; Cell Survival; Deferasirox; Gene Expression Profiling; Gene Expression Regulation; Hematopoietic Stem Cells; Humans; Iron Chelating Agents; Leukocytes, Mononuclear; Mitochondria; Oxidation-Reduction; Reactive Oxygen Species; Signal Transduction; Transcription Factors; Triazoles | 2015 |
GFR in Patients with β-Thalassemia Major.
Topics: Adult; Benzoates; beta-Thalassemia; Biomarkers; Creatinine; Deferasirox; Female; Glomerular Filtration Rate; Humans; Inulin; Iron Chelating Agents; Israel; Kidney; Kidney Diseases; Male; Models, Biological; Outpatient Clinics, Hospital; Predictive Value of Tests; Reproducibility of Results; Transfusion Reaction; Triazoles; Young Adult | 2015 |
Inducing iron deficiency improves erythropoiesis and photosensitivity in congenital erythropoietic porphyria.
Topics: Adult; Benzoates; Bone Marrow Cells; Cells, Cultured; Deferasirox; Erythropoiesis; Fatal Outcome; Female; Humans; Infant; Iron Chelating Agents; Iron Deficiencies; Light; Off-Label Use; Porphyria, Erythropoietic; Radiation Tolerance; Siblings; Triazoles | 2015 |
Self-assembled penetratin-deferasirox micelles as potential carriers for hydrophobic drug delivery.
Topics: Animals; Benzoates; Carrier Proteins; Cell Line; Cell Membrane Permeability; Cell-Penetrating Peptides; Chromatography, High Pressure Liquid; Circular Dichroism; Curcumin; Deferasirox; Drug Carriers; Hydrophobic and Hydrophilic Interactions; Micelles; Microscopy, Electron, Transmission; Rats; Spectrometry, Fluorescence; Spectrometry, Mass, Electrospray Ionization; Triazoles | 2015 |
Cationic albumin-conjugated chelating agent as a novel brain drug delivery system in neurodegeneration.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Benzoates; Brain; Cations; Deferasirox; Drug Carriers; Drug Delivery Systems; Humans; Iron Chelating Agents; Male; Neuroprotective Agents; Oxidative Stress; PC12 Cells; Rats; Rats, Wistar; Serum Albumin; Triazoles | 2015 |
Transfusion-dependent thalassaemic patients with renal Fanconi syndrome due to deferasirox use.
Topics: Acidosis, Renal Tubular; Adolescent; Benzoates; Blood Transfusion; Child; Child, Preschool; Deferasirox; Fanconi Syndrome; Female; Hospitals, University; Humans; Hypophosphatemia; Incidence; Iron Chelating Agents; Male; Retrospective Studies; Risk Factors; Taiwan; Thalassemia; Triazoles; Young Adult | 2015 |
Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization.
Topics: Benzoates; Cell Line; Deferasirox; Deferiprone; Deferoxamine; Drug Synergism; Humans; Intracellular Space; Iron; Iron Chelating Agents; Pyridones; Triazoles | 2015 |
Effect of combined deferasirox and 5-azacytidine treatment on human leukemia cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzoates; Deferasirox; HL-60 Cells; Humans; Iron Chelating Agents; Leukemia; Triazoles; U937 Cells | 2015 |
Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Treatment Outcome; Triazoles; Young Adult | 2015 |
Deferasirox-TAT(47-57) peptide conjugate as a water soluble, bifunctional iron chelator with potential use in neuromedicine.
Topics: Animals; Benzoates; Blood-Brain Barrier; Cell Line; Cell Membrane; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Peptide Fragments; Rats; Solubility; tat Gene Products, Human Immunodeficiency Virus; Triazoles; Water | 2015 |
Mineral Levels in Thalassaemia Major Patients Using Different Iron Chelators.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Female; Humans; Iron; Iron Chelating Agents; Male; Minerals; Pyridones; Triazoles; Young Adult | 2016 |
Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Pyridones; Triazoles | 2015 |
Iron Chelation in Patients with Transfusion Dependent Thalassemia: An Insight on Response to Deferasirox.
Topics: Adolescent; Benzoates; Child; Deferasirox; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Treatment Outcome; Triazoles; Young Adult | 2015 |
Effects of Iron Chelators on the Formation and Development of Aspergillus fumigatus Biofilm.
Topics: Antifungal Agents; Aspergillus fumigatus; Benzoates; Biofilms; Chlorides; Deferasirox; Deferiprone; Deferoxamine; Ferric Compounds; Iron; Iron Chelating Agents; Microbial Sensitivity Tests; Plankton; Pyridones; Spores, Fungal; Tetrazolium Salts; Triazoles | 2015 |
Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.
Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Kaplan-Meier Estimate; Male; Medicare; Myelodysplastic Syndromes; Risk Reduction Behavior; Triazoles; United States | 2015 |
Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase.
Topics: Aged; Benzoates; Chelation Therapy; Deferasirox; Erythrocyte Indices; Erythropoiesis; Female; Fibrosis; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myeloproliferative Disorders; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles | 2016 |
Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzoates; Child, Preschool; Deferasirox; Female; Glucuronosyltransferase; Humans; Iron Chelating Agents; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Polymorphism, Single Nucleotide; Thalassemia; Triazoles | 2016 |
Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies.
Topics: Adolescent; Adult; Benzoates; Child; Deferasirox; Female; Ferritins; Hemoglobinopathies; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Myocardium; Retrospective Studies; Stroke Volume; Transfusion Reaction; Treatment Outcome; Triazoles; Ventricular Function, Left; Young Adult | 2015 |
The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amyloid-β Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer's Disease.
Topics: Administration, Oral; Aging; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Benzoates; Brain; Deferasirox; Ferritins; Gene Expression Regulation; Iron; Iron Chelating Agents; Neprilysin; NF-kappa B; Oxidative Stress; Peptide Fragments; Protein Carbonylation; Rats; Rats, Wistar; Receptors, Transferrin; Spectrophotometry; Triazoles | 2016 |
Sensorineural hearing loss in β-thalassemia patients treated with iron chelation.
Topics: Adolescent; Adult; Audiometry, Pure-Tone; Benzoates; beta-Thalassemia; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Female; Hearing Loss, Sensorineural; Humans; Iron Chelating Agents; Male; Middle Aged; Pyridones; Triazoles; Young Adult | 2015 |
Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.
Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Ferritins; Follow-Up Studies; Hospitals, University; Humans; Iron Chelating Agents; Iron Overload; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles | 2016 |
Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria.
Topics: Adult; Benzoates; Calcium; Case-Control Studies; Creatinine; Deferasirox; Dose-Response Relationship, Drug; Female; Humans; Hypercalciuria; Male; Triazoles | 2016 |
Iron chelator-induced apoptosis via the ER stress pathway in gastric cancer cells.
Topics: Apoptosis; Benzoates; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Deferasirox; Deferoxamine; Endoplasmic Reticulum Stress; Humans; Iron Chelating Agents; JNK Mitogen-Activated Protein Kinases; Microscopy, Confocal; Neoplasm Staging; Prognosis; Reactive Oxygen Species; Siderophores; Signal Transduction; Stomach Neoplasms; Triazoles; Tumor Cells, Cultured | 2016 |
Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice.
Topics: Animals; Benzoates; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cardiovascular Diseases; Deferasirox; Deferiprone; Deferoxamine; Dihydropyridines; Heart; Iron Chelating Agents; Iron Overload; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Mitochondria; Nitrophenols; Organophosphorus Compounds; Pyridones; Thalassemia; Triazoles | 2016 |
Low oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells.
Topics: Benzoates; Cell Hypoxia; Cell Line, Tumor; Combined Modality Therapy; Deferasirox; Drug Resistance, Neoplasm; Glioblastoma; Humans; Iron Chelating Agents; Oxygen; Triazoles | 2016 |
Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Female; Fetus; Humans; Infant, Newborn; Iron Chelating Agents; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Pyridones; Triazoles | 2016 |
Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzoates; Cell Proliferation; Deferasirox; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; Humans; Imatinib Mesylate; Iron Chelating Agents; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Signal Transduction; Triazoles | 2016 |
[Efficacy and safety of deferasirox in aplastic anemia patients with iron overload: a single arm, multi-center,prospective study in China].
Topics: Anemia, Aplastic; Benzoates; Blood Transfusion; China; Deferasirox; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Prospective Studies; Triazoles | 2016 |
Development of a biphasic dissolution test for Deferasirox dispersible tablets and its application in establishing an in vitro-in vivo correlation.
Topics: Benzoates; Biopharmaceutics; Chemistry, Pharmaceutical; Deferasirox; Intestinal Absorption; Solubility; Tablets; Triazoles | 2016 |
Deferasirox and children: From clinical trials to the real world.
Topics: Age Factors; Benzoates; beta-Thalassemia; Child; Clinical Trials as Topic; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Transfusion Reaction; Treatment Outcome; Triazoles | 2016 |
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypogonadism; Hypothyroidism; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Osteoporosis; Prevalence; Pyridones; Retrospective Studies; Transfusion Reaction; Triazoles | 2016 |
The potential of deferasirox as a novel therapeutic modality in gastric cancer.
Topics: Antineoplastic Agents; Apoptosis; Benzoates; Blotting, Western; Cell Cycle; Cell Proliferation; Cisplatin; Deferasirox; Drug Synergism; Humans; Iron Chelating Agents; Stomach Neoplasms; Triazoles; Tumor Cells, Cultured | 2016 |
Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Deferasirox; Deferiprone; Drug Therapy, Combination; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Prospective Studies; Pyridones; Thalassemia; Transfusion Reaction; Triazoles | 2016 |
Role of pharmacogenetics on deferasirox AUC and efficacy.
Topics: Adult; Alleles; Area Under Curve; Benzoates; Cohort Studies; Deferasirox; Female; Genotype; Glucuronosyltransferase; Humans; Male; Pharmacogenetics; Polymorphism, Single Nucleotide; Triazoles | 2016 |
Ag Nanoparticles-enhanced Fluorescence of Terbium-Deferasirox Complexes for the Highly Sensitive Determination of Deferasirox.
Topics: Benzoates; Deferasirox; Fluorescence; Humans; Hydrogen-Ion Concentration; Metal Nanoparticles; Molecular Structure; Particle Size; Silver; Spectrometry, Fluorescence; Tablets; Terbium; Triazoles | 2016 |
Synthesis, characterization and in vitro anticancer evaluations of two novel derivatives of deferasirox iron chelator.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoates; Chemistry Techniques, Synthetic; Deferasirox; HT29 Cells; Humans; Iron; Iron Chelating Agents; Mice; Reactive Oxygen Species; Triazoles | 2016 |
Deferasirox AUC efficacy cutoff and role of pharmacogenetics.
Topics: Area Under Curve; Benzoates; beta-Thalassemia; Deferasirox; Female; Genotype; Humans; Iron Chelating Agents; Male; Pharmacogenetics; Polymorphism, Single Nucleotide; Treatment Outcome; Triazoles | 2016 |
Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients.
Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Cohort Studies; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Treatment Outcome; Triazoles | 2017 |
Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox.
Topics: Benzoates; Blood Transfusion; Combined Modality Therapy; Deferasirox; Humans; Iron Chelating Agents; Primary Myelofibrosis; Remission Induction; Treatment Outcome; Triazoles | 2016 |
A theoretical study on the electronic structures and equilibrium constants evaluation of Deferasirox iron complexes.
Topics: Benzoates; Deferasirox; Iron; Models, Theoretical; Molecular Structure; Triazoles | 2016 |
Iron-chelating agent, deferasirox, inhibits neutrophil activation and extracellular trap formation.
Topics: Benzoates; Cells, Cultured; Deferasirox; Dose-Response Relationship, Drug; Extracellular Traps; Humans; Iron Chelating Agents; Neutrophil Activation; Phagocytosis; Reactive Oxygen Species; Triazoles | 2016 |
Deferasirox in thalassemia patients with end-stage renal disease.
Topics: Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Kidney Failure, Chronic; Male; Middle Aged; Thalassemia; Triazoles | 2016 |
A combination of an iron chelator with an antioxidant effectively diminishes the dendritic loss, tau-hyperphosphorylation, amyloids-β accumulation and brain mitochondrial dynamic disruption in rats with chronic iron-overload.
Topics: Acetylcysteine; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Benzoates; Brain; Deferasirox; Deferoxamine; Dendrites; Diet; Disease Models, Animal; Drug Therapy, Combination; Iron; Iron Chelating Agents; Iron Overload; Male; Mitochondrial Dynamics; Neurodegenerative Diseases; Phosphorylation; Random Allocation; Rats, Wistar; tau Proteins; Triazoles | 2016 |
Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats.
Topics: Acetylcysteine; Animals; Benzoates; Cardiomyopathies; Cardiotonic Agents; Deferasirox; Deferiprone; Deferoxamine; Drug Combinations; Drug Synergism; Humans; Iron; Iron Chelating Agents; Iron Overload; Iron, Dietary; Male; Malondialdehyde; Mitochondria; Pyridones; Rats; Rats, Wistar; Triazoles; Ventricular Function, Left | 2016 |
Fulminant Liver Failure in a Child With β-Thalassemia on Deferasirox: A Case Report.
Topics: Benzoates; beta-Thalassemia; Child, Preschool; Deferasirox; Fanconi Syndrome; Female; Humans; Liver Failure, Acute; Triazoles | 2017 |
Iron depletion-induced downregulation of N-cadherin expression inhibits invasive malignant phenotypes in human esophageal cancer.
Topics: Animals; Benzoates; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deferasirox; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Iron Deficiencies; Mice; Neoplasm Invasiveness; Neoplasm Transplantation; Phenotype; Triazoles | 2016 |
Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Creatinine; Cross-Sectional Studies; Deferasirox; Deferiprone; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Proteinuria; Pyridones; Transfusion Reaction; Triazoles; Young Adult | 2017 |
Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Benzoates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deferasirox; Flow Cytometry; Humans; Immunohistochemistry; Iron Chelating Agents; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Triazoles; Xenograft Model Antitumor Assays | 2016 |
The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoates; beta Catenin; Cation Transport Proteins; Cell Line, Tumor; Cell Proliferation; Deferasirox; Dose-Response Relationship, Drug; Focal Adhesion Kinase 2; Humans; Iron; Iron Chelating Agents; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Phosphorylation; Reactive Oxygen Species; Time Factors; Triazoles; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2016 |
ELECTRORETINOGRAPHIC AND VISUAL-EVOKED POTENTIAL CHANGES IN RELATION TO CHELATION MODALITY IN CHILDREN WITH THALASSEMIA.
Topics: Administration, Oral; Adolescent; Benzoates; Cross-Sectional Studies; Deferasirox; Deferoxamine; Dose-Response Relationship, Drug; Electroretinography; Evoked Potentials, Visual; Eye Diseases; Female; Humans; Iron Chelating Agents; Male; Optic Nerve; Retina; Retinal Diseases; Retrospective Studies; Siderophores; Thalassemia; Treatment Outcome; Triazoles; Visual Acuity | 2017 |
Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment.
Topics: Adult; Area Under Curve; Benzoates; beta-Thalassemia; Biomarkers; Chromatography, High Pressure Liquid; Creatinine; Deferasirox; Drug Monitoring; Female; Ferritins; Half-Life; Humans; Iron Chelating Agents; Male; Spectrophotometry, Ultraviolet; Triazoles | 2016 |
Determination of deferasirox in human plasma by short-end injection and sweeping with a field-amplified sample stacking and micellar electrokinetic chromatography.
Topics: Adult; Benzoates; Chromatography, Micellar Electrokinetic Capillary; Deferasirox; Female; Humans; Iron Chelating Agents; Male; Triazoles; Young Adult | 2016 |
Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients.
Topics: Aged; Aged, 80 and over; Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles | 2017 |
Successful desensitization to deferasirox in a paediatric patient with β-Thalassaemia major.
Topics: Benzoates; beta-Thalassemia; Child, Preschool; Deferasirox; Desensitization, Immunologic; Female; Humans; Iron Chelating Agents; Triazoles | 2017 |
The questioning for routine monthly monitoring of proteinuria in patients with β-thalassemia on deferasirox chelation.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Female; Humans; Male; Proteinuria; Retrospective Studies; Triazoles; Young Adult | 2017 |
Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Female; Hemochromatosis; Humans; Iron Chelating Agents; Middle Aged; Triazoles | 2016 |
Aceruloplasminaemia: a disorder of diabetes and neurodegeneration.
Topics: Adult; Benzoates; Brain; Ceruloplasmin; Copper; Deferasirox; Diabetes Mellitus, Type 2; Diagnosis, Differential; Ferritins; Humans; Insulin; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Magnetic Resonance Imaging; Male; Neurodegenerative Diseases; Triazoles | 2017 |
Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells.
Topics: Animals; Apoptosis; bcl-X Protein; Benzoates; Caspase 3; Cell Survival; Cytoprotection; Deferasirox; Down-Regulation; Enzyme Activation; Iron; Kidney Tubules, Proximal; Mice; Mitochondria; Models, Biological; Necrosis; Receptor-Interacting Protein Serine-Threonine Kinases; Stress, Physiological; Triazoles | 2017 |
Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin.
Topics: Antineoplastic Agents; Apoptosis; Benzoates; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deferasirox; Doxorubicin; Extracellular Signal-Regulated MAP Kinases; Humans; Iron; Leukemia; Phosphorylation; Reactive Oxygen Species; Triazoles | 2017 |
Deferasirox-Iron Complex Formation Ratio as an Indicator of Long-term Chelation Efficacy in β-Thalassemia Major.
Topics: Adolescent; Adult; Amino Acids; Benzoates; beta-Thalassemia; Deferasirox; Drug Monitoring; Female; Humans; Iron; Iron Chelating Agents; Liver; Male; Triazoles; Young Adult | 2017 |
Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective.
Topics: Benzoates; beta-Thalassemia; Cohort Studies; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Routes; Health Care Costs; Humans; Iron Chelating Agents; Italy; Pyridones; Treatment Outcome; Triazoles | 2017 |
Efficacy and Safety of Combined Oral Chelation With Deferiprone and Deferasirox in Children With β-Thalassemia Major: An Experience From North India.
Topics: Adolescent; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; India; Iron Chelating Agents; Kidney Function Tests; Liver Function Tests; Male; Prospective Studies; Pyridones; Tertiary Care Centers; Triazoles | 2017 |
Acute Liver Failure During Deferasirox Chelation: A Toxicity Worth Considering.
Topics: Anemia, Sickle Cell; Benzoates; Bilirubin; Blood Transfusion; Child; Deferasirox; Ferritins; Humans; Iron Chelating Agents; Liver Failure, Acute; Male; Transaminases; Triazoles | 2017 |
Iron overload induces apoptosis of murine preosteoblast cells via ROS and inhibition of AKT pathway.
Topics: Animals; Apoptosis; Benzoates; Caspases; Cells, Cultured; Deferasirox; Down-Regulation; Ferric Compounds; Iron Chelating Agents; Mice; Mitochondria; Osteoblasts; Phosphorylation; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Quaternary Ammonium Compounds; Reactive Oxygen Species; Signal Transduction; Triazoles | 2017 |
Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5-year observational study (ENTRUST).
Topics: Benzoates; Chelation Therapy; Child, Preschool; Deferasirox; Female; Hematologic Diseases; Hemosiderosis; Humans; Iron Chelating Agents; Male; Transfusion Reaction; Triazoles | 2017 |
Adrenal insufficiency: An emerging challenge in thalassemia?
Topics: Adrenal Gland Neoplasms; Adrenal Insufficiency; Adult; Benzoates; Blood Transfusion; Combined Modality Therapy; Deferasirox; Humans; Hypoglycemia; Hypogonadism; Hypothalamo-Hypophyseal System; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelolipoma; Pituitary-Adrenal System; Shock, Septic; Thalassemia; Triazoles | 2017 |
The positive effect of deferasirox on erythropoiesis in a patient with a dual diagnosis of myelofibrosis and diffuse large B-cell lymphoma.
Topics: Aged; Benzoates; Bone Marrow; Deferasirox; Erythropoiesis; Female; Humans; Image-Guided Biopsy; Immunohistochemistry; Iron Chelating Agents; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Positron-Emission Tomography; Primary Myelofibrosis; Triazoles | 2017 |
Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major.
Topics: Adult; Antiviral Agents; Benzimidazoles; Benzoates; beta-Thalassemia; Cryoglobulinemia; Deferasirox; Deferoxamine; Elasticity Imaging Techniques; Female; Ferritins; Fluorenes; Hepatitis C, Chronic; Humans; Iron Chelating Agents; Iron Overload; Liver Cirrhosis; Male; Quality of Life; Sofosbuvir; Triazoles; Viral Load | 2017 |
Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Benzoates; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Decitabine; Deferasirox; Drug Synergism; Gene Expression Regulation; Humans; Iron Chelating Agents; Leukemia; Reactive Oxygen Species; Triazoles | 2017 |
Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Erythrocyte Transfusion; Female; Ferritins; Humans; Iron Chelating Agents; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome; Triazoles | 2017 |
A case of Fanconi syndrome due to a deferasirox overdose and a trial of plasmapheresis.
Topics: Benzoates; Deferasirox; Drug Overdose; Fanconi Syndrome; Half-Life; Humans; Iron Chelating Agents; Male; Plasmapheresis; Triazoles; Young Adult | 2017 |
Expanding the Therapeutic Potential of the Iron Chelator Deferasirox in the Development of Aqueous Stable Ti(IV) Anticancer Complexes.
Topics: Antineoplastic Agents; Apoptosis; Benzoates; Cell Line, Tumor; Coordination Complexes; Deferasirox; Drug Design; Drug Stability; Humans; Iron; Iron Chelating Agents; Ligands; Models, Chemical; Molecular Structure; Serum Albumin; Titanium; Transferrin; Triazoles | 2017 |
Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles | 2018 |
Pregnancy Outcome among Women with Beta-Thalassemia Major in North Sardinia.
Topics: Abortion, Spontaneous; Adult; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Diabetes, Gestational; Female; Fetal Growth Retardation; Humans; Iron Chelating Agents; Italy; Pregnancy; Pregnancy Outcome; Premature Birth; Triazoles | 2017 |
Utilisation and Safety of Deferasirox: Results from an Observational Cohort Study in England.
Topics: Adolescent; Adult; Aged; Benzoates; Child; Child, Preschool; Cohort Studies; Deferasirox; England; Female; General Practice; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Triazoles; Young Adult | 2018 |
Protective effects of deferasirox and N-acetyl-L-cysteine on iron overload-injured bone marrow.
Topics: Acetylcysteine; Animals; Benzoates; Colony-Forming Units Assay; Deferasirox; Disease Models, Animal; Flow Cytometry; Free Radical Scavengers; Hematopoiesis; Hematopoietic Stem Cells; Iron Chelating Agents; Iron Overload; Male; Mice, Inbred C57BL; Protective Agents; Reactive Oxygen Species; Reference Values; Reproducibility of Results; Time Factors; Treatment Outcome; Triazoles | 2017 |
Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Female; Humans; Male; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Receptors, Calcitriol; Regression Analysis; Triazoles; Vitamin D; Vitamin D3 24-Hydroxylase | 2018 |
Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Female; Humans; Iron Chelating Agents; Iron Overload; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Pyridones; Retrospective Studies; Triazoles | 2018 |
Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome.
Topics: Aged; Benzoates; Biopsy; Deferasirox; Drug Eruptions; Female; Humans; Iron Chelating Agents; Myelodysplastic Syndromes; Triazoles; Urticaria; Vasculitis | 2017 |
A simple LC-MS/MS method for determination of deferasirox in human plasma: Troubleshooting of interference from ferric ion in method development and its application.
Topics: Benzoates; Chromatography, Liquid; Deferasirox; Ferric Compounds; Humans; Iron Chelating Agents; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Triazoles | 2018 |
Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience.
Topics: Adolescent; Adult; Benzoates; Blood Component Transfusion; Chelation Therapy; Child; Deferasirox; Deferiprone; Female; Humans; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Pyridones; Retrospective Studies; Thalassemia; Treatment Outcome; Triazoles; Turkey | 2018 |
Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Dialysis Solutions; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Treatment Outcome; Triazoles | 2018 |
Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload.
Topics: Anemia, Aplastic; Animals; Benzoates; Deferasirox; Deferoxamine; Disease Models, Animal; Drug Therapy, Combination; Female; Iron Chelating Agents; Iron Overload; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Triazoles | 2018 |
A 3-year study of deferasirox therapy in sickle cell disease patients in Basra, Southern Iraq.
Topics: Abdominal Pain; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood Transfusion; Creatinine; Deferasirox; Female; Ferritins; Humans; Iraq; Iron Chelating Agents; Iron Overload; Male; Treatment Outcome; Triazoles | 2018 |
Synthesis, Biological Evaluation and Molecular Docking of Deferasirox and Substituted 1,2,4-Triazole Derivatives as Novel Potent Urease Inhibitors: Proposing Repositioning Candidate.
Topics: Canavalia; Deferasirox; Dose-Response Relationship, Drug; Enzyme Inhibitors; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship; Triazoles; Urease | 2020 |
Using of deferasirox and deferoxamine in refractory iron overload thalassemia.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Triazoles | 2021 |
Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multi-center nation-wide cohort.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Risk Assessment; Risk Factors; Thalassemia; Triazoles | 2022 |
Outcome of iron reduction therapy in ex-thalassemics.
Topics: Adolescent; Allografts; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Female; Ferritins; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Iron; Iron Chelating Agents; Iron Overload; Male; Phlebotomy; Triazoles | 2021 |
Economic burden in the management of transfusion-dependent thalassaemia patients in Malaysia from a societal perspective.
Topics: Benzoates; Blood Transfusion; Cost of Illness; Cross-Sectional Studies; Deferasirox; Deferoxamine; Humans; Malaysia; Quality of Life; Thalassemia; Triazoles | 2021 |
Serum Zinc Level in β-Thalassemia Major: A Retrospective Study in Southwest Iran.
Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Female; Humans; Iran; Iron Chelating Agents; Iron Overload; Male; Pyridones; Retrospective Studies; Thalassemia; Triazoles; Young Adult; Zinc | 2021 |
Deferasirox-Induced Hyperammonemia in an Adult Patient After Allogeneic Stem Cell Transplantation.
Topics: Adult; Deferasirox; Hematopoietic Stem Cell Transplantation; Humans; Hyperammonemia; Triazoles | 2022 |
Drug utilization study and cost analysis of adult β-thalassemia major patient therapy at Dr. Soetomo General Hospital Surabaya.
Topics: Adult; Benzoates; beta-Thalassemia; Costs and Cost Analysis; Deferasirox; Deferiprone; Drug Utilization; Ferritins; Hospitals, General; Humans; Iron Chelating Agents; Pharmaceutical Preparations; Retrospective Studies; Triazoles | 2021 |
[Deferasirox and Complex Proximal Tubulopathy. Presentation of two clinical cases].
Topics: Acute Kidney Injury; Adolescent; Anemia, Diamond-Blackfan; Benzoates; Child, Preschool; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Kidney; Male; Triazoles | 2021 |
Effects of dual chelation therapy with deferasirox and deferoxamine in patients with beta thalassaemia major.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Retrospective Studies; Triazoles | 2022 |
Characterisation of individual ferritin response in patients receiving chelation therapy.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Hemoglobinopathies; Humans; Iron; Iron Chelating Agents; Pyridones; Triazoles | 2022 |
Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo.
Topics: Animals; Benzoates; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Mice; Triazoles; Uterine Cervical Neoplasms | 2022 |
Dose of deferasirox correlates with its effects, which differ between low-risk myelodysplastic syndrome and aplastic anaemia.
Topics: Anemia, Aplastic; Benzoates; Creatinine; Deferasirox; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Triazoles | 2022 |
Nephrolithiasis in two patients on iron chelation therapy: A case report.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Nephrolithiasis; Triazoles | 2023 |